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 General introduction to immunology 
The immune system is a network of cells, tissues, and organs that work together to protect 
the body from infection. The overall function of the immune system is to prevent or limit 
infection.  
The immune response is generally divided into innate and adaptive immunity:  
Innate immune system provides immediate defence against infection. Innate immunity 
recognizes and responds to pathogens in a generic way, but it does not confer long-lasting 
or protective immunity to the host. This response depends on a group of proteins and 
phagocytic cells that recognize conserved features of pathogens and become quickly 
activated to help destroy invaders called pathogen-associated molecular patterns 
(PAMPs). Innate immune cells express genetically encoded receptors, called Toll-like 
receptors (TLRs), which recognize general PAMPs (1). Collectively, these receptors can 
broadly recognize viruses, bacteria, fungi, and even non-infectious problems. However, 
they cannot distinguish between specific strains of bacteria or viruses. There are 
numerous types of innate immune cells with specialized functions, including neutrophils, 
eosinophils, basophils, mast cells, monocytes, dendritic cells (DCs), macrophages and 
natural killer (NK) cells. Their main feature is the ability to respond quickly and broadly 
when a problem arises, typically leading to inflammation. These cells release cytokines 
that help to destroy the pathogen in other cells by inducing a series of distinct processes. 
Cytokines are important in the activation, proliferation, differentiation and chemotaxis of 
immune cells (2). Innate cells are critical for host defence, and disorders in innate cell 
function may cause chronic susceptibility to infection. When the invader escapes or 
survives the innate immune system, the adaptive response is activated. 
Adaptive immunity occurs later, as it relies on the coordination and expansion of specific 
immune cells. Therefore, the adaptive immune responses are highly specific to a 
particular pathogen that induced them. The function is to destroy invading pathogens and 
any toxic molecules they produce. Because these responses are destructive, it is crucial 
that they be made only in response to molecules that are foreign to the host and not to the 
molecules of the host itself. The ability to distinguish what is foreign from what is self in 
this way is a fundamental feature of the adaptive immune system. Any substance capable 
of eliciting an adaptive immune response is referred to as an antigen. Antigens are usually 
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proteins that are too large to bind as a whole to any receptor so only specific segments 
that form the antigen, bind with a specific receptor. Such segments are called epitopes. A 
conformational epitope is a sequence of subunits (usually amino acids) composing an 
antigen that come in direct contact with a receptor of the immune system. Adaptive 
immune responses are carried out by white blood cells called lymphocytes. There are two 
broad classes of such responses: antibody responses and cell-mediated immune responses 
that are carried out by different classes of lymphocytes, called B cells and T cells, 
respectively (3). In this thesis we will focus on T cell lymphocytes. 
1.1 T-cell lymphocytes 
T cell lymphocytes are antigen-specific and can help eliminate pathogens that reside 
inside host cells. T cells maturate in the thymus and then T lymphocytes migrate to 
peripheral lymph organs. First, T cells are activated by foreign antigen to proliferate and 
differentiate into effector cells only when the antigen is displayed on the surface of 
antigen-presenting cells (APC). T cells recognize through the T cell receptor (TCR), short 
peptides of antigens (8-15 amino acids) that have been partly degraded inside the APC. 
The peptide fragments are then carried to the surface of the APC on special molecules 
called major histocompatibility complex (MHC). Once activated, effector T cells act only 
at short range, either within a secondary lymphoid organ or after they have migrated into 
a site of infection. They interact directly with another cell in the body, which they either 
kill or signal in some way.  
The human MHC is coded by the human leukocyte antigen (HLA) system. The HLA 
system is located on chromosome 6 and it is divided into three regions (Figure 1A). The 
class I region contains the classical HLA-A, HLA-B and HLA-C genes that encode the 
heavy chains of class I molecules. The class II region consists of a series of subregions, 
each containing A and B genes encoding  and  chains, respectively. The DR gene 
family consists of a single DRA gene and up to nine DRB genes. HLA-DR specificities 
are determined by the polymorphic DR1 chains encoded by DRB1 alleles. The DQ 
molecules are formed by DQA1 and DQB1 gene products and DPA1 and DPB1 products 
associate to form DP molecules. The class III region does not encode HLA molecules, 
but contains genes for the complement components (C2, C4, factor B), tumour necrosis 
factors (TNFs) and some others (4). 
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Class I molecules consist of a heavy chain formed by three extracellular domains (1, 2 
and 3), a transmembrane region and an intracytoplasmic domain, and a noncovalently 
bound extracellular 2-microglobulin (2m) (Figure 1B). The products of the class II 
genes DR, DP and DQ are heterodimers of two noncovalently associated chains,  and 
. An extracellular portion composed of two domains (1 and 2, or 1 and 2) is anchored 
on the membrane by a short transmembrane region and cytoplasmic domain. The HLA 
system is known to be the most polymorphic in humans. This polymorphism is not evenly 
spread throughout the molecule, but is clustered in the antigen binding groove. 
 
Figure 1. Gene map of the HLA region. Adapted from Cambridge University Press (A). Schematic diagram 
of HLA class I and class II molecules (B). 
MHC proteins function as carriers to present antigens on cell surfaces. MHC class I 
proteins are essential for presenting viral antigens and are expressed by nearly all cell 
types, except red blood cells. Any cell infected by a virus has the ability to signal the 
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problem through MHC class I proteins. MHC class II proteins are generally only 
expressed by B lymphocytes, DCs and macrophages. MHC class II antigens are varied 
and include both pathogen- and host-derived molecules (5). 
The TCR are complexes composed of two variable chains responsible for antigen 
recognition and CD3 subunits and chains, both of which initiate signalling cascades. 
The variable chains of most lymphocytes are the product of random rearrangements of 
the  and  genes (the large repertoire of the receptors of T cells). Some T lymphocytes 
contain, as variable chains, the products of the  and  genes, called  T cells (6). This 
random generation of receptors allows the immune system to respond to unforeseen 
problems and also explains why T cells are highly specific and, upon re-encountering 
their specific pathogen, can immediately induce a neutralizing immune response. 
There are two main classes of T cells that present the TCR as well as either CD8 or CD4 
on their surfaces. Both CD8 and CD4 are important for the recognition of the MHC 
presenting the antigen to the T cells. Cytotoxic CD8+ T cells (CTLs) directly kill cells 
that are infected with a virus or some other intracellular pathogen whereas CD4+ T cells 
help stimulate the responses of other cells (mainly B cells and cytotoxic cells) (Figure 2).  
 
Figure 2. TCR interaction with the MHC complex on CD8+ T cells (MHC-I) (A) and CD4+ T cells (MHC-
II) (B). 

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1.1.1 CD4+ T helper cells 
CD4+ T helper cells mainly recognize through the TCR peptides with an average length 
of 12-15 amino acids derived from extracellular proteins; these are associated with MHC 
class II molecules. The major role of CD4+ T cells is to coordinate the immune response 
by direct communication with B lymphocytes and macrophages through immunological 
synapses, and by the production of cytokines. T helper cells could be divided based on 
the type of cytokines they released. T helper 1 (Th1) cells secret mainly interleukin (IL)-
2, interferon gamma (IFN) and TNF. Th1 cells promote proinflammatory responses, 
activate macrophages and are highly effective in clearing intracellular pathogens. T helper 
2 (Th2) cells produce IL-4, IL-5, IL-6, IL-10 and IL-13 cytokines and they promote the 
antibody responses (7). T helper 17 (Th17) cells produce IL-17, IL-21, IL-6 and TNF. 
Th17 cells and their effector cytokines mediate host defensive mechanisms to various 
infections, especially extracellular bacterial infections, and are involved in the 
pathogenesis of many autoimmune diseases. The effector cytokines of Th17 cells, 
therefore, mediate the crucial crosstalk between immune system and tissues, and play 
indispensable roles in tissue immunity (8). And finally, regulatory T cells (Tregs) that 
monitor and inhibit the activity of other T cells. They prevent adverse immune activation 
and maintain tolerance, or the prevention of immune responses against the body's own 
cells and antigens (9). 
1.1.2 Cytotoxic CD8+ T cells 
CD8+ T cells are crucial for recognizing and removing virus-infected cells and cancer 
cells. CTLs have specialized compartments, or granules, containing cytotoxins that cause 
apoptosis. CD8+ T cells recognize intracellular peptides with an average length of 8-10 
amino acids and are associated with MHC class I molecules. Cytotoxic CD8+ T cells carry 
out their killing function by releasing two types of preformed cytotoxic proteins: 
granzymes, which seem able to induce apoptosis in any type of target cell, and the pore-
forming protein perforin, which punches holes in the target-cell membrane through which 
the granzymes can enter. Cytotoxic CD8+ T cells also produce cytokines such as IFNγ, 
which is an inhibitor of viral replication and is an important inducer of MHC class I 
expression and macrophage activation, TNF and IL-2.  
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After activation, the T-cell response is characterised by a stable pool of memory cells that 
can persist for many years. Then, upon re-exposure to the antigen, memory T cells can 
respond faster and develop into effector cells more efficiently (10). 
1.2 Antigen processing 
As it has been previously mentioned, T helper cells and CTLs use their TCRs to recognize 
peptide antigens presented by molecules encoded by the MHC. The preference for 
different classes of MHC molecules relates to a demarcation in the antigen-processing 
pathways that supply peptides. MHC class II molecules generally present peptides 
derived from exogenous antigens that enter the cell by the endocytic route, whereas MHC 
class I molecules present endogenously derived antigens, usually synthesized within the 
cell presenting the antigen. Therefore, CTLs target directly cells infected with virus (11). 
The endogenous pathway is used to present intracellular peptide fragments on the cell 
surface on MHC class I molecules (viral peptides would also be presented, allowing the 
immune system to recognize and kill the infected cell). Short peptides are generated from 
the catabolism of endogenous proteins in the cytoplasm through the action of proteasomes 
and other enzymes, and these peptides arte actively transported into the lumen of the 
endoplasmic reticulum (ER) by the heterodimeric transporter associated with antigen 
processing (TAP) where bind to MHC class I molecules. Those peptides will be presented 
to CD8+ T cells (Figure 3A). 
The exogenous pathway is utilized by specialized APC to present peptides derived from 
proteins that the cell has endocytosed. The peptides are presented on MHC class II 
molecules. Proteins are endocytosed and degraded by acid-dependent proteases in 
endosomes where bind to MHC class II molecules. Then, the peptides will be presented 
to CD4+ T cells (Figure 3B). 
Some peptides derived from extracellular proteins can be presented in the context of MHC 
class I, named cross-presentation. The cell starts off with the exogenous pathways but 
diverts the antigens to the endogenous pathway. The TAP dependence of such cross-
presentation indicates that it involves diversion of the cellular antigens into the 
conventional MHC class I pathway (11) (Figure 3C). 
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Figure 3. Different antigen-processing pathways for the MHC class I and class II molecules. MHC 
class I molecules present peptides that are derived from endogenously synthesized proteins of either self or 
pathogen origin (A). MHC class II molecules present exogenous proteins that enter the cell through the 
endocytic route (B). Cross-presentation pathway (C). Adapted from Health WR. et al. 2001. Nat Rev 
Immunol. 
 Allogeneic haematopoietic stem cell transplantation 
Haematopoietic stem cell transplantation (HSCT) is a well-established clinical procedure 
introduced more than half a century ago, consisting of the infusion of stem cells to re-
establish haematopoietic function in patients whose bone marrow or immune system is 
damaged or defective. Over the last 20 years, HSCT practice has increased almost tenfold, 
becoming the primary indicator for many haematological malignancies and inherited or 
acquired non-malignant disorders of blood cells (Table 1) (12-14).  
In the early 1960s, allogeneic HSCT (allo-HSCT) became feasible after the identification 
of MHC molecules and typing of HLA. The procedure of allo-HSCT requires partial or 
total elimination of the recipient´s haematopoietic and immune systems through pre-
transplant chemotherapy that is sometimes combined with radiotherapy. This 
conditioning treatment provides space for incoming cells to engraft, helps in preventing 
graft rejection and kills most residual cancer cells. In this situation, the immune system 
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plays a crucial role for the transplant success in order to avoid graft failure, graft versus 
host disease (GvHD) and control of infection. 
Table 1. Main malignant and non-malignant haematological disorders of blood cells that are indicated for 
allogeneic-HSCT. 
Malignant disorders Non-malignant disorders 
Acute lymphoblastic leukaemia (ALL) Bone marrow failure syndromes 
Acute myeloid leukaemia (AML) Chronic granulomatous disease 
Chronic lymphocytic leukaemia (CLL) Fanconi anaemia 
Myelodysplastic syndrome (MDS) Metabolic storage disorders 
Non-Hodgkin lymphoma (NHL) Severe aplastic anaemia (SAA) 
Hodgkin lymphoma (HL) Sickle cell anaemia 
Multiple myeloma Thalassemia 
High-risk of solid tumours, under certain 
circumstances 
 
There are several factors to consider for a successful cell transplant procedure, such as 
HLA disparity, the disease and its prognosis, time between the diagnosis and the 
transplant, donor/recipient age and donor/patient viral serostatus. 
The HLA system is the major histocompatibility barrier in allo-HSCT as a foreign HLA 
is recognized by the immune system, and the degree of HLA matching is predictive of 
the clinical outcome. There are several levels of HLA compatibility between the recipient 
and the donor that have to be defined prior to performing an allo-HSCT. Based on HLA 
high-resolution typing for class I (HLA-A, -B, -C) and class II (HLA-DRB1, -DQB1, -
DPB1), a well-matched donor is defined as 12/12, 10/10 (when DP is not considered) or 
8/8 (when both DQ and DP are not taken into account). DPB1 is only included if several 
10/10 matched donors are available. If there is any difference it is considered as a 
mismatch. In this case, it is possible to have HLA disparity in 1 or 2 loci. There are 
different types of donors within the allo-HSCT depending on the HLA compatibility: 
Related donor 
- A sibling that is genotypically identical in both HLA class I and II. 
- A sibling or other related familiar donor with HLA disparity in 1 or 2 loci. 
- A haploidentical donor that shares one haplotype with the recipient. 
- If the sibling is a monozygotic twin, it is a syngeneic transplant. 
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Unrelated donor 
These donors are recorded in the ‘Bone Marrow Donor Worldwide’ database and the best 
HLA matched donor will be chosen when possible. 
2.1 Stem cell source 
There are three main sources of haematopoietic stem cells (HSCs) for clinical 
transplantation: bone marrow (BM), peripheral blood stem cells (PBSCs) and umbilical 
cord blood (UCB). BM is obtained by repeated aspiration of the posterior iliac crest while 
the donor is under general or local anaesthesia. Its use as a source of HSCs has decreased 
over the years due to the discomfort caused to the donor during the BM isolation. The 
principal source of HSCs used for both autologous and most allo-HSCTs are PBSCs 
obtained by an apheresis following patient or donor HSCs mobilization by using 
granulocyte-colony stimulating factor (G-CSF), which active principle is filgrastim (15). 
G-CSF causes the proliferation of neutrophils and the release of proteases. Proteases 
degrade the proteins anchoring the stem cells to the marrow stroma and, together with 
protease-independent mechanisms, liberate the stem cells to enter the circulation. 
The European Group for Blood and Marrow Transplantation (EBMT) survey of over 651 
centres about HSCTs activity in Europe during 2011 reported a total of 35,660 HSCT 
(42% allo-HSCT) and found that over 72% of allo-HSCT were performed using PBSCs 
(16). Several trials have reported that allogeneic PBSC transplantation can produce a 
substantially faster engraftment than BM with a reduced rate of relapse, especially in 
patients with late-onset disease. Moreover, allo-PBSCs improve overall and disease-free 
survival in patients with more advanced hematologic malignancies. However, in allo-
transplantation, PBSCs, which contain more T cells than BM does (despite having similar 
correlation with incidence of acute graft versus host disease (aGvHD)), increase the 
incidence and prolong the treatment of chronic graft versus host disease (cGvHD) 
compared to BM (17). For that reason, BM is a preferable source of HSCs when treating 
non-malignant diseases. 
The use of UCB as source of HSCs has been associated with a decreased incidence of 
graft versus host disease (GvHD), with the benefits relating to reduced histocompatibility 
requirements. However, its use has largely been restricted to paediatric and small adults 
due to the dose limitations, as UCB collections contain a significantly reduced total 
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number of CD34+ cells, compared with PBSCs. This, can result in delayed or failed 
engraftment in adults. In the recent years, double UCB transplantations have been carried 
out to improve survival in adult UCB transplantation, increasing CD34+ cell numbers, 
therefore reducing the time of engraftment in adult recipients (18). 
2.2 Conditioning treatment  
Conditioning regimens in allo-HSCT vary in their intensity and can be classified as 
myeloablative (MA) conditioning and non-myeloablative conditioning or reduced 
intensity conditioning (RIC) treatments. The purpose of using MA conditioning regimen 
prior to transplantation is to eradicate the underlying disease and suppress the recipient’s 
immune system to allow engraftment of donor stem cells. The initial MA conditioning 
treatment was a combination of cyclophosphamide (Cy) and total body irradiation (TBI) 
(19). In order to avoid possible side effects of TBI, such as pneumonitis, cataracts, 
endocrinological disturbances, secondary tumours and decreased growth in children, the 
use of busulfan (Bu) was implemented. Randomized trials comparing Cy-TBI and Bu-Cy 
in patients with acute myeloid leukaemia (AML) or chronic myeloid leukaemia (CML) 
found no differences in leukaemia free survival and overall survival between the two 
conditioning regimens (20). 
Due to the high transplant related mortality associated with using the MA conditioning 
regimen, allo-HSCT was restricted to healthy young patients who are more tolerant to the 
high dose chemo-radiotherapy regimens. However, the introduction of RIC regimens 
before allo-HSCT has allowed transplantation in elderly patients and in younger patients 
with comorbidities (21). RIC regimens minimize toxicities related to MA conditioning 
treatment but it is necessary profound immunosuppression to allow engraftment of the 
HSCs, as there is not an eradication of the endogenous bone marrow cells. RIC regimen 
is based on combination of different drugs such as fludarabine (a purine analogue) 
combined with melfalan, Bu or Cy. 
2.3 Complications following transplant 
The high doses of chemotherapy and/or radiotherapy in conditioning regimens affects all 
organs and tissues of the recipient, producing several early and late secondary effects of 
variable intensity. The most common early effects are related to gastrointestinal toxicities 
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as mucositis, esophagitis or gastrointestinal disorders. Other toxicities related to lung, 
liver and brain have also been described. 
However, the main complications that occur after allo-transplantation include 
engraftment failure, GvHD and infection. In order to avoid the two first complications 
there are different immunosuppressive prophylaxis treatments available. Thus, both MA 
and RIC conditioning treatments are combined with cyclosporine-A (Cs-A) or 
mycophenolate mofetil (MMF) and methotrexate (MTX) to provide post-grafting 
immunosuppression that impairs T-cell functions (19, 22). Furthermore, when receiving 
a transplant from an unrelated donor T-cell depletion with alentuzumab or anti-thymocyte 
globulin (ATG) are also used to avoid GvHD. 
a) Failure engraftment can occur when either the haematopoietic process cannot 
recovering following transplantation or when a recipient’s immunocompetent residual 
cells survive conditioning treatment and refuse donor’s stem cells. 
b) GvHD is the most frequent complication following allo-HSCT. It can occur 
despite aggressive immunosuppressive prophylaxis, even when the donor is 
genetically matched. It is a consequence of interactions between antigen presenting 
cells of the recipient and mature T-cells of the donor. It can be classified as aGvHD, 
which normally occurs within the first 100 days post-transplant and cGvHD that 
normally appears after four months post transplantation. Characteristic tissue damage 
that normally affects the skin, liver or gut. GvHD is treated with high doses of 
immunosuppressive drugs (steroids). 
c) Infectious complications are one of the major problems that can occur following 
transplantation. They are due to neutropenia and mucosal and skin damage caused after 
conditioning and immunosuppression treatments. Most opportunistic infections are 
caused through viral infections mainly Cytomegalovirus, Herpes simplex, Varicella-
zoster and Epstein-Barr (EBV), and bacterial and fungal infectious agents such as 
Aspergillus and Candida. 
 Cytomegalovirus  
Human cytomegalovirus (CMV) is a member of the -herpesvirus family that infects 
approximately 70% of the population in developed countries (23, 24). The CMV virion 
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consists of an icosahedral nucleocapsid (100 nm in diameter) containing a double-
stranded linear deoxyribonucleic acid (DNA) genome (230 Kbp). This is surrounded by 
a proteinaceous layer, defined by a lipid bilayer containing a large number of viral 
glycoproteins. The mature virion particle is approximately 150-200 nm in diameter 
(Figure 4).  
 
Figure 4. Structure of the cytomegalovirus virion and its components. 
Virions gain entry through a membrane fusion event involving the outer membrane of the 
cell and glycoproteins on the lipid envelope of virions. Once the fusion of these two 
membranes occurs, the DNA-containing protein capsid and the tegument proteins are 
released into the cell. During the lytic infection, viral immediate-early genes are 
expressed which results in the production of viral immediate-early proteins that modulate 
the host cell environment and stimulate the expression of viral early genes. These proteins 
are responsible for replicating the double-stranded viral genomic DNA; after DNA 
replication, these immediate-early genes turn on the expression of viral late genes. CMV-
infected cells also produce non-infectious enveloped particles and dense bodies. Non-
infectious enveloped particles are defective viral particles composed of enveloped 
immature capsids that lack DNA, but contain the viral assembly protein (they contain an 
identical assortment of envelope, tegument and capsid proteins). Dense bodies are 
enveloped particles that lack an assembled nucleocapsid and viral DNA, but contain 
several tegument proteins located between the outer lipid membrane and the icosahedral 
protein capsid. Upon release into the cytoplasm, tegument proteins become functionally 
Membrane
Genome
Tegument
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active, where they play important roles in all stages of the viral life cycle, including, viral 
entry, gene expression, immune evasion, assembly and egress. Several tegument proteins 
are of particular interest due to their role in the CMV replication cycle, including 
phosphoprotein 65 (pp65), pp71, pp150 and pp28. These proteins are processed through 
the proteasome to generate short peptides that would be transported into the ER by TAP 
to bind to MHC class I molecules and therefore be presented to CD8+ T cells. The pp65 
is the most abundant tegument protein and the major constituent of extracellular virus 
particles and it is delivered to the nucleus of permissive cells at the very start of a lytic 
infection. Further, pp65 is implicated in countering both innate and adaptive immune 
responses during CMV infection. Pp65 not only prevents immediate-early proteins from 
being recognized by components of the immune system, but also inhibits the synthesis of 
various components involved in the host cell’s immune response. The most 
immunodominant pp65 epitope is NLVPMVATV which has HLA-A*02:01 restriction; 
however, other CMV-encoded T-cell epitopes with other HLA restriction have also been 
studied, including major histocompatibility complex (MHC) class II epitopes (25, 26) 
(Table 2). 
Table 2. Most common pp65 epitopes sequences and their HLA restriction. 
Pp65 epitopes MHC class I restriction Pp65 epitopes MHC class II restriction 
Residues Epitope sequence 
HLA 
restriction 
Residues Epitope sequence HLA restriction 
123-131 IPSINVHHY HLA-B35 41-55 LLQTGIHVRVSQPSL HLA-DQ6 
188-195 FPTKDVAL HLA-B35/B68 361-376 PQYSEHPTFTSQYRIQ HLA-DR11 
341-349 QYDPVAALF HLA-A24 489-503 AGILARNLVPMVATV HLA-DR3/DR11 
417-426 TPRVTGGGAM HLA-B7 509-523 KYQEFFWDANDIYRI HLA-DR52 
495-503 NLVPMVATV HLA-A2    
501-509 ATVQGQNLK HLA-A11    
By looking at the different HLA class I restrictions of CMVpp65 antigen presentation 
studied, approximately 0.26 (0.18-0.34) of the Caucasian population present HLA-
A*02:01 restriction, according to the allele frequencies in the world population website 
(http://www.allelefrequencies.net/). HLA-A*24:02 restriction is present in 0.10 (0.05-
0.21). Around 0.10 (0.01-0.19) of the Caucasian population present HLA-B*07:02 
restriction whereas 0.07 (0.03-0.13) have HLA-B*35:01 restriction and 0.06% (0.01-
0.13) present HLA-A*11:01 restriction. 
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The phospholipid envelope contains glycoproteins that play essential roles in viral entry 
into host cells, cell-to-cell spread and virion maturation. There are two glycoprotein 
complexes required for virus entry: glycoprotein complex I composed of homodimeric 
glycoprotein B (gB) molecules and heteroligomeric complex III composed of gH and gL. 
gB is an essential glycoprotein that plays a crucial role in virus binding, as it is the major 
cell surface, heparan sulfate proteoglycan-binding glycoprotein. It also participates in 
viral entry, cell-to-cell spread and cell fusion. On the contrary, gH and gL are necessary 
for the final stage of virus entry via pH-independent fusion between the viral envelope 
and the cell membrane. The immunodominant gB epitope is DYSNTHSTRYV (residues: 
217-227), whereas HELLVLVKKAQL is the immunodominant gH epitope (residues: 
276-287) (27). 
3.1 Opportunistic cytomegalovirus infection and host balance 
CMV represents one of the most common infections among healthy people and it is a 
major problem within immunosuppressed patients. 
Following primary infection in healthy immunocompetent individuals, the virus and the 
immune system reach a homeostatic balance, and life-long asymptomatic latency is 
established. This occurs predominantly in cells of the myeloid lineage, where intermittent 
sub-clinical reactivations are successfully controlled by the immune system (28). The 
immunological control of CMV exerted by the host requires a high proportion of the 
immune repertoire to be directed against this pathogen, with competent CMV-specific 
CD4+ and CD8+ T cell subpopulations involved (29, 30). 
By contrast, CMV infection/reactivation can cause severe disease and even mortality in 
the absence of an effective immune response, such as immunocompromised individuals 
and immunological immature of neonates or newborns (31, 32). Recipients of allo-
HSCTs are treated with immunosuppressive drugs which target both the CD8+ and CD4+ 
T-cell compartments, which are critical for CMV immune control. This deficit allows 
uncontrolled CMV replication and may lead to development of life-threatening end-organ 
damage. The incidence of CMV reactivation during the post-transplant period is 
approximately 70–80% in adults and 30–40% in paediatric allo-HSCT (33); primary 
infection following HSCT occurs in 20-40% of CMV seronegative patients whose donor 
is CMV seropositive (34). The most common clinical manifestations of CMV disease are 
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pneumonia and gastrointestinal disease, but retinitis, central nervous system disease and 
marrow suppression may also be observed (35). 
 CMV immune responses 
4.1 Healthy individuals 
The time course of the appearance of CMV-specific immune responses in healthy 
individuals is difficult to follow, as the beginning of primary infection normally goes 
unnoticed. Once CMV establishes primary infection, several mechanisms and pathways 
of the innate immune response are activated. Following infection, monocytes, 
macrophages and dendritic cells release inflammatory cytokines and upregulate co-
stimulatory molecules that slow down the pathogen before an adequate adaptive immune 
response is developed (36). Once the virus disseminates to monocytic cells of myeloid 
lineage including monocytes and CD34 cells, it establishes latent infection (37, 38). A 
model of primary CMV infection has been proposed by studying CMV-naïve individuals 
that received a donor kidney from CMV carriers (24). Based on in vitro culture, one week 
after the peak of CMV replication CMV-specific CD4+ T cells emerge and synthetize Th1 
cytokines (IFN and TNF) (39, 40). Following primary CMV infection, CMV-specific 
CD4+ T cells show a phenotype of recently activated naïve T cells co-expressing 
CD45RA and CD45RO surface markers, co-stimulatory receptors CD27 and CD28 and 
the cell cycle-associated nuclear marker ki67 (Figure 5A). Then, CMV-specific CD8+ T 
cells become detectable in peripheral blood and have an effector memory (TEM) 
phenotype, characterised by the loss of CD45RA and CCR7 cell surface markers (41). 
These virus-specific CD8+ T cells express perforin, granzyme B and CD95 and have the 
capacity of lysing CMV-peptide presenting target cells (42, 43). In the months following 
primary infection, CMV-specific CD8+ T cells gradually lose CD27 and re-acquire 
CD45RA expression (known as terminally differentiated effector-memory CD45RA T 
cell (TEMRA)). This seems to increase with age, however the CMV-specific CD8
+ T cells 
still maintain their cytolytic potential (Figure 5B). On the contrary, CMV-specific CD4+ 
T cells keep an effector memory phenotype which is not related to age (44).  
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Figure 5. CMV-specific T-cell differentiation. Phenotypic evolution of CD4+ (A) and CD8+ (B) T cells. 
CMV-experienced T cytotoxic cells exhibit a different functional phenotype compared with naïve cells. 
Expression of different molecules such as CD45RA, CCR7, CD28, CD27, CD57 or mediators of 
cytotoxicity, such as IFN, granzyme B (GzmB) or perforin.  
During latency, CMV-specific cells express the senescence marker CD57 and lose ki67 
expression. However, these specific cells are not exhausted and can respond to 
reactivation of latent virus in vivo (45, 46). T-cell exhaustion is characterised by a 
progressive loss in the ability of CD8+ T cells to produce cytokines (IL-2, TNF, IFN), 
as well as to survive, proliferate and kill targets. Notably, during chronic CMV infection 
in healthy individuals, CMV-specific T cells do not upregulate programmed cell death 
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(PD)-1, an inhibitory molecule strongly associated with antigen-driven T-cell exhaustion 
(47). Indeed, even in the absence of CD4+ T cells, which accelerates CD8+ T cell 
exhaustion after chronic CMV infection (48, 49), only a small proportion of CD8+ T-cells 
are dysfunctional (50, 51). Importantly, the release of Th1 cytokines characterise early 
and late virus-specific T cells that accumulated during latency. CMV-specific T cells of 
infected subjects dominate the memory compartments where CD4+ and CD8+ comprise 
approximately 10% in peripheral blood. However, these T cells, despite restraining viral 
replication and preventing disease, do not eliminate the virus, which persists as a latent 
infection in the host (52). 
4.2 Immunocompromised individuals 
As it was previously mentioned, allo-HSCT recipients are treated with 
immunosuppressive drugs that target both the CD4+ and CD8+ T-cell compartments. 
Susceptibility to viral, bacterial or fungal infections in those patients is the result of 
profoundly reduced innate and adaptive immunity in the immediate post-transplant period 
caused by the immunoablative effect of the host bone marrow (53, 54). One of the main 
mechanisms that underlie the immunological tolerance is engraftment of donor HSCs in 
the host bone marrow. This is followed by the production of donor-derived pro-
thymocytes, which undergo maturation in the host thymus and thereby acquire central 
tolerance to host tissue (Figure 6).  
 
Figure 6. T-cell immune reconstitution after allogeneic haematopoietic stem-cell transplantation. A) Recipient’s 
T-cell recovery is generated after maturation of donor’s T-cells from the haematopoietic stem cells (HSCs) after 
engraftment in host’s bone marrow. Donor-derived cells undergo maturation in patient’s thymus in the presence of both 
host and donor tissue. These T cells not only are functionally competent but also fully tolerant of both host and donor 
tissue. This process takes at least 100 days. B) Mature donor T cells that from the HSC graft can engraft directly in the 
host, thereby more rapidly providing cellular immunity. However, these T cells are responsible for GvHD and therefore 
are frequently depleted from the HSC graft during HSC processing or are controlled by the administration of 
immunosuppressive drugs. Adapted from Moss P.et al. 2005. Nat Rev Immunol. 
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In this microenvironment, restoration of adaptive immunity following allo-HSCT is a 
slow process. Naïve (CD45RA+CCR7+) T cells first appear approximately four months 
after allo-HSCT, and the complete recovery of the naïve T-cell pool may take one to two 
years. T-cell counts recover much earlier by peripheral expansion (55). Post-thymic 
donor-derived T cells expand rapidly after allo-HSCT. These cells are central memory 
(CD45RA-CCR7+) (TCM) and TEM cells, which are crucial for the success or failure of 
allo-HSCT due to their impact on the engraftment, GvHD, graft versus leukaemia (donor 
T-cells that eliminate malignant residual host T-cells) and antiviral therapy (56). In the 
early stages post-transplant, the mature T-cell repertoire from the donor interacts with the 
new recipient’s environment, leading to clonal expansion against diverse antigens driven 
by lymphopenia and cytokines. Early clonal expansion of CMV-specific cytotoxic T 
lymphocytes (CMV-CTLs) depends on the presence of cells with these specificities in the 
donor (57) and other factors in patient’s microenvironment. 
Most studies have focused on CD8+ T-cell immunity and have shown that following 
primary infection there is an increase of CMV-specific CD8+ T cells which is related to a 
reduction in both CMV reactivation and disease (58-60). Later on during persistent 
infection, an equilibrium is reached between viral replication and cellular immune 
responses.  
However, several studies suggest that functional CMV-specific CD8+ T cells are not 
sufficient to control viral replication and that effector-memory CD4+ T cells are necessary 
for the recovery of infection. It is interesting to mention that whereas in 
immunocompetent subjects CMV-specific CD4+ T-cell responses precede CMV-specific 
CD8+ T-cell responses, in allo-HSCT recipients the CMV-specific effector-memory 
CD4+ T-cell responses are delayed. The CMV-specific CD4+ T-cell response is 
dominated by large oligoclonal expansions of cells with cytotoxic activity and 
predominant production of IFN (61). The impaired control of viral replication can be 
explained by the lack of IFNsecreting effector memory CD4+ T cells at the side of 
infection in allo-HSCT patients (62). Consequently, functional recovery of specific CD8+ 
cell-mediated cytotoxicity after transplantation may require expansion and activation of 
virus-specific T-helper cells (63). In that sense, CD4+ T cells seem to be necessary for the 
regulation of cell-mediated immunity, promoting cytotoxic T-cell activity through Th1 
cytokine elaboration and activation of APCs (64). 
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Recipients with poor CMV-specific CD4+ and CD8+ T cells responses within the first 100 
days post-transplantation have been associated with a high risk of recurrent viral 
reactivation (65). On the contrary, patients with a positive response against CMV have 
seemed to harbour lower a virus load and a more rapid clearance of CMV compared to 
their negative counterparts, suggesting the importance of CMV immunity in clearing the 
infection in those patients (66).  
 Factors that can module CMV immune reconstitution in allogenic stem cell 
recipients 
CMV reactivation may be influenced by several factors, including donor/recipient CMV 
serology, degree of HLA disparity, immunosuppression, conditioning regimens and graft 
manipulation. 
5.1 Donor and recipient serostatus 
CMV serostatus of the donor has been demonstrated to affect the outcome of the allo-
HSCT (67). Therefore, the selection of the donor may depend on the allo-HSCT recipient 
CMV serostatus. For a CMV-seronegative recipient (R-), it is preferable to use a CMV-
seronegative donor (D-), in order to reduce the possibility of primary CMV infection 
associated with a seropositive allograft (68, 69). On the contrary, stem cells from a 
seropositive donor (D+) are preferred for a seropositive recipient (R+) (70). CMV-
seropositive patients have shown much a higher incidence of CMV infection than CMV-
seronegative recipients (71). However, this post-transplant CMV reactivation represents 
the major factor driving CMV-specific immune reconstitution (72, 73). There are some 
cases in which immunity was reconstituted in the absence of detected infection, probably 
due to a silent infection occurring in a target organ. This mechanism may be similar for 
the immune recovery in seropositive donors and seronegative patients. However, an 
antigen-dependent, cytokine-driven expansion may help immune reconstitution (74).  
Recent studies suggest that D+/R+ transplants generate higher levels of multifunctional 
CMV-specific T cells, even in the absence of detectable CMV reactivation and also 
require less antiviral therapy compared with D-/R+, in which CMV-specific cellular 
immunity reconstitution is dependent on CMV antigen exposure during CMV 
reactivation (31, 75). This fact may be explained by the transfer of T cells present in the 
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allograft from a CMV seropositive donor, in which both naïve and memory/effector 
CMV-CTLs are transferred to the recipient, while grafts from seronegative donors only 
transfer naïve CMV-specific T cells. Approximately 30% of D+/R- develop primary 
CMV infection. Despite there being low risk of CMV disease due to pre-emptive 
treatment of CMV infection, the mortality caused by fungal or bacterial infections is 
higher in D+/R-compared to D-/R- (18.3% vs. 9.7%, respectively). This is possibly 
because of the immunosuppressive effects of CMV therapy (76). The kinetics of CMV-
CTL reconstitution is different in CMV-seropositive recipients between receiving a 
transplant from either a CMV-seropositive or a seronegative donor. R+/D- showed a 
delayed reconstitution of CMV immunity compared to R+/D+ (day +120 vs. day +30, 
respectively) (77). Besides, CMV-CTLs levels are normally higher in the D+/R+ group 
compared with significantly lower numbers in the other groups (D-/R+, D-/R-, D+/R-) 
(78). 
5.2 Degree of HLA disparity 
HLA disparity between the host and the donor is another factor that may contribute to a 
high risk of CMV infection. As it has been previously mentioned, HLA disparity is 
associated with aGvHD. The use of steroids drugs to treat GvHD is related to the 
inhibition of immune function and blockage of T-cell activation. Functional recovery of 
both CMV-specific CD4+ and CD8+ T cells is impaired due to steroid administration. 
However, there is not a clear explanation of why HLA disparity may contribute to the 
risk of CMV infection. According to a study by Borchers et al., GvHD is more frequently 
observed in patients receiving a transplant from a mismatched donor and therefore, they 
received steroids treatment that lead to a delay on CMV-specific T-cell immune recovery 
(78). These observations agree with the results obtained by Mead et al. where CMV 
infection was more frequent in mismatched unrelated donors compared to matched 
unrelated donors (56% vs. 30%) (79). Similarly, the study developed by Jaskula and 
collaborators showed that a lack of optimal donor/recipient HLA matching was associated 
with a higher risk of aGvHD and a higher rate of CMV reactivation/infection (68). 
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5.3 Immunosuppression treatment 
The immunosuppressive regimens that allow the recipient to keep the graft and avoid 
GvHD associated complications also play a role in CMV replication. The state of 
immunosuppression experienced by the recipient is modulated by factors, such as 
pharmacologic therapies (type, timing, duration, and sequence), immunogenetic 
characteristics (HLA match), the presence or absence of immunomodulating viruses, and 
metabolic abnormalities. Allo-HSCT recipients treated with high-dose corticosteroids (>1 
mg/kg/day), MMF and certain anti–T-cell strategies (eg, Campath or ATG) are 
considered at high risk for CMV disease. In one study, an increased risk of CMV disease 
or CMV-related complications in allo-HSCT patients was associated with MMF 
treatment, which seems to upregulate CMV replication (80). Highly immunosuppressed 
recipients have delayed or reduced immune reconstitution, which has a direct effect on 
the viral replication dynamics in vivo (81). The progression from viral detection to overt 
disease with a rapidly increasing viral load is occurred in highly immunosuppressed 
patients (eg, those taking >1 mg/kg/d of corticosteroids) such that any positive test should 
trigger a requirement for immediate treatment in these patients. Further, viral load may 
increase in highly immunosuppressed individuals receiving antiviral drugs (82). 
5.4 Conditioning regimens 
Some studies have investigated CMV immune recovery after allo-HSCT of patients 
according to pre-allo-HSCT treatment. RIC-allo-HSCT has been associated with lower 
risk of high-grade of CMV infection; however, this effect does not appear to protect 
against complications of CMV (83). These observations agree with a study by Kim et al. 
in which they observed that CMV reactivation was less common in RIC-allo-HSCT 
patients compared to MA, early following allo-HSCT, while there is no difference during 
the late-recovery period (84). Patients that have received the RIC regimen with 
alemtuzumab treatment have shown a high rate of early CMV reactivation (85). The 
numbers of CD4+ and CD8+ T cells remained low within the first three months but they 
started to recover on day 90. CMV-specific T-cell levels increased 180 days post allo-
HSCT. In summary, the higher incidence of CMV reactivation has been related to an 
inadequate or defective recovery of CD8+ T cells as a consequence of the conditioning 
regimen (58). 
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5.5 Graft manipulation 
The use of T-cell depletion and G-CSF-mobilized stem cell conditioning protocols are 
used to improve engraftment and reduce GvHD. However, as these manipulations may 
be involved in increasing the risk of CMV infection, non-T-cell depleted transplants are 
preferred when possible.  
CD34-positive selection of PBSCs allows GvHD to be minimized by effective reduction 
of T cells in the graft. A study developed with young patients found that CMV-specific 
T-cell reconstitution was significantly delayed in patients receiving T-cell depleted grafts 
by collection of CD34+ progenitor cells, compared to those who received unmanipulated 
HSCT (median time of CMV-specific T-cell reconstitution of 75 vs. 47 days, 
respectively) (86). 
In contrast to CD34-positive selection, CD3/CD19-depleted peripheral allografts contain 
other immune components, such as NK cells, DCs and monocytes that may be used to 
generate anti-leukemic, anti-viral or graft-facilitating effects. Recent studies have shown 
that T-cell recovery after CD3/CD19-depleted grafts achieves normal values within the 
first 60 days post- transplantation (87, 88). However, when CD3/CD19-depletion is used 
in combination with RIC regimen, T-cell reconstitution is delayed to 3 months after 
HSCT (89). 
A recently developed method is based on depletion of  T lymphocytes couples with B-
cell depletion. This approach allows to transfer to the recipient not only high numbers of 
CD34+ cells and mature donor NK cells, but also  T cells which can exert their 
protective effect against both leukaemia cell regrowth and life-threatening infections.  
T cells participate in anti-CMV responses, particularly when conventional adaptive 
immunity is insufficient to clear the viral infection, It has been reported that patients with 
CMV reactivation after allo-HSCT have a significant expansion of cytotoxic  T-cells 
compared to recipients who did not reactivate (90). 
 Anti-CMV treatment 
Prophylactic or pre-emptive antiviral strategies are widely used to control CMV infection 
following HSCT. The administration of antiviral drugs, which also able to restrain other 
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herpesviruses, has now become the standard first line therapeutic treatment against 
primary or reactivated CMV infection and disease. The aim of prophylaxis therapy is to 
reduce the incidence of CMV infection/disease after transplantation, while the purpose of 
pre-emptive therapy consists of monitoring the CMV reactivation and early intervention 
when CMV reactivation is detected.  
The first anti-CMV drug used was immune-globulin, however its use as a prophylaxis has 
had no effect in reducing the incidence of CMV disease (69) or CMV infection (91) in 
allo-HSCT recipients.  
Acyclovir and valacyclovir have been used as prophylactic treatment to treat herpes-
simplex virus with a reduction in the risk of CMV infection/disease, improving survival 
within 100 days post- transplantation. However, it should be combined with a pre-emptive 
strategy by using sensitive assays in order to monitor CMV reactivation (92).  
Ganciclovir (GCV) has been used not only as prophylactic therapy for preventing early 
CMV disease after transplantation, but also as pre-emptive therapy in patients with CMV 
viremia. Although GCV prophylaxis is considered an effective strategy for preventing 
CMV disease early after transplantation, it is associated with drug-related toxicities 
(myelosuppressive and immunosuppressive effects) (93) and it has been found to impair 
and delay the development of CMV-CTLs (94, 95). The use of GCV at the onset of CMV 
viremia and discontinuing treatment once follow up monitoring assays become negative 
has been shown to provide adequate CMV disease prevention with less toxicity than 
prophylactic treatment (96-98). However, it is associated with delayed CMV immune 
recovery. Patients treated pre-emptively developed protection against CMV at a median 
time of 139 days compared to those that resolved CMV infection or did not have infection 
(median of 70 days) (86). 
Valganciclovir (VGC), which is an oral pro-drug of GCV, has also been found to be an 
adequate alternative to intravenous GCV for the prevention of CMV disease in 
haematopoietic transplant patients as its bioavailability is 10-fold higher (99); however 
its use is limited by neutropenia (100).  
An alternative to GCV is foscarnet, which is as effective as GCV (101). GCV and 
foscarnet have different toxicity profiles; GCV is associated with myelotoxicity whereas 
foscarnet produces nephrotoxicity. It has been shown that foscarnet causes less 
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neutropenia than GCV. Therefore, it should be used in the pre-emptive therapy against 
CMV infection for patient with neutropenia or developing neutropenia during therapy 
with GCV, however it also delays CMV immune reconstitution (86). Cidofovir is a new 
antiviral drug that can be used when patients fail the first-line of antiviral treatment (35, 
102).  
Newly available drugs are currently being studied for their potential as prophylactic 
treatment, such as maribavir which causes inhibition of viral encapsidation. In vitro 
studies have shown that maribavir is more potent than GCV against CMV. In a phase II 
dose-ranging study, it has been found that maribavir was safe and well tolerated and 
effectively reduced CMV infection after allo-HSCT, compared to placebo (103). 
However, it was also associated with an increase of adverse events, such as an increased 
incidence of taste disturbance, nausea and vomiting, but laboratory adverse effects were 
not more common than in placebo recipients. By contrast, in a phase III study (104), 
maribavir prophylaxis did not show superiority to placebo in prevention of CMV disease 
when started after engraftment. Instead, it only showed a modest antiviral effect in 
prevention of CMV reactivation. There were some explanations provided for the failure 
of the trial and further trials might be necessary to sufficiently test the potential of this 
antiviral drug. 
Brincidofovir (CMX001) is another available antiviral agent that has shown potent in vitro 
activity against CMV (105). It is converted intracellularly to cidofovir. It is not 
concentrated in renal proximal tubules and is unlikely to have renal toxicity. It has been 
shown to reduce the incidence of CMV events, as compared with placebo and no 
evidences of increased myelosuppression or nephrotoxicity were found. 
Letermovir is another antiviral drug that has been studied (106). Oral letermovir is 
currently in a phase II trial and seems to be a highly active anti-CMV agent with a novel 
mechanism of action compared to GVV, VGC, foscarnet and cidofovir. It provides a 
potential new treatment option for patients infected with CMV strains that are resistant to 
approved previous antiviral drugs. It reduces the incidence of CMV infection in allo-
HSCT, when comparing with the placebo and the incidence of neutropenia was similar to 
placebo (7% vs. 6%), which is quite different from neutropenia observed with VGC 
(58%). Further to this, it was found to be as safe as placebo, with no apparent safety 
concerns, such as haematological and renal toxicity. 
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Despite the need of prophylactic or pre-emptive treatment for CMV infection early after 
transplantation, life threatening complications are related to the, such as secondary 
bacterial and fungal infections (107, 108). The incidence of CMV disease within the first 
4 months in patients following allo-HSCT has been reduced due to the use of prophylactic 
and pre-emptive strategies to less than 5% (33, 109). These treatments, however,  can lead 
to myelosuppression, thrombocytopenia and other drug related toxicities such as renal 
and metabolic damage (35). However, approximately between 10%-30% of patients 
develop a delayed onset of CMV disease after 100 days post-transplant as a result of 
antiviral prophylaxis and early intervention (110, 111). This may be due to the resistance 
to the drugs, as they share similar mechanisms of action (112), or due to delayed 
reconstitution of CMV-specific T-cell responses, representing one of the leading causes 
of mortality after allo-HSCT (94, 113, 114). For all these reasons, many trials have 
assessed the effects of the combination of antiviral drugs with therapies based on infusion 
of virus-specific primed T cells (115). 
6.1 Viral-specific adoptive immunotherapy after allogeneic HSCT 
It has previously been demonstrated that there is correlation between levels of CMV-CTL 
responses and improved control of CMV viremia in immunocompromised HSCT 
patients. Looking at these observations, many groups have focused their interest on 
developing strategies for adoptive transfer of CMV-specific T cells. Previous studies have 
shown that infusion of donor-derived CMV-specific CD8+ T-cell clones or cell lines can 
successfully transfer protective immunity (116-118), and numerous in vitro studies have 
defined the best methodology for the expansion and selection of virus-specific T 
lymphocytes for clinical use. This includes: 1) classic ex vivo expansion, where T cells 
are stimulated with APCs that have been transduced with either a viral vector or plasmids 
encoding the antigens of interest; 2) multimer selection of the specific T cells with 
magnetic beads; 3) capture of T cells that secret cytokines after stimulation with viral 
antigens, allowing antigen-specific T-cell isolation by magnetic selection (119-123); 
methods based on genetic engineering that redirect the specificity of T cells, in order to 
make them recognize the antigen of interest, by the introduction of TCR genes or chimeric 
antigen receptors (124). Studies by Feuchtinger et al. and Einsele et al. have indicated the 
significance of antiviral effector functions of T-helper cells in maintaining CTL responses 
after adoptive transfer (117, 125). Few studies in phase I/II have demonstrated the 
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feasibility of transferring CMV-specific T cells whereby CMV-specific immune 
restoration can be accelerated without serious immediate infusion-related toxicities. 
However, some patients can develop GvHD after infusion, which is correlated with 
clinical protection (117, 118, 126, 127). 
These promising results confirm that cellular immunotherapy can accelerate recovery of 
antiviral immunity in allogeneic HSCT recipients, with important clinical benefits, such 
as reduction of secondary viral infection episodes (128, 129). 
6.2 Mesenchymal stem cells for treatment of CMV infection 
One of the primary complications in patients following allo-HSCT is the development of 
GvHD. Due to the lack of efficiency of existing methods for GvHD prophylaxis, new 
methods are being actively explored, including the use of donors’ multipotent 
mesenchymal stem cells (MSCs). These cells are fibroblast that can differentiate into 
osteoblasts, chondrocytes, adipocytes and myoblasts. MSCs exhibit extensive 
immunomodulatory activities and they affect a broad panel of immune cells of the innate 
and adaptive immunity. It has been demonstrated that upon stimulation with 
inflammatory cytokines, MSCs exhibit broad-spectrum antimicrobial effector functions 
directed against a range of clinically relevant bacteria, protozoal parasites and viruses; 
therefore, exhibiting a potent antimicrobial effector function (130). However, a later study 
has shown that CMV-infected MSCs lose their cytokine-induced immunosuppressive 
capacity and are no longer able to restrict microbial growth (131). Nevertheless, some 
researchers remain interested in the use of MSCs as treatment for viral infections and it 
is currently being evaluated the efficacy of MSCs is currently being evaluated in the 
treatment of refractory CMV infection after allo-HSCT in a clinical trial 
(https://clinicaltrials.gov/ct2/show/NCT02083731). 
 Detection methods for CMV presence and virus-specific T-cell responses 
Detection of early CMV replication is essential in order to initiate CMV antiviral 
treatment before CMV disease and related-complications occur. During the past years, 
several assays have been developed to detect the presence of CMV in blood and to 
measure antigen-specific T-cell responses, which can be compared, depending on their 
applicability in research and clinical monitoring. 
   Introduction 
 
 
29 
 
7.1 CMV antigenemia assay  
A CMV antigenemia assay has been commonly used for more than a decade for 
quantification of CMV in blood specimens (132, 133). Detection of the viral pp65 
antigen, a structural protein expressed in blood leukocytes during the early phase of the 
CMV replication cycle, has been performed in allo-HSCT recipients to guide pre-emptive 
therapy of CMV reactivation, preventing its progression to disease (134). The test result 
gives a quantitative measurement with a strong correlation between viremia and clinical 
disease severity. Nevertheless, looking at its use in the clinical practice it has several 
limitationss: samples should be processed within 6-8 hours of blood extraction, the result 
is influenced by leukocyte number and operator subjectivity. The lack of evidence to 
define breakpoints of the test and conflicting evidence on its sensitivity and specificity in 
detecting CMV disease provide the need in the search for newer testing methods that may 
be more reliable for clinical monitoring.  
7.2 Polymerase chain reaction 
The CMV specific polymerase chain reaction (PCR) has been established as a way to 
detect the presence of CMV DNA and to reduce the duration and side effects of antiviral 
therapy-based on patients following allo-HSCT (135). However, qualitative PCR may not 
discriminate latent CMV infection from replication CMV infection. The sensitivity of this 
technique has been shown to be 100% but the specificity for CMV disease was less than 
50% (136). Therefore new advances in this technique were developed in order to detect 
virus replication. 
Quantitative PCR (qPCR) is used to simultaneously amplify and quantify a targeted DNA 
molecule. The general principle of PCR is maintained but with the feature that the 
amplified DNA is detected as the reaction progresses in real time (137). This method is 
an important monitoring tool, being of increased sensitivity for detection of early viral 
replication, even during severe neutropenia. This method has been widely used for the 
monitoring of CMV reactivation in allo-HSCT patients in the early post-transplant period. 
It enable processing a great number of samples with high sensitivity in a short period of 
time. However, occasional unspecific reactions have led to false positive results and there 
is currently no clear agreement on the ideal cut-off for the diagnosis of active CMV 
infection. 
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Several authors have compared this method with the CMV antigenemia assay suggesting 
that qPCR could be more useful due to its effectiveness in monitoring CMV disease 
progression and in guiding therapy (138). Besides, qPCR could be more valuable for an 
early diagnose of CMV-gastrointestinal disease compared to the antigenemia assay (139). 
This method could therefore be useful not only for monitoring viral reactivation but also 
for establishing new preventive and therapeutic strategies against the virus (140). 
7.3 Intracellular cytokine staining  
Intracellular cytokine staining (ICS) is a flow cytometry-based method, which allows the 
determination of both the phenotype and cytokine-production, after stimulation with an 
antigen of interest, of individual cells (141, 142). This method allows the measurement 
of a broad spectrum of different phenotypic markers and cytokines at the same time. CD8+ 
or CD4+ antigen-specific T cells can be detected when using the respective antigens in a 
single assay (HLA-class I or HLA-class II restricted peptides, peptide pools or proteins) 
(143, 144). The detection limit of ICS is in the region of 0.1% or slightly lower, however, 
populations lower than 0.01% cannot be analysed as they would be within the background 
generated by spontaneous cytokine-secreting cells (145-147). This assay is commonly 
used by researchers to study CMV-specific immune recovery after allo-HSCT. Cells are 
stimulated with pp65 protein, CMV lysate or pp65/immediate early (IE)-1 peptides, and 
the production of IFN or TNF by CMV-specific CD8+ or CD4+ T cells is quantified.  
7.4 ELISPOT 
The enzyme-linked immunosorbent spot (ELISpot) assay allows the detection of 
individual cells secreting a particular cytokine. Cells are stimulated with the antigens of 
interest to detect antigen-specific cells in wells coated with anti-cytokine antibodies. The 
secreted cytokines can then be detected by using an enzymatically labelled agent and an 
insoluble chromogenic substrate reaction produces a spot at the side of each cytokine 
secreting cell (143, 148). The ELISpot analysis is the ex vivo assay with the lowest limit 
detection to identify cytokine-producing T-cells (146, 149). Moreover, this technique 
requires a 10-fold less blood sample volume than flow cytometry analysis and has the 
lowest background compared with other methods of measuring virus-specific cells, such 
as multimer or ICS. ELISpot assay has been used to monitor the reconstitution of CMV-
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specific T cells in allogeneic transplanted patients’ blood (150). It can be used to 
simultaneously screen a much higher number of samples with antigens of interest 
compared to other methods, as it is performed on 96-well plates (151). However, this 
method has some disadvantages. As it is not possible to determine the phenotype or the 
intra-cytoplasmic markers of the cytokine secreting cells, the specific cells cannot be 
isolated based on their physical characteristics. It also has long time-consuming protocols 
(i.e. 4 days) (94, 150, 152). Furthermore, ELISpots may underestimate the magnitude of 
the T-cell response (145, 148). There is also a certain degree of subjectivity in the 
interpretation of the results, as a threshold for the size, intensity and gradient of spots are 
user-defined. Several authors have used this methodology to monitor CMV-immune 
responses by measuring IFN production. In that sense, studies based on ELISpot and 
ICS have shown that CMV responses were only detectable at day 45 with ELISpot, 
compared to ICS (median response in patients with viremia of 82 spot-forming cells 
compared to 0% of both CD4+ and CD8+ CD69+IFN+) (153). Sukdolak and colleagues 
have shown that the detection of memory T cells with IFN-ELISpot assay correlates with 
the detection of IFN after stimulation with CMV pp65 epitopes (154). 
7.5 Multimer technology 
The development of multimer technology has been largely developed to monitor and 
purify T cells with a known antigenic specificity. The basis for this technology resides in 
the recognition of antigen-specific TCRs by a recombinant class I or class II molecule 
complex bound to a certain immunodominant peptide. Identification of antigen-specific 
CTLs regardless of their biological activity allows the preparation of a heterogeneous T-
cell population. This avoids previous phenotypic characterisations required for the 
identification of primed subpopulations with long-term survival capacities. 
Consequently, this staining technology allows the isolation of T cells with a given antigen 
specificity from seropositive donors without any further manipulation (128). This 
technique enables the visualization, enumeration, phenotypic characterisation and 
isolation of virus-specific CTLs from ex vivo samples. This technology enables to assess 
the dynamics of immune response to viral infections, allowing us to determine the 
frequencies of antigen-specific T cells. Multimer staining can be easily implemented in 
clinical routine of monitoring patients for immune reconstitution and the results are 
available within 2-3 hours. Besides, multimers enable the characterisation of T-cell 
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phenotype in ex vivo samples without requiring the alteration of phenotype by antigenic 
stimulation. It is possible to identify T cells that keep the T-cell receptor (TCR) but do 
not maintain their functional activity.  
Nowadays, there is a wide variety of available MHC multimer molecules, such as dimers, 
tetramers, pentamers (PMs), streptamers, dextramers and octamers (155). The most 
common format in use are MHC class-I tetramers, which are recombinant molecules 
formed by 4 MHC subunits that have been biotinylated. They are folded with the peptide 
of interest and tetramerized by a fluorescence-labelled streptavidin molecule (156). 
Tetramers (Figure 7A) are commonly used by researchers when studying the immune 
response to CMV in allo-HSCT recipients (77, 157, 158). However, the tetrahedral 
disposition of MHC molecules in the complex enables it to bind to just three TCR 
molecules at once, in comparison to PMs, which can bind to five TCRs at a time. PM 
complexes (Figure 7B) complexes contain five MHC class I subunits that are 
multimerized by a self-assembling coiled coil domain. All five MHC-peptide molecules 
face in the same direction resulting in a very high avidity interaction with the TCR. It also 
comprises up to five fluorescent or biotin tags for bright and efficient labelling compared 
to tetramer staining (159). PM has also been used to monitor CMV responses (160). More 
recently, reversible multimers, such as streptamers or histamers have been developed, 
allowing the dissociation of the multimer from the antigen-specific cell by adding a 
competitor molecule (161, 162). To constitute the streptamer (ST) complex (ST) (Figure 
7C), Strep-tags are fused to MHC-molecules forming MHC-I-Strep fusion proteins, 
which allow MHC oligomerization by joining to the Strep-Tactin structure that can be 
either fluorescently or magnetically labelled. These can be used for efficiently stain or 
isolate antigen-specific T cells (MHC Streptamer Manual, IBA, www.iba-
lifesciences.com). The addition of the competitor molecule D-biotin allows the 
monomerization of the MHC molecules that are spontaneously released from cell surface. 
These ST-selected specific-CTLs can either be expanded or cloned and then be adoptively 
transferred to the patient (163), offering a new therapeutic approach at good 
manufacturing practice. STs have been extensively used to identify and select CMV, EBV 
and Adenovirus-specific T cells from healthy donors. Their transfer to 
immunocompromised hosts has shown excellent results, and they are being tested in 
various clinical trials. 
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New advances in flow cytometry have shown the possibility of parallel detection of a 
multitude of different T-cell populations in a single sample by using a multidimensional 
encoding of MHC multimers (164, 165) enhancing the sensitivity of detection. 
However, while multimers are powerful research tools, they also have some 
disadvantages as multimer staining is HLA-specific and peptide-specific. Furthermore, it 
is not possible to assess the functional status of antigen-specific T cells. It is therefore 
necessary to combine multimer staining with other techniques, such as ICS to assess 
whether the virus-specific T cells detected are functional or not. The main limitation of 
multimer staining is MHC polymorphism requiring a multimer for each HLA allele would 
be necessary. In addition, for each allele, specific restricted epitopes have to be identified. 
Therefore, this technique is limited by available HLA alleles and known epitopes (143). 
Whilst there are various MHC class I molecules available, MHC class II multimers are 
more difficult to obtain presumably due to structural differences between class I and II 
molecules and low avidity of binding between the TCR and MHC class II-peptide 
complexes. Unfortunately, there is no good class II multimer available for CMV detection 
(152). 
All of these assays detect specific-T cells without in vitro expansion; but each assay has 
several advantages and disadvantages. As a summary, multimer analysis can detect 
peptide-specific T cells and characterise them phenotypically, however, it is limited to 
certain HLA alleles and does not provide functional activity information of the detected 
T cells. It is possible to analyse antigen-specific cytokine expression by using enzyme-
linked-immunosorbent-based assay (ELISA), ELISpot and qPCR (IFN, TNF, 
granzyme B), but the phenotype cannot be analysed at the same time. Besides, the time 
of performance of each assay varies between few hours (multimer) to several days 
(ELISpot). Taken these points together, it is not possible to definitively recommend one 
assay over the others due to the benefits each assay offers. Nevertheless, a combination 
of some of them could give a better idea of the behaviour of these cells.  
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Figure 7. Structure of MHC class I multimers. A) Tetramer complex consists of four MHC class I molecules 
that are biotynilated and bind to streptavidin fluorochrome-labelled. B) Pentamer complex contains five MHC 
class I molecules facing the same direction that are multimerized by a self-assembling coiled-coil domain. C) 
Streptamer complex consists of MHC molecules that are bound to Strep-Tactin by Strep-tag. 
7.5.1 Improving MHC class II detection 
The majority of the CMV-specific CD4+ T cell monitoring after transplantation is based 
on cytokine production following stimulation with viral lysates or peptides, or the use of 
T-cell clones (71). This is due to the lack of reagents, allowing analysis directly ex vivo 
at a single cell level.  
The development of class II multimers to characterise CD4+ T cells have shown much 
slower progress and have been less successful than MHC class-I multimers (166). One 
limiting factor is that as the - and -chain complex is formed irrespective of the antigenic 
peptide, the proportion of folded class II/peptide complexes in the preparation can be 
highly variable for different peptides. Another limiting factor is the binding affinity of 
antigenic peptides derived from tumour and self-antigens, which is generally lower than 
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that of peptides from pathogens (167). In peripheral blood, frequencies of antigen-specific 
CD4+ T cells are lower compared to CD8+ T cells: 10-3 to 10-4 for boosted cells, 10-4 to 
10-5 for resting memory cells and 10-5 to 10-7 for naïve cells (168, 169). Another limiting 
factor is the insensitivity of detection in ex vivo samples and paucity of defined CD4+ T-
cell epitopes with known HLA restriction. In the last years, more epitopes have been 
defined, so the utility of HLA class II tetramers is expanding (170). CMV-MHC class II 
tetramers have been previously studied without successful results, suggesting that it is 
necessary an enrichment step using magnetic beads to allow accurate definition of a 
responder population (171). Fortunately, the development of MHC class II multimer 
complexes is being encouraged by biotechnology companies (172) and some studies are 
now incorporating them for identification of CMV-specific CD4+ T cells upon in vitro 
stimulation (28, 173).
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Hypothesis 
Immunological monitoring of CMV-specific CD8+ T cells, in conjunction with virology 
monitoring after transplantation may allow prediction of CMV reactivation after allo-
HSCT and assess the risk of CMV-related complications. The characterisation of CMV-
specific CD4+ T cells by tetramer technology in healthy donors could help to identify 
their role in CMV reactivation control prior to its implementation in the monitoring of 
CMV following allo-HSCT. 
These are the aims of this thesis: 
1. To optimize new multimer approaches of detection of CMV-specific CD8+ T cells 
in order to select the best strategy for the incorporation into clinical monitoring 
practice. 
2. To correlate CMV-specific CD8+ T-cell levels and their functionality with CMV 
reactivation characteristics in allo-HSCT recipients. 
3. To characterise the phenotype and functionality of CMV-specific CD4+ T cells by 
direct staining with tetramer multimer ex vivo in healthy individuals prior to 
introducing it in CMV immune monitoring in allo-HSCT recipients. 
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 Healthy donors 
Samples from 34 healthy volunteers were used to compare two multimer staining 
techniques for the monitoring of CMV-specific CD8+ T cells. Repeatability, sensitivity 
and specificity was assessed for each technique before application in patient samples. 
Their characteristics are shown in Table 3. 
Table 3. HLA and CMV serology of healthy donors. 
Donor HLA restriction IgG CMV serology 
1 A*32, A*36 positive 
2 A*24, A*33 positive 
3 A*26, A*31 positive 
4 A*01, A*03 positive 
5 A*29, A*68 positive 
6 A*03, A*24 negative 
7 A*01, A*24 negative 
8 A*29, A*29 negative 
9 A*03, A*30 negative 
10 A*11, A*23 negative 
11 A*02:01, - negative 
12 A*02:01, A*24 negative 
13 A*02:01, A*24 negative 
14 A*02:01, A*03 negative 
15 A*02:01, - negative 
16 A*02:01, A*29 positive 
17 A*02:01, - positive 
18 A*02:01, A*01  positive 
19 A*02:01, A*24 positive 
20 A*02:01, A*30 positive 
21 A*02:01, A*24 positive 
22 A*02:01, A*24 positive 
23 A*02:01, A*33 positive 
24 A*02:01 positive 
25 A*02:01 positive 
26 A*02:01 positive 
27 A*02:01 positive 
28 A*02:01 positive 
29 A*02:01 positive 
30 A*02:01 positive 
31 A*02:01 positive 
32 A*02:01 positive 
33 A*02:01 positive 
34 A*02:01 positive 
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 Patients  
This research was approved by the Navarra Government Institutional Review Board. A 
total of 25 HLA-A*02:01 patients (median age, 42, range 24-65) who underwent allo-
HSCT between May 2010 and September 2014 were studied for CMV-specific T-cell 
reconstitution after written informed consent was obtained. We have performed the study 
in HLA-A*02:01-restricted recipients because approximately 30% of the Spanish 
population present this HLA restriction (by looking at http://www.allelefrequencies.net/). 
Patients were recruited from the Haematology Service from the Complejo Hospitalario 
of Navarra (CHN). All donor-recipient pairs were typed at the allelic level for HLA class 
I and class II loci on DNA samples by reverse PCR-sequence specific oligonucleotide 
(SSO) methodology (LifeMatch assay; Gen-Probe, Inc., Stamford, CT) and for high-
resolution by direct sequencing (AlleleSEQR assay; Abbot Labs, Des Plaines, IL) at the 
Immunology Unit from CHN. Before transplantation, serological screening of IgG and 
IgM for CMV was developed by using a chemiluminescent microparticle immunoassay 
in the Architect system (Abbot Laboratories) at the Microbiology Service of CHN. Values 
of more than 6 arbitrary units (AU)/mL were considered as positive for CMV serology. 
Routine PCRs were also performed by using qPCR serum samples from recipients by 
using a thermocycler (Smartcycler, Cepheid). Demographic and clinical characteristics 
of each patients are list in Table 4. 
2.1 Monitoring of CMV viral load, pre-emptive therapy and schedule of T-cell 
monitoring 
Monitoring of CMV viral load in whole blood was performed by qPCR (Cepheid, Izasa, 
Scientific) methodology. From the day of transplant viral load was assessed by PCR on a 
weekly basis from months 1-3 post-transplant, on a biweekly basis months 4-6 post-
transplant. Thereafter, patient CMV viral load is assessed on a monthly basis. In addition, 
PCR was performed weekly during reactivation, or during continuous high 
immunosuppressive therapy when GvHD was developed. No patient received CMV 
prophylaxis. Pre-emptive therapy was initiated when viral loads above 500 copies/mL 
were detected. Patients were treated with intravenous (i.v.) ganciclovir (5 mg/kg/12h) or 
oral (p.o.) valganciclovir (900 mg/12h) for 2 weeks. Maintenance dose of i.v. ganciclovir 
(5 mg/kg/day) or p.o. valganciclovir (900 mg/day) for additional 1-2 weeks was 
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administered. Foscarnet (i.v. 90 mg/kg/12h) was added to the therapy schedule or used to 
replace ganciclovir or valganciclovir after initiation of pre-emptive therapy in case of 
neutropenia (<1.0 x 109/L) or increasing DNA-viremia (DNAemia) despite therapy. Pre-
emptive therapy was discontinued after negative PCR result or a clinically significant 
decrease in viral load. Cidofovir (i.v. 3-5 mg/kg/week) was administered to three patients 
to treat either CMV disease or CMV resistance to antiviral drugs. 
Table 4. General characteristics of each patient analysed. 
Patient Sex Age 
Type of 
HSCT 
Donor/patient 
CMV serology 
Conditioning 
treatment 
1 F 43 SIB pos/pos RIC 
2 F 41 URD neg/pos MAT 
3 F 33 URD neg/pos RIC 
4 M 55 SIB pos/pos MAT 
5 F 32 SIB pos/pos MAT 
6 F 64 SIB pos/pos RIC 
7 M 58 URD neg/pos RIC 
8 M 57 URD pos/pos MAT 
9 F 39 URD pos/pos MAT 
10 M 27 SIB neg/pos MAT 
11 M 44 URD neg/pos MAT 
12 F 65 SIB pos/pos RIC 
13 M 65 SIB pos/pos RIC 
14 F 30 SIB pos/neg RIC 
15 F 52 URD neg/pos MAT 
16 M 39 URD pos/pos MAT 
17 F 24 haplo pos/pos RIC 
18 M 34 URD pos/pos RIC 
19 M 39 haplo pos/pos RIC 
20 M 37 URD pos/pos MAT 
21 M 53 SIB neg/pos RIC 
22 F 28 URD pos/pos RIC 
23 M 47 SIB pos/pos RIC 
24 F 64 URD pos/pos RIC 
25 M 42 URD neg/pos MAT 
M = male; F = female; SIB = sibling; URD = unrelated donor; haplo = haploidentical donor; 
pos = positive; neg = negative; RIC = reduced intensity conditioning; MAT = myeloablative 
treatment. 
Immunologic monitoring was performed every 15 days post-transplant until day +90, 
monthly until day +200 and every two months to complete the year follow up. A total of 
330 blood samples from the 25 patients (median 13 samples; range 4-24 samples) were 
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analysed. One patient withdrew from the study after two months post-transplant and 5 
patients died before the 1 year follow up. 
2.2 Management of patients for HSCT 
All patients but one received progenitor cells following mobilization from donor 
peripheral blood, and only one patient received donor BM cells. MA conditioning 
regimen was performed in 11 patients and 14 patients received RIC regimen. GvHD 
prophylaxis consisted of Cs-A associated with MTX for patients receiving and HLA-
identical sibling allograft. Patients transplanted from an unrelated donor were given 
alemtuzumab on days -10 to -5 before transplantation in addition to Cs-A and short-term 
MTX. Acute GvHD, developed in 11 patients, was initially treated with steroids, whereas 
patients with steroid-resistant disease received MMF (n=3) and mesenchymal stromal 
cells (n=3). 
 Blood sampling 
Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-PaqueTM separation 
solution (GE Healthcare Bio-Sciences, Uppsala, Sweden) density gradient centrifugation 
from ethylendiaminetetraacetic acid (EDTA) anticoagulated blood samples. A total of 15 
mL of blood was extracted at each time point from patients. The viability of PBMCs was 
always >95%, as determined by Trypan blue staining (0.4% Trypan Blue Solution; Gibco, 
Carlsbad, CA) using a Neubauer chamber (Hausser Scientific, Horsham, PA). 
A Detection of CMV-specific CD8+ T cells 
 CMV-specific CD8+ T-cell detection by multimer staining 
Two available strategies of multimerization directed against the epitope NLVPMVATV 
(495-503) of the CMV pp65 protein in the context of HLA-A*02:01 were used: 
Pentamer 
Pentamer (PM) complex (Figure 3B), HLA-A*02:01/CMVpp65495-503 PM*phycoerythrin 
(PE) that was synthesized at Proimmune (Oxford, UK). 
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Streptamer 
Streptamer (ST) molecule (Figure 3C), HLA-A*02:01/CMVpp65495-503 ST*PE which 
was synthesized at IBA (Gottingen GmbH, Germany). To constitute the ST complex, 0.75 
g PE-labelled Strep*Tactin were combined with 0.5 g of HLA-A*02:01/STpp65495-503 
for 45 minutes at 4ºC in the dark. 
1.1 Multimer staining optimization 
A total of 1 x 106 human PBMCs were blocked with AB serum to avoid non-specific 
binding between MHC-multimers and FcR expressed on CD14 and CD19 cells (174). 
After washing, cells were incubated with 5 L PM or 0.2 g ST complex and incubated 
for 10 minutes at room temperature (RT) or 45 minutes at 4ºC in the dark, respectively. 
Both, multimer concentrations’ used and incubation times were optimised previously in 
our laboratory (unpublished data). For multiparametric analysis, anti-CD3*HorizonV450 
(Beckton Dickinson (BD), Heidelberg, Germany), anti-CD8* fluorescein isothiocyanate 
(FITC) and anti-CD45*peridin chlorophyll protein (PerCP-Cy5.5) monoclonal anti-
human antibodies (Ab) (Biolegend, San Diego, CA) were added at RT for 15 minutes or 
20 minutes at 4ºC in the dark, respectively. After lysis with PharmlyseTM Lysing buffer 
(BD) to eliminate residual red blood cells, stained cells were acquired in a FACSCanto II 
flow cytometry (BD) equipment with FACSDiva 6.0 software (BD). A minimum of 
500,000 events were acquired in all cases. Viable lymphocytes were gated based on their 
forward-scatter (FSC) and side-scatter (SSC) distribution and CD45 expression. 
CD3+CD8+ CTLs were gated and PM+CD3+CD8+ and ST+CD3+CD8+ percentages were 
determined.  
The repeatability, correlation, sensitivity and the specificity of both multimers’ 
techniques were evaluated in order to select the best strategy for the incorporation into 
clinical monitoring practice. 
1.1.1 Repeatability analysis 
Repeatability was examined by taking several measurements on a series of subjects. Then 
calculating the standard deviation between the repeated measures obtained for each 
subject. The variability observed between the independent values refers to the precision 
of the method. Therefore, in order to determine both the repeatability and the precision 
of PM and ST techniques, the frequency of CMV-specific CD8+ T cells was evaluated in 
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6 HLA-A*02:01, CMV-seropositive and multimer-positive healthy donors per 
multimeric complex (n = 12). For each subject, six tubes were stained with either PM or 
ST multimers as described previously and percentages of CD3+CD8+PM+ and 
CD3+CD8+ST+ were determined. 
1.1.2 Sensitivity assay 
Correlation between both multimer staining was evaluated in 18 HLA-A*02:01 and CMV 
seropositive healthy volunteers. In order to compare the sensitivity of the quantification 
of CMV-specific T cells by each multimer (PM and ST), PBMCs from 5 HLA-A*02:01 
CMV seropositive healthy donors were serially diluted with PBMCs from HLA-A2 
negative healthy donors. CMV-specific cells were analysed and quantified as previously 
described according to CD3+CD8+PM+ or CD3+CD8+ST+ frequencies. The obtained 
results were compared with theoretical values of virus-specific T cells.  
1.1.3 Specificity analysis 
Specificity of PM and ST was tested in order to demonstrate that both multimers bind to 
CMV-specific CTLs with HLA-A*02:01 restriction. A total of 20 subjects with different 
HLA antigen expression and CMV-specific serological status combination were 
included: 5 HLA-A*02:01 and CMV seronegative, 5 HLA-A*02:01 negative and CMV 
seropositive, 5 HLA-A*02:01 negative and CMV seronegative and 5 HLA-A*02:01 
positive and CMV seropositive. PBMCs were stained with PM and ST complex as 
described above and CD3+CD8+PM+ and CD3+CD8+ST+ frequencies were quantified.  
 CMV-specific CD8+ T cells monitoring by multimer’s staining 
Both multimers were used in order to monitor CMV immune recovery. A total of 1 x 106 
human AB serum-blocked PBMCs were incubated with either 5 L PM or 0.2 g ST 
complex and incubated for 10 minutes at RT or 45 minutes at 4ºC in the dark, respectively. 
For multiparametric analysis, anti-CD3*HorizonV450 (BD), anti-CD4*allophycocyanin 
(APC), anti-CD8*FITC and anti-CD45*PerCP-Cy5.5 monoclonal anti-human Ab 
(Biolegend) were added at RT for 15 minutes or 20 minutes at 4ºC in the dark, 
respectively. After lysing with PharmlyseTM Lysing buffer (BD), stained cells were 
acquired in a FACSCanto II flow cytometry (BD) equipment with FACSDiva 6.0 
software (BD). A minimum of 500,000 events were acquired in all cases. Cells with 
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lymphocyte morphology were gated based on their FSC and SSC distribution and CD45+ 
expression. CD3+CD8+ CTLs were gated and PM+CD3+CD8+ and ST+CD3+CD8+ 
percentages were determined. Absolute numbers of multimer-staining cells were 
quantified using total lymphocyte counts from clinical laboratory analysis by using a cell 
counter (Beckman Coulter) and additional flow cytometry quantification of CD8+ T-cell 
frequencies. The absolute number of multimer stained cells was calculated as the product 
of the following: (lymphocyte count)x(frequency of CD3+ cells co-expressing CD8+ in 
the lymphocyte CD45+ gate)x(frequency of multimer stained cells in the CD8+ T-cell 
subset). 
 CMV-specific CD8+ T-cell detection by intracellular cytokine staining 
To assess cytokine expression by CMV-specific CD8+ T cells, 2 x 106 PBMCs from 
patients were incubated with 10 g/mL of pp65495-503 peptide (Proimmune, Oxford, UK) 
for 1 hour at 37ºC. Unstimulated PBMCs were used as negative control. Afterwards, cells 
were incubated in the presence of brefeldin A (10 g/mL, Sigma-Aldrich, St Louis, MO, 
USA) for 5 hours at 37ºC. Following incubation, cells were washed with cold phosphate 
buffer saline (PBS) and then re-suspend in 200 L of 0.02% EDTA (Sigma-Aldrich) for 
15 minutes at 37ºC. Cells were then fixed using FACS Lysing solution/FACS Perm (BD) 
according to the manufacturer’s instructions. Following fixation and permeabilization, 
cells were washed and stained with anti-CD3*HorizonV450 (BD), anti-CD8*FITC and 
anti-CD45*PerCP-Cy5.5 (Biolegend) and the intracellular marker anti-IFN*APC (BD) 
monoclonal anti-human antibodies for 30 minutes at RT. After washing in PBS, cells 
were analysed by flow cytometry. A minimum of 200,000 events were acquired in all 
cases. Cells with lymphocyte morphology were gated based on their FCS and SSC 
distribution and CD45+ expression. The percentage of IFN-producing CD8+ T cells was 
determined. The absolute number of IFN-staining cells was calculated as the product of 
the following: (lymphocyte count) x (frequency of CD3+ cells co-expressing CD8+ in the 
lymphocyte CD45+ gate) x [(frequency of IFN-staining cells in the CD8+ T-cell 
subset)activated cells - (frequency of IFN-staining cells in the CD8+ T-cell subset)control cells]. 
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 Detection of INF secreting cells by pentamer-positive cells 
Cytokine secretion assay was developed in 9 patients. The assay was performed according 
to manufacturer’s instructions (IFN Secretion Assay-Detection Kit, Miltenyi Biotec). 
Briefly, 1 x 106 PBMCs were stained with HLA-A*02:01/CMVpp65495-503 PM*PE for 1 
hour at 4ºC. After washing, cells were stimulated with 10 g/mL of pp65495-503 peptide 
for 2 hours at 37ºC. Unstimulated PBMCs served as negative control. Cells were then 
stained for IFN-secretion for 90 minutes at 37ºC. After washing, cells were stained with 
anti-CD3*Horizon V450, anti-CD8*FITC and anti-IFN*APC for 10 minutes at 4ºC. 
Cells were lysed before being acquired using flow cytometry. A minimum of 500,000 
events were analysed in all cases. Viable lymphocytes were gated based on their FCS and 
SSC distribution. The percentage of IFN-production by PM+ CD8+ T cells was 
determined. The absolute numbers of PM+IFN+-staining cells were calculated as the 
product of the following: (lymphocyte count) x (frequency of CD3+ cells co-expressing 
CD8+ in the lymphocyte gate) x (frequency of PM+IFN+-staining cells in the CD8+ T-
cell subset). 
B Phenotypic characterisation of CMV-specific CD4+ T cells 
 Healthy donor characteristics 
The study was approved by the West Midlands Research Ethics Committee. A total of 55 
blood samples were obtained from healthy donors after informed consent was obtained. 
The donor cohort was split into three groups according to their age: young (18-40 years), 
middle aged (41-60 years) and older adults (over 60 years). 
 Blood sampling 
PBMCs were isolated by density gradient centrifugation using LympholyteR-H cell 
separation media (Cedarlane laboratories, Canada) from 20-120 mL of heparin 
anticoagulated blood samples. Vials of 10x106 cells were cryopreserved in RPMI (Sigma, 
Aldrich) containing 20% fetal calf serum (FCS) and 10% dimethyl sulfoxide (DMSO) 
(Fisher Scientific).  
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 Anti-CMV antibodies detection in whole blood 
CMV serostatus of healthy donors was evaluated by an ‘in house’ CMV-ELISA. Each 
plate was prepared with both negative control (mock lysate) and the CMV lysate (UV-
inactivated) diluted 1/4000 carbonate-bicarbonate buffer (Sigma-Aldrich). Fifty 
microliters of diluted mock lysate or CMV lysate were added into each well, using a 96 
well Nunc MAXISORP plate, and incubated overnight (o/n) at 4ºC in a sealed plated. The 
following day, the standard curve was made using serum from three pooled CMV 
seropositive healthy donors. The highest concentration was a 1/5 dilution from this 
positive mixture using PBS + 1% BSA (Sigma-Aldrich) + 0.05% TWEEN (Life 
Technologies) and subsequently, serial dilutions 1/4 were performed to provide a standard 
curve. Both samples and the standard curve were diluted 1/60 in PBS + 1% BSA + 0.05% 
TWEEN before addition to the plate. The ELISA plate was washed 3 times with washing 
buffer (PBS + 0.05% TWEEN) before adding the samples and the standard curve in a 
final dilution of 1/600 and incubated for 1 hour at RT. The plate was again washed 3 times 
before addition of 100L of the anti-IgG-HRP conjugated detection antibody (Southern 
Biotech). A final dilution of 1/8000 of this antibody was incubated for 1 hour at RT. A 
further 3 wash steps were performed before addition of 100L of the 
tetramethylbenzidine (TMB) substrate solution (eBiosciences). Substrate was incubated 
on the plate for 15 minutes at RT in the dark. The reaction was stopped by addition of 
100L of 1 M Hydrochloric acid (HCl) (Sigma-Aldrich). The plate was read at 450nm in 
a spectrophotometer within 20 minutes to prevent degradation of values obtained. IgG 
values over 10 were considered as seropositive for CMV. 
 Genomic DNA extraction and genotype HLA class-II 
4.1 DNA extraction 
Genomic DNA of CMV-seropositive donors was isolated from PBMCs according to 
manufacturer’s instructions (GenEluteTM Blood Genomic DNA Kit, Sigma-Aldrich). 
Briefly, PBMCs were incubated with proteinase K and lysis solution for 10 minutes at 
55ºC to ensure efficient cell lysis and DNA release. After adding ethanol to the lysate, 
samples were transferred to the columns and centrifuged. The flow-through liquid was 
discarded and two consecutives washes were performed. To eliminate all the ethanol, the 
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column was air dried. Samples were eluted from the column by addition of RNAase-
DNAase free water. DNA eluted from the column was quantified and purity assessed 
using the nanodrop spectrophotometer. 
4.2 HLA class-II determination by PCR 
Class-II PCR was performed as previously described (175). It consists of a method 
developed for DNA typing which uses sequence-specific primer (SSP) reactions to detect 
DRB1, DRB3 and DQB1 specificities. Our HLA of interest are DRB1*07:01, 
DRB3*02:02 and DQB1*06:02 (referred here as DR7, DR52b and DQ6, respectively). 
In Table 5 it is shown the primers used for each HLA-PCR. Donors’ HLA restrictions are 
shown in Table 6. 
Table 5. HLA class-II PCR conditions 
HLA-type Sense 5’3’ Anti-sense 5’3’ 
DR7 CCTGTGGCAGGGTAAGTATA CCCGTAGTTGTGTCTGCACA
C 
DR52b GGAGTACCGGGCGGTAGAG CGTATGCAGACACAACTACC
A DQ6 
TTTCGTGCTCCAGTTTAAGGC/ 
GACGTGGGGGTGTACCGC 
CCGCGGAACGCCACCTC 
DQ6 GGAGCGCGTGCGTCTTGTA 
TGCACACCGTGTCCAACTC/ 
TGCACACCCTGTCCACCG 
Table 6. Characteristics of the 55 healthy donors analysed. 
Donor 
No. of 
donors 
HLA-type 
Median age 
(range) 
Young 
(20-40 years) 
11 DR7 
30 (25-39) 3 DR52B 
2 DQ6 
Middle aged 
(40-60 years) 
9 DR7 
49 (45-59) 12 DR52B 
5 DQ6 
Older adults 
(over 60 years) 
9 DR7 
73 (61-87) 2 DR52B 
2 DQ6 
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 CMV-specific CD4+ T-cell cloning 
Requirements for CD4+ T-cell cloning: 
- B-lymphoblastic cell lines with the proper HLA restriction (DR7, DR52b or DQ6) 
- PBMCs from 3 different donors to serve as feeder cells 
- CMV-specific CD4+ T cells from CMV seropositive donors with DR7, DR52b 
and DQ6 restriction  
5.1 B-Lymphoblastic cell line (LCL) generation 
A total of 5 x 106 PBMCs from healthy donors were plated in 24-well plates containing 
RPMI media supplemented with 10% heat inactivated FCS, 1% L-glutamine, 
1%penicillin/streptomycin and 1g/mL of the immunosuppressor Cs-A (Sandoz 
Pharmaceuticals Inc, Washington, DC). Concentrated supernatant from B95-8 cultures, a 
human type I EBV-transformed B-cell line, was added for infection. Once B95-8 infected 
LCL were established, they were expanded into 25cm2 flasks with LCL media (RPMI + 
10% FCS).
5.2 PBMCs isolation  
PBMCs were obtained by ficoll-hypaque density gradient centrifugation as described in 
section B2. PBMCs from 3 different healthy donors were filtered before isolating 
PBMCs. PBMCs from each buffy coat cell were re-suspended in 50mL of LCL media in 
a 75cm2 flask. PBMCs were stimulated with 10g/mL of phytohaemaglutinin (PHA) at 
37ºC o/n. The following day, PBMCs were washed 3 times in LCL media and re-suspend 
in 30mL of media prior to -irradiation with 4000rads (CIS Bio International, IBL 437C). 
After irradiation, the pooled PBMCs were washed twice with LCL media and counted. 
5.3 IFN capture of CMV-specific CD4+ T cells 
Before performing the selection of the IFN-secreted cells, a CD8+ T-cell depletion was 
performed using anti-CD8 Dynabeads (Invitrogen). PBMCs were re-suspended in 2 mL 
of RPMI media in a 15mL tube and incubated with anti-CD8 dynabeads. It is assumed 
based on manufacturer’s instructions that 1/3 of the cell population will be CD8+ T cells, 
therefore 4 beads per cell are added to the tube prior to incubation at 4ºC. Then, 3 mL of 
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RPMI were added and the tube was placed in a magnet. The supernatant from this 
isolation was collected and a twice more with 5 mL of media. Resultant isolated cells 
were counted and pelleted at 2000g. After CD8+ T-cell depletion, cells were stimulated 
in a 15mL tube with 5 mg/mL of gB217-227, pp6541-55 or pp65489-503 peptides for 3 hours at 
37ºC. After washing with cold RPMI media for 10 minutes at 4ºC and 2000g, cells were 
re-suspended in 80L of cold media and stained for IFN production according to 
manufacturer’s instructions (IFN Secretion Assay-Detection Kit, Miltenyi Biotec). 
Briefly, cells were incubated with 20L of the IFN catch reagent for 5 minutes on ice. 
Then, cells were incubated lying horizontally on a rotator at 37ºC for 45 minutes with 
10mL of warm media. After washing, cells were stained with the IFN detection antibody 
PE-conjugated for 10 minutes on ice. Cells were then washed and stained with anti-PE 
microbeads for 20 minutes at 4ºC. Cells were washed again, then re-suspended in L 
of cold buffer (PBS supplemented with 0.5%BSA and 2mM EDTA). Subsequently, a MS 
column (Miltenyi Biotec) was placed in a magnetic field of a MACs separator. The 
column was rinsed with L of cold buffer and the effluent was discarded. The 
magnetically labelled cells were applied to the column and allowed to pass through by 
gravity flow. Three washes with L of cold buffer were performed and the collected 
effluent was the negative fraction. Afterwards, the column was removed from the magnet 
and 1mL of cold buffer was added to the column. By using a plunger, the retained cells 
were firmly flushed out from the column and the positive CD4+ T cells specific for gB217-
227, pp6541-55 or pp65489-503 peptides were obtained. 
5.4 Limiting dilution cloning 
IFN-producing CD4+ T cells following stimulation with CMV epitopes were sorted into 
96-well plates by seeding at 0.3 cell/well or 3 cells/well. For each condition, ten 96-well 
V-bottom plates were prepared. A total of 10 x 106 peptide-pulse -irradiated LCL, 100 x 
10 -irradiated pre-activated buffy cells and either 300 CMV-specific CD4+ T cells 
(gB217-227, pp6541-55 or pp65489-503 specific) for condition of 0.3 cells/well or 3000 CMV-
specific CD4+ T cells for condition of 3 cells/well were needed and make up to 100 mL 
with media (RPMI supplemented with 10% FCS, 5% human serum and 1% 
penicillin/streptomycin). Then, 100 L per well were plated out and cells were incubated 
for 3 days at 37ºC. After 3 days of incubation, 100 L of media (RPMI supplemented 
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with 10% FCS, 5% human serum, 1% penicillin/streptomycin, 30% supernatant from the 
MLA144 cell line (176, 177) and 50 U/mL recombinant IL-2) was added per well and 
clones were left growing during 3 weeks before testing. MLA144 cell line was a 
lymphoblastoid line established from a spontaneous lymphosarcoma of the gibbon. It 
supports the growth of T cells as it constitutively produces IL-2, IL-3 and TGF. 
5.5 Specificity of CMV-specific CD4+ T-cell clones 
After 3 weeks in culture, specificity of potential CMV-specific CD4+ T cell clones was 
assessed. For that purpose, autologous HLA-matched LCLs from CMV-seropositive 
donors were pulsed with either 5 g/mL of the specific CMV-peptide (gB217-227, pp6541-
55 or pp65489-503) or DMSO solvent (the carrier agent for the CMV-peptides and therefore 
they would be the negative control) in 1mL of LCL media, for 2-3 hours at 37ºC. A total 
of 50 L of cell suspension of each clone were transferred into V-bottom microtest plate 
wells. After washing, cells were split out into 4 wells and duplicates of each clone-
analyses were performed (two wells with DMSO-pulsed LCLs and two wells peptide-
pulsed LCLs). A total of 5 x 104 stimulated-LCLs/well were added. Cells were left over 
night (o/n) for IFN production. 
5.5.1 INF production by CMV-specific CD4+ T cells detection by ELISA. 
IFN production of clones was evaluated by an in house IFN-ELISA. Briefly, ELISA 
plates were coated o/n with the primary antibody (IFN clone 2G1, Fisher Scientific) in 
a 1/1333 dilution with coating buffer (0.1M NaHPO4 buffer, pH=9). Before addition of 
sample, plates were blocked with 50 L of PBS + 1% BSA + 0.05% TWEEN per well 
for 1 hour. A standard curve was constructed by serial dilution from a known stock 
concentration of recombinant IFN. After washing 3 times, 50 L of the IFN standard 
curve or the supernatant from the LCL-stimulated clones were added and incubated for 2 
hours. After 6 times washes, the secondary antibody (IFN clone 2G1 biotin-labelled, 
Fisher Scientific) was added at a dilution of 1/1333 and incubated for one hour at RT. Six 
more washes were performed before incubation with streptavidin-peroxidase (Sigma-
Aldrich) at a concentration of 1/1000 for 30 minutes. Plates were washed a final 3 times 
before incubation with 100L per well with TMB substrate for 30 minutes. The reaction 
was stopped by addition of 100L 1M HCl. Absorption was measured at 450nm by a 
spectrophotometer.  
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 Detection of CMV-specific CD4+ T cells by multimer staining 
Tetramer 
Class-II tetramer staining is more technically challenging than class-I as antigen-specific 
CD4+ T cells are less common than antigen-specific CD8+ T cells and the affinity between 
the T-cell receptor and HLA-peptide complex is generally lower. MHC class II tetrameric 
complexes were purchased from Benaroya Research Institute at Virginia Mason (Seatle, 
Washington). The three available tetramers were directed against the epitope 
DYSNTHSTRYV (217-227) of the CMV glycoprotein B (gB) in the context of HLA-
DRB1*07:01 (DR7) restricted (27), or against the epitope AGILARNNLVPMVATV 
(489-503) of the CMV phosphoprotein 65 (pp65) in the context of HLA-DRB3*02:02 
(DR52b) (26) restricted or against the epitope LLQTGIHVRVSQPSL (41-55) (25) of the 
CMV pp65 in the context of HLA-DQB1*06:02 (DQ6) restricted (Figure 8). 
 
Figure 8. Structure of MHC class-II tetramers. 
6.1 Tetramer sensitivity assay 
To assess the sensitivity of the tetramers, 1 x 106 PBMCs from CMV-seronegative healthy 
donors DR7, DR52b or DQ6-restricted were mixed with decreasing amounts of CD4+ T-
cell clones (5%, 1%, 0.5%, 0.25%, 0.1%) specific for DYS, AGI or LLQ epitopes, 
respectively. In addition, the CD4+ T-cell clone alone and PBMCs from the CMV-
seronegative donor were also analysed. Cells were stained with LIFE/Dead fixable violet 
stain (Invitrogen) for 15 minutes at RT. After washing with PBS, cells were re-suspended 
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in 50 L of human serum and incubated with 0.5 L of the PE-conjugated MHC class II 
tetramer (DR7, DR52b or DQ6) for 1 h at 37oC and 5% CO2. Cells were then washed and 
subsequently co-stained with surface monoclonal anti-CD4*PerCP-Cy5.5 (eBioscience) 
antibody. All stained cells were acquired using a LSRII flow cytometer (BD) and all data 
were processed using Kaluza 1.3 software (Beckman Coulter). At least, 300,000 viable 
single lymphocytes were analysed in all cases. Viable single lymphocytes were gated 
based on their FSC and SSC distribution, from those, CD4+ T cells were gated and 
CD4+tetramer+ percentages were determined.  
6.2 CMV-specific CD4+ T-cells phenotype 
Donor PBMCs were thawed in warm RPMI, counted and re-suspended in PBS. A total 
of 1 x 106 PBMCs were stained with LIVE/Dead fixable violet stain (Invitrogen) for 15 
minutes at RT. Cells were washed with PBS and re-suspended in 50 L of human serum 
and incubated with 0.5 L of the PE-conjugated MHC class II tetramer (DR7, DR52b or 
DQ6) for 1 h at 37oC and 5% CO2. Cells were then washed and subsequently co-stained 
with surface monoclonal anti-human antibodies (Table 7) for 15 minutes at 4oC and then 
washed.  
Table 7. Panels of CMV-specific CD4+ T-cell phenotyping. 
phenotype 
mAb Company  mAb Company 
CD14*Pacific Blue (Biolegend) 
exhausted 
CD14*Pacific Blue (Biolegend) 
CD19*Pacific Blue  (eBioscience) CD19*Pacific Blue  (eBioscience) 
CD3*AmCyan  (BD) CD3*AmCyan (BD) 
CD4*PerCP-Cy5.5  (eBioscience) CD4*PE-CF594 (BD) 
CD27*APC-eFluor780  (eBioscience) CD45RA*Alexa 
Fluor700  
(Biolegend) 
CD28*PE-Cy7  (Biolegend) CD69*PE-Cy7  (Biolegend) 
CD45RA*Alexa Fluor700  (Biolegend) CCR7*FITC  (R&D) 
CD45RO*PE-CF594  (Biolegend) PD-1*PerCP-Cy5.5  (Biolegend) 
CD57*APC  (Biolegend) Tim-3*APC  (eBioscience) 
CCR7*FITC  (R&D)    
cytotoxic 
CD14*Pacific Blue  (Biolegend) 
regulatory 
CD14*Pacific Blue  (Biolegend) 
CD19*Pacific Blue  (eBioscience) CD19*Pacific Blue  (eBioscience) 
CD3*AmCyan   (BD) CD3*AmCyan  (BD) 
CD4*PE-CF594  (BD) CD4*PE-CF594  (BD) 
CX3CR1*PerCP-Cy5.5 (Biolegend) CD25*APC-Cy7  (Biolegend) 
FasL*AF488  (AbD Serotec) CD127*PerCP-Cy5.5 (BD) 
GranzymeB*AF647  (Biolegend) FoxP3*AF647  (Biolegend) 
Perforin*PE-Cy7  (eBioscience)   
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For the detection of intracellular perforin and granzyme B, cells were fixed by addition 
of 4% paraformaldehyde/PBS for 15 minutes at RT in the dark after surface staining was 
performed. Anti-perforin*PE-Cy7 (eBioscience) and anti-granzyme B*AF647 
(Biolegend) were added to the cells in the presence of 0.5% saponin (Sigma) in PBS, for 
30 minutes at RT in the dark and then washed. 
For the detection of intracellular FoxP3, cells were stained with surface markers and after 
washing they were fixed for 30 minutes using 1X Fix/Perm buffer (eBioscience). Cells 
were washed and permeabilized in Perm buffer (eBioscience) for 15 minutes in the dark 
and subsequently anti-FoxP3*AF647 (Biolegend) was added for 30 minutes at RT in the 
dark following one wash. 
All stained cells were acquired using a LSRII flow cytometer (BD) and all data were 
processed using Kaluza 1.3 software (Beckman Coulter). A minimum of 300,000 viable 
single lymphocytes were analysed in all cases. Viable single lymphocytes were gated 
based on their FSC and SSC distribution, from those CD3+CD4+ T cells were gated and 
CD3+CD4+tetramer+ percentages were determined. 
 Statistics analysis 
Descriptive data are presented as mean with standard deviation for parametric data and 
median with median range for non-parametric data. Normality was studied with 
Kolmogorov-Smirnov test. Statistical analyses were performed by using parametric test 
(t-test) and non-parametric test (U-Mann Whitney and Kruskal-Wallis). To assess both 
the repeatability and sensitivity of each multimer technique two mixed effects models 
were performed by using statistical package R 2.13.1. Log-rank or Breslow tests were 
used for cumulative incidence of CMV reactivation during the first year after allo-HSCT. 
For correlation analyses the Spearman rank test was used. For correlation between the 
predicted positive values and the obtained with class II tetramers the Intraclass 
Correlation Coefficient (ICC) was used. For evaluation of both number of cells before 
and after reactivation and IFN production measured by ICS and the commercial kit, 
paired-Wilcoxon test was used. All p-values were two-tailed and values less than 0.05 
were considered statistically significant. Statistical analyses were performed by using 
SPSS v.13 for Windows and GraphPad Prism 5.03. 
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A Detection of Cytomegalovirus-specific CD8+ T cells 
 Technique’s optimization 
As described in Materials and Methods (section A1), a total of 34 healthy volunteers were 
used in order to optimize the techniques (PM and ST) that are used for the monitoring of 
CMV-specific CD8+ T cells immune recovery in allo-HSCT recipients. For that purpose, 
the repeatability, sensitivity and specificity of these two multimers used were evaluated. 
1.1 Precision and repeatability analysis 
The repeatability of each multimer technology was evaluated in order to determine the 
precision of both multimers staining. For that purpose, a total of 12 HLA-A*02:01/CMV-
seropositive healthy donors were evaluated and six tubes per donor were stained with 
either PM or ST multimer. Frequencies of CMV-multimer+CD8+ T cells detected with 
both methodologies are shown in Table 8.  
Table 8. Repeatability test that shows the percentage of CMV-specific CD8+ T cells in HLA-
A*02:01/CMV-seropositive healthy volunteers. 
  Number of dilution  
 Donor 1 2 3 4 5 6 SD. 
% of PM CMV 
pp65495-503-
specific CD8+ 
T cells 
  20* 0.994 1.044 1.002 0.912 1.015 0.973 0.045 
27 2.402 2.444 2.359 2.646 2.467 2.492 0.099 
28 0.872 0.851 0.812 0.884 0.829 0.846 0.027 
  29* 0.946 0.863 0.818 0.956 0.909 0.865 0.054 
30 0.045 0.047 0.049 0.043 0.044 0.046 0.002 
31 0.524 0.694 0.655 0.652 0.650 0.672 0.060 
% of ST CMV 
pp65495-503-
specific CD8+ 
T cells 
16 3.417 3.323 3.380 3.386 3.310 3.440 0.051 
  20* 0.590 0.603 0.585 0.573 0.574 0.550 0.018 
26 0.755 0.703 0.725 0.701 0.722 0.700 0.021 
  29* 0.432 0.461 0.487 0.424 0.461 0.482 0.026 
32 1.619 1.464 1.421 1.443 1.370 1.335 0.099 
34 1.930 1.830 1.797 1.835 1.855 1.741 0.063 
*Those analyses were not performed at the same time, explaining the differences observed in the frequencies of 
CMV-multimer+CD8+ T cells. 
As shown by the standard deviation (SD) of each measurement, both techniques are 
repetitive with a mean value of the SD of 0.048 (SD=0.033) for PM and 0.046 (SD=0.031) 
for ST. According to the mixed effect model results, both technologies showed low intra-
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individual variability ( 2
e = 3.2x10
-3 and 3.0x10-3, for PM and ST staining respectively), 
demonstrating that both methods could be considered equally precise. 
1.2 Sensitivity study 
Firstly, we wanted to compare both multimer staining and for this reason the correlation 
between both techniques was estimated. In this case, a total of 18 HLA-A*02:01/CMV-
seropositive samples were analysed with both PM and ST multimers. The median 
frequencies of CMV-specific CD8+ T cells were 1.990% (range: 1.161-3.587) and 
1.933% (1.073-3.549) for PM and ST positive staining, respectively. Both multimers 
showed a strong correlation when more than 1% of antigen-specific cells was detected 
(rSpearman = 0.9422, p<0.001, Figure 9).  
 
Figure 9. Correlation between pentamer and streptamer multimers of 18 HLA-A*02:01/CMV-seropositive 
donors. 
As, during the first months post-HSCT, the proportion of virus-specific cells is quite low 
(71, 78), the detection of low frequencies of virus-specific cells is of special interest. For 
this reason, we evaluated the sensitivity of detection of each multimer. To define the 
sensitivity technique, PBMCs from HLA-A*02:01/CMV seropositive healthy donors 
were serially diluted with PBMCs from HLA-A2 negative healthy donors. A decrease of 
CMV-specific T cells by 50% in each subsequent sample was expected as 1:2 dilutions 
of the previous sample were prepared. 
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The detection levels of the smallest dilution (dilution nº7) were different between both 
techniques with a median frequency of PM positive cells of 0.049% (0.029-0.158) 
compared to 0.015% (0.003-0.037) of ST positive cells (Table 9). It is noticeable that PM 
staining provided higher values than ST staining mainly starting at dilution nº4, where 
frequencies of multimer positive CD8+ T cells were equal or lower than 0.117 % (range: 
0.028-0.130) (according to the theoretical data). However, the positive results given by 
the PM technique differed from the theoretical ones. By using a mixed effects model 
which takes into account the technique, the dilution and the individual, and looking at the 
differences between the observed values and the expected ones, it was shown that the ST 
technique gave closer values to the expected theoretical ones than PM, and those 
differences were significant (p < 0.001). Mean values of the differences between the 
observed values and the theoretical ones obtained by each technique at each dilution point 
are represented in Figure 10. 
Table 9. Multimer positive CD8+ T cells detected in each dilution, where 1 is the undiluted fraction and 7 
is the highest dilution. 
 
 
Dilution number 
Donor Multimer 1 2 3 4 5 6 7 
16 
PM 0.948 0.599 0.289 0.163 0.097 0.081 0.039 
Theoretical data 0.841 0.371 0.175 0.085 0.042 0.021 0.010 
ST 0.889 0.492 0.196 0.116 0.064 0.03 0.015 
21 
PM 0.885 0.583 0.505 0.242 0.210 0.184 0.156 
Theoretical data 1.008 0.504 0.252 0.126 0.063 0.032 0.016 
ST 0.721 0.399 0.208 0.103 0.061 0.030 0.014 
24 
PM 0.742 0.340 0.359 0.168 0.140 - 0.058 
Theoretical data 0.742 0.162 0.063 0.028 0.014 0.007 0.003 
ST 0.699 0.257 0.177 0.088 0.051 0.024 0.014 
25 
PM 1.162 0.820 0.591 0.555 0.287 0.302 0.158 
Theoretical data 1.003 0.503 0.252 0.126 0.063 0.032 0.016 
ST 1.213 0.903 0.461 0.231 0.118 0.069 0.037 
26 
PM 0.708 0.244 0.156 0.087 0.073 0.026 0.029 
Theoretical data 1.016 0.514 0.259 0.130 0.065 0.032 0.016 
ST 0.913 0.407 0.198 0.115 0.077 0.032 0.013 
27 
PM 0.759 0.387 0.241 0.108 0.095 0.066 0.039 
Theoretical data 1.000 0.497 0.248 0.124 0.062 0.031 0.015 
ST 0.939 0.679 0.591 0.154 0.085 0.037 0.030 
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Figure 10. Sensitivity assay of CMV-specific multimer+ CD8+ T cells. Peripheral blood mononuclear 
cells (PBMCs) from 6 HLA-A*02:01/CMV seropositive healthy donors were serially diluted with PBMCs 
from 6 HLA-A2 negative healthy donors. Mean values of the absolute differences between the observed 
values and the theoretical ones of multimer+CD8+T cells obtained by each technique (PM and ST) in each 
dilution point where 1 is the undiluted fraction and 7 the highest dilution are shown. 
This fact could be explained by the observed differences in the median fluorescence 
intensity (MFI) between PM and ST staining. ST multimer gave considerably brighter 
staining than achieved with PM technology with higher MFI values (Figure 11). The 
median MFI values of the undiluted fraction of CMV-specific CD8+ T cells were 19255 
(10067 - 41913) and 8191 (5700 - 17127) for ST and PM respectively (Table 10). Similar 
differences were observed with all dilutions (data not shown), allowing a good 
identification of CMV-specific T cells with the ST technique but not with PM multimer 
in those individuals with small percentage of these cells. The MFI of staining with ST 
was more than 2.4-fold brighter than with PM (p=0.009) (Table 3). 
Therefore, PM technology despite detecting higher amounts of cells is less accurate than 
ST. 
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Figure 11. Representative bi-exponential dot plots of the undiluted CMV-specific CD8
+
 T cells obtained 
with both multimers, pentamer (PM) (A) and streptamer (ST) (B) from subjects 1, 2 and 5. Frequencies of 
multimer-staining cells were gated within the CD8
+
 T-cell subset co-expressing CD3+ in the lymphocyte 
gate CD45
+
. At least 100,000 events were analysed within the CD8
+
 T-cell population. Median 
Fluorescence Intensity (MFI) values were obtained from 6 subjects using those dot plots. 
Table 10. Median Fluorescence Intensity values of the undiluted CMV-specific CD8+ T cells stained with 
each multimer. 
Donor Multimer MFI Range 
16 
PM 6401 2062-15344 
ST 18855 4799-51671 
21 
PM 5700 1086-35791 
ST 10067 1389-38944 
24 
PM 8979 3171-25099 
ST 41913 13231-104183 
25 
PM 7438 3356-26937 
ST 25024 9412-71634 
26 
PM 17127 5520-39665 
ST 19655 2537-60857 
27 
PM 8944 3897-32523 
ST 13167 2350-38944 
1.3 Validation of multimer specificity 
In order to confirm previous data, specificity of each multimer was analysed in 20 healthy 
volunteers with different CMV serostatus and HLA characteristics (Table 11). In all 5 
Subject 1 Subject 2 Subject 5
CD8-FITC
S
T
-P
E
P
M
-P
E
0,742% 1,162% 0,708%
0,699% 1,213% 0,913%
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HLA-A*02:01/CMV-seropositive healthy donors, similar values of CMV-specific CD8+ 
T cells were detected with both multimers with no statistic differences (median of 3.705% 
(0.407-6.880) and 3.474% (0.347-7.154), for PM and ST positive cells respectively). 
However, when comparing the staining in non-HLA-A*02:01/CMV-seronegative (n=5), 
non-HLA-A*02:01/CMV-seropositive (n=5) and HLA-A*02:01/CMV-seronegative 
(n=5) volunteers, higher background levels could be detected with the PM technique. The 
median frequency of positive cells observed with the PM technology was 0.035% (0.000-
0.136), whereas a median of 0.007% (0.000-0.021) positive cells was detected with the 
ST technology (p = 0.003).  
These results confirm that ST multimer technology is more specific for the capture of 
HLA-A*02:01-restricted CMV495-503-specific CD8
+ T cells compared to PM multimer 
staining. 
Table 11. Percentage of CD8+ T cells that bind to pentamer or streptamer multimers in HLA-A*02:01 
and non- HLA-A*02:01 CMV-seropositive or negative healthy donors. 
Volunteer HLA-A CMV serostatus 
Percentage of 
pentamer 
positive cells (%) 
Percentage of 
streptamer 
positive cells (%) 
1 A*32, A*36 positive 0.010 0.013 
2 A*24, A*33 positive 0.018 0.003 
3 A*26, A*31 positive 0.006 0.009 
4 A*01, A*03 positive 0.008 0.000 
5 A*29, A*68 positive 0.050 0.000 
6 A*03, A*24 negative 0.005 0.009 
7 A*01, A*24 negative 0.089 0.021 
8 A*29, A*29 negative 0.076 0.007 
9 A*03, A*30 negative 0.023 0.005 
10 A*11, A*23 negative 0.007 0.006 
11         A*02:01, - negative 0.136 0.007 
12 A*02:01, A*24 negative 0.047 0.008 
13 A*02:01, A*24 negative 0.071 0.015 
14 A*02:01, A*03 negative 0.074 0.003 
15        A*02:01, - negative 0.000 0.000 
16 A*02:01, A*29 positive 1.886 1.700 
17        A*02:01, - positive 4.746 4.248 
18 A*02:01, A*01 positive 0.407 0.347 
19 A*02:01, A*24 positive 3.705 3.474 
20 A*02:01, A*30 positive 6.880 7.154 
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 Immune reconstitution of CMV-specific CD8+ T cells after allogeneic 
haematopoietic stem cell transplantation 
2.1 Patient demographic data 
A total of 25 HLA-A*02:01 recipients who underwent allo-HSCT were studied for T-cell 
immune reconstitution during one year following transplant. One patient gave up the 
study two months after transplantation and only those data were taken into account. 
Median follow-up was 12 months (2-12). Shorter follow-up times were primarily because 
of early deaths (n=5).  
A total of 13 (52%) males and 12 (48%) females were transplanted with a median age of 
42 years (24-65). The diagnosis of the patients were as follows: 4 recipients with 
lymphoma (Hodgkin and no Hodgkin, 16%), 18 patients had leukaemia (72%), two 
people presented myelodysplastic syndrome (8%) and only one person had an inherit 
disease, Fanconi anaemia (4%). 
Eleven of 25 patients received a sibling transplant, two patients received a transplant from 
a haploidentical relative and a total of 12 patients received transplant from an unrelated 
donor. A total of 11 recipients (44%) received MA conditioning treatment whereas 14 
patients (56%) received RIC therapy. Those patients whose donors were unrelated 
received in vivo T-cell depletion with either Alentuzumab or Campath® or ATG. Most 
patients (96%) received PBSCs as stem cell source whereas only one patient received BM 
as stem cell source. 
A total of 16 CMV-seropositive recipients received a graft from a CMV-seropositive 
donor whereas 8 CMV-seropositive recipients received a transplant from CMV-
seronegative donors. Only one patient of 25 was CMV-seronegative before 
transplantation and received a graft from a CMV-seropositive donor. 
Acute GvHD was developed in 11 patients (44%), and chronic GvHD (grade II-IV) was 
developed in eleven of 25 patients that were treated with metilprednisone (1mg/Kg/12h). 
Demographic and clinical characteristics of these patients are shown in Table 12. 
Neutrophil engraftment (more than 0.5 x 109 neutrophils/L) occurred at a median of 20 
days (12-30) and platelet engraftment (more than 20 x 109 platelets/L) at 16 days (10-37). 
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Table 12. Characteristics of the 25 patients analysed 
Characteristics Value 
Age (median (range)) 42 (24-65) 
Sex (M/F) 13/12 
Diagnosis  
   NHL 2 
   HL 2 
   CLL 1 
   AML 13 
   ALL 4 
   MDS 2 
   Fanconi 1 
Donor/recipient CMV serostatus  
   Positive/Positive 16 
   Negative/Positive 8 
   Positive/Negative 1 
Donor type  
      Sibling 11 
      Haploidentical relative 2 
      Unrelated 12 
Stem cell source  
  Bone marrow 1 
  Peripheral Blood 24 
Conditioning treatment  
  Myeloablative conditioning regimen 11 
          Bu/Cy± Campath or ATG 2 
          Cy/TBI±Campath  9 
  Non-myeloablative conditioning regimen 14 
          Flu/Mel±Campath 5 
          Cy/F±Campath 3 
          Flu/Bu±Campath or ATG 6 
GvHD prophylaxis  
  CsA + MTX 21 
  CsA + MMF 2 
  CsA + metilPDN 1 
  MMF +MTX 1 
Acute GvHD grade  
 0 to I 2 
 II to IV 9 
Steroid therapy  
  Yes 7 
  No  17 
  
M = male; F = female; NHL = non-Hodgkin lymphoma; HL = Hodgkin; CLL = chronic 
lymphocytic leukemia; AML = acute myeloid leukemia; ALL = acute lymphoblastic 
leukemia; MDS = myelodysplastic syndrome; Bu = busulfan; Cy = cyclophosphamide; 
ATG = anti-thymocyte globulin; TBI = total body irradiation; Flu = fludarabine; Mel = 
melfalan; CsA = cyclosporine; MTX = methotrexate; MMF = mycophenolate mofetil; 
PDN = prednisone 
As complications following transplant occur during the first three months after 
transplantation it is important to asses T-cell immune reconstitution during that period of 
time. Normal median values of total lymphocyte counts (0.9 - 4.0x103 lymphocytes/L) 
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were reached by day 60 in most recipients (median 0.950 x103 lymphocytes/L (0.1-5.3)) 
as well as CD8+ T cells (>50 CD8+ T cells/L) and CD4+ T cells (>100 CD4+ T cells/L) 
(Table 13). 
Table 13. Median values of total lymphocyte count, CD8+ and CD4+ T cells during the first three months 
post-transplant. 
day 
Median 
lymphocytes 
(cells/L) 
range 
Median 
CD8+ 
(cells/L) 
range 
Median 
CD4+ 
(cells/L) 
range 
30 0.300 0.000-3.800 23.546 0.000-2858.816 63.711 0.000-524.322 
60 0.950 0.100-5.300 65.922 0.000-3927.618 133.972 0.000-642.600 
100 0.800 0.100-3.300 171.120 0.053-2176.499 148.335 0.000-755.918 
2.2 CMV reactivation 
According to CMV reactivation status we have identified two groups of patients. Sixteen 
of 25 recipients (64%) experienced CMV reactivation at least once in the year follow up 
whereas 9/25 patients (36%) did not experience any CMV reactivation during 12 months 
following transplant. The median time to first CMV reactivation was 39 days (1-96). No 
differences were found in the engraftment day between both groups with a median of 21 
days (17-29) and 18 days (12-25) for patients without and with CMV reactivation, 
respectively. 
The cumulative incidence of CMV reactivation during the first year following allo-HSCT 
was not influenced by either HLA compatibility (p=0.145) or conditioning treatment (MA 
vs. RIC; p=0.119). On the contrary, the incidence of CMV reactivation was significantly 
influenced by HSCT donor type (unrelated vs sibling; p=0.036) and T-cell depletion in 
conditioning treatment (p=0.044). Both data are related as all patients that received a 
transplant from an unrelated donor, they also had in vivo T-cell depletion in the 
conditioning treatment.  
The patient that was CMV-seronegative before transplantation and received a graft from 
a CMV-seropositive donor became infected with CMV after HSCT and recurrence of 
CMV reactivations were developed. This patient was not taking into consideration when 
donor CMV serostatus was analysed in order to see its influence on CMV reactivation 
showing that CMV reactivation was not related to donor CMV serostatus (p=0.630). 
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Five of the 8 CMV-seropositive patients whose donor was CMV-seronegative reactivated 
CMV as evidenced by positive PCR at a median of 33 days (1-39) after HSCT (Table 
14). These 5 patients received antiviral therapy with GCV, VGC or foscarnet. Only 1 
patient required cidofovir therapy because of failure of normal antiviral treatment. None 
of these patients developed CMV disease. One patient who did not develop CMV viremia 
was treated with cidofovir because of BK virus infection. This patient died due to GvHD. 
Ten of 16 CMV-seropositive recipients from a CMV-seropositive donor developed CMV 
antigenemia after HSCT; the PCR became positive at a median of 41 days (10-96) after 
HSCT (Table 14). All these patients received antiviral therapy with GCV, VGC or 
foscarnet. Two of these recipients were also treated with cidofovir because of BK virus 
infection. Only one patient developed CMV disease. Four patients died before the year 
follow up due to transplant-related complications. 
Table 14. CMV antigenemia, CMV disease and time of follow up of the 25 allo-HSCT recipients 
Patient 
Onset of 
CMV 
antigenemia* 
No. of 
antiviral 
treatment 
courses* 
Onset 
CMV 
disease* 
Follow 
up* 
1 41 3 - 365 
2 38 2 - 365 
3 - 0 - 365 
4 49 3 - 365 
5 - 0 - 365 
6 - 0 - 365 
7 33 5 - 365 
8 17 2 - 157 
9 25 2 - 365 
10 - 0 - 95 
11 10 3 - 365 
12 - 0 - 365 
13 96 2 - 365 
14 47 3 - 365 
15 39 4 - 365 
16 - 0 - 365 
17 56 3 143 365 
18 41 2 - 346 
19 57 1 - 193 
20 10 2 - 206 
21 - 0 - 328 
22 - 0 - 338 
23 30 2 - 279 
24 - 0 - 60 
25 -3 5 - 365 
*day after haematopoietic stem cell transplantation 
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Absolute counts of CD4+ and CD8+ T cell subsets of recipients with no CMV-DNAemia 
and patients with CMV reactivation were analysed at 30, 60, 100, 200 and 300 days post-
transplant, as some patients reactivated CMV after day +100 post-transplantation. No 
statistics differences in the median number of either CD8+ or CD4+ T cells were observed 
between both groups (Figure 12). 
 
Figure 12. Levels of CD8+ (A) and CD4+ (B) T cells at days 30, 60, 100, 200 and 300 after allogeneic 
haematopoietic stem cell transplantation for recipients without (black circles) or with (white triangles) 
detectable CMV reactivation. 
2.3 Monitoring of cytomegalovirus immune recovery by multimer technology 
2.3.1 CMV-specific T-cell reconstitution and first CMV reactivation 
CMV-specific immune reconstitution following transplant can be measured by the use of 
multimer technology. In our study, we have used streptamer technology, as it has been 
previously shown to be an accurate and precise tool, in order to monitor CMV-specific 
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CD8+ T-cell recovery after allo-HSCT. We have observed, in our cohort of patients that 
CMV-multimer+CD8+ T-cell levels ranged from 0.000 to 678.384 cells/L during the 
year follow up after allo-HSCT in patients with and without CMV-DNAemia. CMV-CTL 
absolute counts and total CD3+CD8+ absolute numbers showed a good correlation, 
regardless of reactivation status during the first 3 months following transplant (Table 15). 
Besides, a correlation between CMV-CTLs and total CD3+CD4+ absolute counts was also 
observed (Table 15). 
Table 15. Correlation between CMV-CTL and T-cell subsets during the first 3 months after HSCT. 
 Correlation CD4 & CD8 CD4 & CMV-CTL CD8 & CMV-CTL 
Day 30 
rSpearman 0.833 0.614 0.564 
p <0.001 0.005 0.005 
Day 60 
rSpearman 0.621 0.443 0.621 
p 0.003 0.044 0.001 
Day 100 
rSpearman 0.715 0.689 0.777 
p 0.001 <0.001 0.002 
By the first month following transplant, most patients have started to recover the immune 
system and it is considered as early post-transplant period. If there is CMV infection, it 
normally occurs within the first three months post-transplant and therefore, CMV-specific 
immune recovery must be monitored. In our cohort of individuals, the onset of CMV-
specific immune response was delayed on recipients with CMV reactivation compared to 
patients without reactivation (median days 48 and 26, respectively), and this delay tend 
to be significant (p=0.061). CMV reactivations occurred between days 30 and 60 after 
transplantation in most recipients, only 6 recipients reactivated before day +30. At that 
time point, no differences were found on CMV-specific T-cell levels between patients 
without reactivation and patients with CMV-DNAemia after 30 days of transplantation 
(median of 0.123 CMV-CTLs/L (0.000-0.630) and 0.070 CMV-CTLs/L (0.000-
26.838), respectively; p=0.738) (Figure 13). Therefore, these results have shown that, in 
our cohort of recipients, the number of CMV-specific CD8+ T cells one month after allo-
HSCT seems to not protect against CMV reactivation. 
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Figure 13. CMV-specific CD8+ T cells of patients without (black circles) and with (white triangles) CMV 
reactivation at day 30 after allogeneic stem cell transplantation. 
The majority of CMV reactivations occurred before day +60 following transplant (median 
39 days (1-96)). The patient that reactivated at day +96 was probably because of 
immunosuppressive treatment due to GvHD. On the contrary to what was observed at day 
+30 following transplant, two months after allo-HSCT there was a significant increase on 
CMV-multimer+ CD8+ T cells in patients with CMV reactivation compared with 
recipients with no CMV DNAemia (median of 3.584 CMV-CTLs/L (0.000-135.892) 
and 0.890 CMV-CTLs/L (0.000-4.530), respectively; p=0.027) (Figure 14). These 
results show that CMV reactivation induces a CMV-specific CD8+ T-cell expansion. 
Median number of CMV-specific CD8+ T cells of both groups during the first three 
months are shown in Table 16. 
Table 16. Median CMV-specific CD8+ T-cell levels during the first three months after allo-HSCT in 
patients without and with CMV reactivation. 
 Patients without CMV reactivation Patients with CMV reactivation 
day 
Median CMV-specific 
CD8+ T cells (cells/L) 
range 
Median CMV-specific 
CD8+ T cells (cells/L) 
range 
30 0.123 0.000-0.630 0.020 0.000-26.838 
60 0.890 0.000-4.530 2.540 0.000-135.892 
100 0.503 0.000-11.248 2.798 0.000-27.837 
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Figure 14. CMV-specific CD8+ T cells of patients without (black circles) and with (white triangles) CMV 
reactivation at day 60 following allogeneic stem cell transplantation. *p<0.05. 
2.3.2 CMV-specific CD8+ T-cell responses and antiviral treatment 
In our cohort of recipients, we have observed two different groups within patients that 
have CMV reactivation (n=16) when looking at the time of antiviral treatment. Twelve 
of 16 recipients were treated for less than 3 weeks (considered as short antiviral treatment) 
when CMV was detected by PCR whereas the rest (n=4) required prolonged antiviral 
treatment (more than 3 weeks). We have observed that patients with short antiviral 
treatment have a significant increase on CMV-CTLs after first CMV reactivation what 
does not occur in patients with prolonged antiviral treatment (Table 17 and Figure 15A). 
Patients that did not have an expansion on CMV-CTLs after CMV reactivation received 
a transplant from a CMV-seronegative donor (Figure 15B and C). These observations 
corroborate the increase on CMV-CTLs observed at day +60 in patients with CMV-
DNAemia compared to recipients without CMV reactivation. 
Table 17. Number of CMV-specific CD8+ T cells detected before and after first CMV reactivation in 
patients with short (less than 3 weeks) and prolonged (more than 3 weeks) antiviral treatment. 
Time of 
antiviral 
treatment 
CMV-CTL 
before first 
CMV 
reactivation 
(cells/L) 
range 
(cells/L) 
CMV-CTL 
after first CMV 
reactivation 
(cells/L) 
range 
(cells/L) 
p value 
< 3 weeks 0.006 0.000-36.710 4.685 0.000-135.892 0.042 
> 3 weeks 0.000 0.000-0.000 0.011 0.000-0.432 0.364 
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Figure 15. CMV-specific CD8+ T cells detected before and after first CMV reactivation in patients that 
received antiviral treatment for less than 3 weeks (A) and recipients that required prolonged antiviral 
treatment to clearance CMV viremia (B and C). *p<0.05. 
When comparing multimer positive CD8+ T cells between both groups after the first CMV 
reactivation, there is a significant increase of CMV-specific CD8+ T cells in patients with 
short antiviral treatment compared to recipients requiring long antiviral therapy time 
(median of 4.685 multimer+CD8+ T-cells/L (0.000-135.892) and 0.011 multimer+CD8+ 
T-cells/L (0.000-0.432), respectively; p=0.015) (Figure 16). 
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Figure 16. Multimer positive CD8+ T cells detected after first CMV reactivation in patients with short 
antiviral treatment and therefore CMV-CTL expansion and patients with prolonged antiviral treatment and 
no expansion of CMV-specific T cells. *p<0.05. 
It is interesting to mention that patients with no expansion of CMV-CTLs have 
significantly longer duration of CMV-DNAemia compared to patients with CMV-CTLs 
expansion after the first CMV reactivation (median of 27.5 days (8-34) vs. 7 days (3-18), 
respectively; p=0.012). Besides, they also had significant higher levels of CMV 
copies/mL when comparing to recipients that expanded CMV-CTLs (median of 29122 
CMV-copies/mL (4790-103089) and 2697 CMV-copies/mL (915-14210), for patients 
without and with CMV-specific CD8+ T-cell expansion respectively; p=0.011). 
It has been previously shown that both CD4+ and CD8+ T-cell recovery was achieved in 
most patients by day +60 after allo-HSCT. However, there were differences within 
patients that experienced CMV reactivation. Recipients that received short antiviral 
treatment had higher levels of both CD4+ and CD8+ T cells compared to patients requiring 
prolonged antiviral therapy (130.809 CD4+ T cells/L (0.000-497.131) and 109.431 
CD8+ T cells/L (0.000-3927.618) vs. 9.889 CD4+ T cells/L (0.000-142.919) and 4.961 
CD8+ T cells/L (0.000-696.958), respectively). No statistical differences were found due 
to the low number of samples in the cohort of patients that received prolonged antiviral 
treatment. This group of recipients started to recover normal values of CD8+ T cells by 
day +200 post-transplantation (median of 152.187 CD8+ T cells/L (81.93-339.240)) 
whereas normal CD4+ T-cell levels started at day +300 following transplant (median of 
307.619 CD4+ T cells/L (9.502-446.380)). 
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According to previous studies, recovery of T-cell function by day +100 after 
transplantation is important in order to avoid future CMV reactivations or disease and 
even mortality. For this reason, median numbers of CMV-CTLs by day +100 were studied 
in the cohort of patients that reactivated the virus. At this time point, patients with short 
antiviral treatment and expansion of specific-cells had significantly higher levels of 
CMV-CTLs compared to patients without CMV-specific T-cell expansion (4.376 
cells/L (0.064-27.837) and 0.000 cells/L (0.000-0.000), respectively; p < 0.001) 
(Figure 17). 
 
Figure 17. CMV-specific CD8+ T-cell levels at day +100 following HSCT in recipients with CMV 
expansion after CMV reactivation and therefore short antiviral treatment and patients with no CMV 
expansion after CMV reactivation requiring prolonged antiviral therapy. ***p<0.001. 
2.3.3 CMV-CTL expansion and multiple CMV reactivations 
We were further interested in studying whether or not this CMV-CTL expansion was able 
to protect to multiples CMV reactivations in the recipient, defined by 2 or more distinct 
episodes of viremia separated by a negative PCR result.  
Five of the 12 patients that have CMV-CTL expansion (and therefore short antiviral 
treatment) had only 1 CMV reactivation before day +100 after transplantation. The 
number of virus-specific T cells after the first and unique CMV reactivation was 
significantly higher in those patients compared with recipients that have several CMV 
reactivations (n=7) (median of 16.038 CMV-CTLs/L (2.800-135.892) and 1.240 CMV-
CTLs/L (0.000-16.110), for patients with one or more than one CMV reactivation, 
respectively; p=0.042). Besides, examination of general T-cell reconstitution data showed 
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that patients with only 1 CMV reactivation had also rapid recovery of total CD4+ cells 
(≥100 cells/L) and total CD8+ cells (≥50 cells/L) (Table 18 and Figure 18). 
Table 18. Median numbers of cells after the first CMV reactivation within patients with short antiviral 
treatment. 
 1 reactivation before 
day +100 
Several reactivations 
before day +100 
p value 
CMV-CTLs(cells/L) 
(range) 
16.038  
(2.800-135.892) 
1.240  
(0.000-16.110) 
0.042 
CD4+ T cells (cells/L) 
(range) 
375.121  
(165.913-497.131) 
27.548  
(0.000-361.810) 
0.049 
CD8+ T cells (cells/L) 
(range) 
630.038  
(67.660-3927.618) 
23.546  
(0.000-588.665) 
0.028 
 
Figure 18. Median values of CMV-CTLs (A) and CD4+ and CD8+ T cells (B) after the first CMV 
reactivation in patients with only 1 reactivation (black circles) or multiple CMV reactivations (black 
triangles) within patients with short antiviral treatment. *p<0.05. 
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As previously mentioned, there were 7 of 12 patients within the CMV-CTL expansion 
group and therefore short antiviral treatment, who experienced more than 1 CMV 
reactivation. A total of 4 patients developed 2 CMV reactivations before day +100 after 
allo-HSCT and three recipients had 3 episodes of CMV-DNAemia during the first three 
months post-transplant. Levels of multimer+CTLs after the second CMV reactivation 
were higher in patients that experienced only 2 episodes of CMV-DNAemia compared 
with recipients that had 3 CMV reactivations (median of CMV-CTL cells after 2nd CMV 
reactivation of 8.754 cells/L (1.596-24.550) and 1.236 cells/L (0.169-3.708), 
respectively). However, no statistical differences were observed, possibly due to the low 
number of samples analysed.  
We were interested in knowing if there was a protective value that those recipients could 
achieve after CMV reactivation which protects against future CMV reactivations. For that 
purpose, we analysed the CMV-specific CD8+ T-cell levels reached after the last CMV 
reactivation of those recipients. Patients that have only one CMV reactivation (n=5) have 
a median of 16.038 multimer+CTLs/L (2.800-135.892) after reactivation, recipients that 
experienced two episodes of CMV-DNAemia (n=4) achieved 8.754 multimer+CTLs/L 
(1.596-24.550) after the second CMV reactivation, and patients who had three 
reactivations (n=3) had 11.840 multimer+CTLs/L (1.348-23.490) after the third episode 
of CMV-DNAemia (Table 19). Our results have shown that the minimum cell number of 
virus-specific T cells reached after CMV reactivation was 1.348 multimer+CTLs/L and 
then no more CMV reactivations were detected.  
Table 19. Median numbers of CMV-specific CD8+ T cells after last reactivation of patients that have 1, 2 
or 3 CMV reactivations. 
Number of CMV 
reactivations 
Median of 
multimer+CTL 
(cells/L) 
Range 
(cells/L) 
1 (n=5) 16.038 2.800-135.892 
2 (n=4) 8.754 1.596-24.550 
3 (n=3) 11.840 1.348-23.490 
As it was previously shown, four patients did not have an increase on CMV-CTLs 
numbers after CMV reactivation. Those patients received antiviral treatment for more 
than 3 weeks (¡Error! No se encuentra el origen de la referencia.B and C).  
Patient 7 (D-/R+) experienced 5 CMV reactivations (day +33, +47, +90, +132 and +181), 
which were treated by VGC. No CMV-CTLs were detectable at these time points. This 
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patient developed GvHD at day 92 and was treated with high levels of 
immunosuppressive drugs which impaired CMV-specific CD8+ T-cell recovery. By day 
+201 this patient had 0.028 CMV-CTLs/L and did not reactivate CMV thereafter.  
Patient 15 (D-/R+) had 4 CMV reactivations (day +39, +87, +130 and +186) that were 
treated with VGC. This patient had 0.25 CMV-CTLs/L by day +130 but they did not 
seemed able to protect against another CMV reactivation on day +186. 
Patient 25 (D-/R+) became infected before transplantation and was initially treated with 
GCV, then foscarnet the day of transplantation. Due to failure of pre-emptive treatment 
it was necessary to use cidofovir. Following this, the patient developed 4 more CMV 
reactivations (day +55, +131, +179 and +277) that were treated by either VGC or 
foscarnet. None CMV-CTLs could be detected until the final reactivation on day +277 
(0.432 CMV-CTLs/L). The number of CMV-specific CD8+ T cells increased and no 
more CMV reactivations were observed.  
Patient 14 (D+/R-) had 4 CMV reactivations that were treated with VGC. This patient 
received ATG and the lymphocyte count was very low until day +100 (less than 200 
lymphocytes/L). The patient then began to recover their lymphocyte function and after 
the last CMV reactivation on day +159, CMV-CTLs could be detected. 
2.3.4 CMV-specific CD8+ T-cell recovery in patients with CMV reactivation 
The results obtained with multimer technology have led us to describe two different 
patterns in our group of patients according to CMV-specific CD8+ T-cell recovery and 
antiviral treatment. 
The most frequent pattern observed is the one where recipients experienced CMV-
specific CD8+ T-cell expansion after CMV reactivation and therefore requiring short 
period of antiviral treatment (n=12). There is a significant increase of those cells by day 
60 compared to patients with no CMV-DNAemia as it has previously been described. The 
median number of CMV-specific CD8+ T cells observed in each time point after 
transplantation was 5.570 cell/L (0.568-8.340) (median numbers of virus-specific cells 
during the year follow up after allo-HSCT) (Figure 19A).  
A second pattern where patients did not have an expansion of CMV-specific CD8+ T-cell 
levels after episodes of CMV-DNAemia and therefore required prolonged time of 
antiviral therapy (n=4) (Figure 19C and D). These patients had very low levels of CMV-
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specific CD8+ T cells following transplant (median of 0.035 CMV-CTLs/L (0.000-
0.195) during one year following allo-HSCT) and experienced CMV reactivations after 
3 months post-transplant. 
 
Figure 19. Different patterns observed in the cohort of individuals that reactivated CMV. Patients 
that had CMV-CTLs expansion after CMV reactivation and required short times of antiviral treatment 
(n=12) (A) and patients with no CMV-specific CD8+ T cells after CMV reactivation requiring prolonger 
cumulative antiviral therapy (n=4) (B and C). The black line indicates the median of CMV-CTL levels at 
days +30, +60, +100, +200 and +300 post-transplan 
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2.4 Functional activity of virus-specific CD8+ T cells 
Another methodology widely used to monitor CMV-specific immune reconstitution is by 
measuring the production of cytokines upon stimulation with virus peptides, virus lysate 
or viral protein.  
Functional assays were performed in order to assess functional activity of virus-specific 
CD8+ T cells by monitoring intracellular IFN production upon stimulation with CMV-
pp65495-503 peptide. We have selected IFN because it is the main cytokine secreted by 
cytotoxic CD8+ T cells upon activation by antigens (178). Due to the low number of cells 
for some patients, only 19 of 25 recipients could be monitored. 
Six of the 19 recipients did not experience CMV-DNAemia during the year follow up 
whereas a total of 13 patients developed CMV reactivation after HSCT. As mentioned 
previously, most CMV reactivations occurred between day 30 and 60 after 
transplantation, only 5 patients reactivated CMV before day +30. At that time point, 
significant differences were found on in vitro IFN production levels between patients 
without CMV reactivation (n=6) and recipients with CMV-DNAemia a month after 
transplantation (n=8) (median of 0.094 IFN+CD8+ T-cells/L (0.000-1.026) and 0.000 
IFN+CD8+ T-cells/L (0.000-0.000), respectively; p=0.022) (Figure 20). 
 
Figure 20. INF production levels by CD8+ T cells upon in vitro stimulation with CMV-pp65495-503 peptide 
in patients without (black circles) and with (white triangles) CMV reactivation at 30 days after 
transplantation.*p<0.05. 
By day 60 post allo-HSCT the majority of CMV reactivations had occurred within 
patients that experienced CMV-DNAemia. After two months following transplant, there 
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was an increase of in vitro IFN-production by CD8+ T cells when comparing patients 
without CMV reactivation and recipients with CMV-DNAemia (median of 0.305 
IFN+CD8+ T-cells/L (0.000-5.830) and 2.108 IFN+CD8+ T-cells/L (0.000-40.02), 
respectively); however this difference was not significant, probably due to the high 
dispersion of the data (Figure 21). 
 
Figure 21. INF production levels by CD8+ T cells upon in vitro stimulation with CMV-pp65495-503 peptide 
in patients without (black circles) and with (white triangles) CMV reactivation at 30 days after 
transplantation. 
2.4.1 Functional CMV-specific CD8+ T cells and antiviral treatment  
According to our previous classification in relation to antiviral treatment duration, a total 
of 10/13 recipients that experienced CMV reactivation were treated for less than 3 weeks, 
defined previously as short treatment, whereas 3 patients received prolonged antiviral 
therapy, defined by more than 3 weeks of treatment. Similar to multimer+CTLs, we 
observed that patients with short antiviral therapy have a significant increase on in vitro 
IFN-production after the first CMV-reactivation (p=0.008) whereas recipients with 
prolonged antiviral therapy do not expanded IFN-producing CD8+ T cells (Table 20 and 
Figure 22). There is no statistical analysis for patients with prolonged antiviral treatment 
as only data for two patients could be analysed.  
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Table 20. Number of IFN producing cells detected before and after first CMV reactivation in patients with 
short antiviral treatment (less than 3 weeks) and prolonged therapy (more than 3 weeks). 
Time of 
antiviral 
treatment 
Median of IFN 
production 
before CMV 
reactivation 
(cells/L) 
range 
(cells/L) 
Median of IFN 
production 
after CMV 
reactivation 
(cells/L) 
range 
(cells/L) 
p value 
< 3 weeks 0.000 0.000-2.855 2.403 1.474-40.015 0.008 
> 3 weeks 0.000 0.000-0.000 0.011 0.000-0.022 - 
 
Figure 22. IFN production by CD8+ T cells upon stimulation with the CMV-pp65495-503 peptide before and 
after CMV reactivation in patients that received short antiviral therapy when CMV was detected (A) and 
recipients requiring prolonged antiviral treatment (B and C). ***p<0.001 
When comparing the in vitro production of IFN levels between both groups after the first 
CMV reactivation, a significant increase in the number of cells responding to CMV-
antigen in patients with short antiviral treatment was observed, when compared to 
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recipients requiring long antiviral therapy time (median of 2.403 IFN+CD8+ T-cells/L 
(1.474-40.015) and 0.011 IFN+CD8+ T-cells/L (0.000-0.022), respectively; p=0.037) ( 
Figure 23). 
 
Figure 23. IFN levels detected after first CMV reactivation in patients with short and prolonged antiviral 
treatment. *p<0.05. 
Functionality of CD8+ T cells upon in vitro stimulation with CMV-pp65495-503 peptide 
was studied at day +100 after transplantation as CMV-specific immune recovery at that 
time point is important in order to avoid future CMV reactivations. When looking at 
patients that experienced CMV-DNAemia, it is observed that recipients with short 
antiviral treatment had significant higher levels of IFN compared to patients with 
prolonged antiviral treatment at day +100 after HSCT (median 2.743 IFN+CD8+ T 
cells/L (1.474-14.110) and 0.000 IFN+CD8+ T cells/L (0.000-0.000), respectively; 
p=0.011) (Figure 24). 
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Figure 24. In vitro IFN production by CD8+ T cells after stimulation with CMV-pp65 peptide at day +100 
following transplant in recipients with short and prolonged antiviral treatment. *p<0.05. 
2.4.2 IFN-production and multiple CMV reactivations 
Five of the 10 patients that experienced an increase in in vitro IFN production levels 
after CMV reactivation and therefore, short antiviral treatment, had only one episode of 
CMV-DNAemia. We have compared the levels of IFN that those recipients produce 
upon in vitro stimulation after the first CMV reactivation with patients that have more 
than 1 reactivation. After the first and unique CMV reactivation, the levels of IFN 
detected were 16.380 IFN+CD8+ T cells/L (1.474-40.015). On the contrary, patients 
with more than one CMV reactivation had 1.241 IFN+CD8+ T cells/L (0.604-2.486). 
No statistical differences were observed due to the low number of samples as only 3 
patients with multiple reactivations could be analysed (Figure 25).  
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Figure 25. IFN+CD8+ T-cell levels detected after first CMV reactivation in patients with 1 or more than 
one CMV reactivation and receiving short antiviral treatment. 
A total of 2 patients within those 10 patients that have short antiviral treatment 
experienced two CMV reactivations before day +100 after allo-HSCT and 3/10 had three 
episodes of CMV-DNAemia during that time. We have evaluated the levels of IFN 
production after the last CMV reactivation in those recipients to see if there is a protective 
value to further reactivations. Patients that have only one CMV reactivation (n=5) have a 
median of 16.380 IFN+CD8+ T-cells/L (1.474-40.020) after reactivation, recipients that 
experienced two episodes of CMV-DNAemia (n=2) achieved 7.179 IFN+CD8+ T-
cells/L (5.744-8.613) after the second CMV reactivation, and patients who had three 
reactivations (n=3) had 1.385 IFN+CD8+ T-cells/L (1.290-20.70) after the third episode 
of CMV-DNAemia (Table 21). These results have shown that the minimum cell number 
of IFN+ production by CD8+ T cells reached after CMV reactivation was 1.290 cells/L 
and then no more CMV reactivations were detected.  
Table 21. Median numbers of CMV-specific CD8+ T cells after last CMV reactivation of patients that 
have 1, 2 or 3 CMV reactivations. 
 
Number of CMV 
reactivations 
Median of 
IFN+CD8+ T 
cells (cells/L) 
Range 
(cells/L) 
1 (n=5) 16.380 1.474-40.020 
2 (n=2) 7.179 5.744-8.613 
3 (n=3) 1.385 1.290-20.700 
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As mentioned previously, three of 19 patients analysed for functional activity did not have 
increased numbers of IFN producing CD8+ T cells after CMV infection and received 
antiviral treatment for more than 3 weeks. 
Patient 7 (D-/R+) experienced 5 CMV reactivations (day +33, +47, +90, +132 and +181), 
that were treated with VGC. Due to GvHD at day 92, high levels of immunosuppressive 
drugs were administered, which impaired CMV-CTL recovery. By day +201 this patient 
had 0.056 IFN+CD8+ T cells/L and did not reactivate CMV thereafter.  
Patient 15 (D-/R+) had 4 CMV reactivations (day +39, +87, +130 and +186) that were 
treated with VGC. This patient achieved 0.286 IFN+CD8+ T cells/L by day +300 and 
did not further reactivate CMV anymore. 
Patient 14 (D+/R-) had 4 CMV reactivations that were treated with VGC. This patient 
received ATG and the lymphocyte count was very low until day +100 (less than 200 
lymphocytes/L). Then, the patient started to recover the lymphocyte function and after 
the last CMV reactivation on day +159, functional CD8+ T cells were detected upon in 
vitro stimulation (1.036 IFN+CD8+ T cells/L). 
2.4.3 Functional CMV-specific CD8+ T-cell recovery patterns 
In this case, we have been able to describe three different patterns in our cohort of patients. 
As it was observed with multimer technology for the monitoring of CMV-specific 
immune reconstitution, two of the three patterns are classified according to functional 
recovery and antiviral treatment of the recipients; however, a third pattern has been 
described when analysing in vitro IFN production by CD8+ T cells upon stimulation with 
CMV-pp65495-503 peptide. 
This new pattern is formed by a group of patients that never experienced CMV 
reactivation during the year follow up after allo-HSCT (n=6). Despite finding no 
differences in the number of virus-specific cells when multimer technology was used at 
early time points after transplantation (day +30), we have observed that those cells were 
functional, as measured by in vitro IFN production whereas this did not occur in patients 
with reactivation. Therefore, they may protect against CMV reactivation. Median number 
of IFN production levels all over the year was 0.630 IFN+CD8+ T-cells/L (0.094-
13.542) (Figure 26A). 
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The second and most frequent pattern is formed by a group of patients that experienced 
an increase on the in vitro IFN production levels by CD8+ T cells after CMV reactivation 
and therefore requiring short antiviral treatment (n=10). The median number of IFN 
production levels during the year follow up was 2.590 IFN+CD8+ T-cells/L (0.000-
6.157) (Figure 26B). 
The third pattern described was formed by patients who did not have an increase on IFN 
levels upon in vitro stimulation after CMV reactivation episodes and therefore requiring 
prolonged time of antiviral therapy (n=3) (Figure 26C and D). These patients had no 
functional CD8+ T cells until day 200 (median of 0.050 IFN+CD8+ T-cells/L (0.000-
0.661)) and experienced CMV reactivations after 3 months post-transplant. 
 
Figure 26. . Different patterns observed in our cohort of individuals. Patients with early functional 
CMV immune reconstitution in the absence of CMV reactivation (n=6) (A). Patients that had an increase 
on in vitro IFN levels after CMV reactivation and required short times of antiviral treatment (n=10) (B) 
and patients with no in vitro IFN production levels after CMV reactivation requiring prolonged cumulative 
antiviral therapy (n=3) (C and D). The black line indicates the median of CMV-CTL levels at days +30, 
+60, +100, +200 and +300 post-transplant 
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These results obtained after monitoring CMV-specific immune reconstitution by 
measuring in vitro IFN production upon stimulation with CMV-pp65495-503 peptide have 
led us to explain the observations that we had with multimer technique. It is necessary to 
have not only CMV-specific CD8+ T cells detected by multimer technology but also 
functional T cells (detected by in vitro IFN production). 
2.5 CMV-CTL levels and functional activity 
The previous methods have allowed us to monitor CMV-specific CD8+ T cells recovery 
by identifying these cells with multimer technology or by measuring their function after 
stimulation with the specific peptide. The peptide CMV-pp65495-503 has HLA-A*02:01 
restriction and it is therefore supposed that only CMV-specific CD8+ T cells with that 
restriction will recognize and respond to the antigen. However, it is also possible to 
monitor CMV-specific immune reconstitution by measuring cytokines-produced upon 
stimulation with a specific peptide by CMV-specific T cells that are stained with 
multimer. 
A new technique has recently been described in order to monitor functional activity of 
CMV-specific CD8+ T cells detected by multimer technique. In our study, we have been 
able to incorporate this -capture-based kit only in 9 of the 25 patients to monitor the in 
vitro IFN produced by multimer+CD8+ T cells upon stimulation with CMV-pp65495-503 
antigen. 
Firstly, we wanted to evaluate and to compare if the number of multimer positive cells 
detected with both processes was the same (direct staining with multimer and multimer 
detected in the -capture process). Due to the low number of processed samples, we have 
grouped all measurements (n=33) for the analysis. According to what was expected, a 
strong correlation is observed between both of them (rSpearman = 0.940, p<0.001) 
suggesting that the number of multimer positive cells is maintained after in vitro 
stimulation with the antigen (Figure 27).  
Similar to multimer analysis, we wanted to compare if the in vitro IFN production 
detected with both methodologies, extracellular (-capture) and intracellular (ICS) IFN 
staining upon CMV-pp65495-503 peptide stimulation, was the same. However, in this case 
the IFN detected by intracellular staining provided significant higher values than the 
IFN detected by the extracellular staining (p = 0.002) (Figure 28A and B). The 
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correlation observed between both of them is not as good as that obtained with multimer 
technology (rSpearman=0.601, p<0.001, Figure 28C). 
 
 
Figure 27. Correlation of multimer positive CD8+ T cells detected with the normal protocol of CMV-
specific CD8+ T cells detection (y-axis) and the protocol used for the -capture (x-axis). 
Furthermore, when comparing the in vitro IFN production levels by CD8+ T cells with 
both techniques, higher IFN levels were observed when analysing the intracellular 
staining at +60 days following transplant compared against extracellular staining (median 
of 1.194 IFN+CD8+ T cells/L (0.000-40.015) and 0.010 IFN+CD8+ T cells/L (0.000-
38.743) respectively; p=0.069).  
We studied the IFN production levels by the -capture technique at day +30 and +60 by 
multimer positive cells in patients without (n=4) and with (n=5) CMV reactivation to see 
if we could find any difference to explain the above observation. In this case, two patients 
of the 9 analysed reactivated CMV during the first month following transplant and they 
were not considered for the analysis at 30 days after allo-HSCT but they were included 
at 60 days post-transplantation analysis. No differences were found between patients 
without and with CMV-DNAemia neither at +30 nor +60 days post-transplant, probably 
due to the low number of samples analysed at each time point (Table 22).  
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Figure 28. Extracellular and intracellular IFN levels detected with both methodologies (A and B) and 
correlation of IFN positive CD8+ T cells detected with intracellular (y-axis) and extracellular staining (x-
axis) (C). **p<0.01. 
Table 22. Median of in vitro IFN production levels by multimer positive cells after stimulation with 
CMVpp65495-503 antigen in patients without and with CMV reactivation at +30 and +60 days after allo-
HSCT. 
 
  
Median IFN production 
by multimer positive cells 
Range 
Day +30 CMV reactivation 
no 0.050 0.000-0.272 
yes 0.000 0.000-0.004 
Day +60 CMV reactivation 
no 0.120 0.000-3.223 
yes 0.010 0.000-38.743 
This technology could be a useful tool for the monitoring of CMV-specific CD8+ T-cell 
immune recovery and its functionality. However, future experiments with higher number 
of patients would be necessary to arrive to some conclusions. 
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B Phenotypic characterisation of Cytomegalovirus-specific CD4+ T 
cells 
The presence of CMV-specific CD4+ T cells has been shown through in vitro culture. 
However their phenotype and functional activity are less understood compared to CD8+ 
T cells and it has been suggested to be altered during culture. In this study, we are going 
to characterise CMV-specific CD4+ T cells by the direct ex vivo staining with tetramer 
technology in healthy individuals prior to its implementation in the monitoring of allo-
HSCT recipients 
 Specificity CMV-specific CD4+ T-cell clones 
In order to study CMV-specific CD4+ T cells as explained below (section B3), it was 
necessary to generate CD4+ T-cell clones to test specificity and evaluate the sensitivity of 
MHC class II tetramers. The ‘potential’ CMV-specific CD4+ T-cell clones generated were 
directed against the CMV glycoprotein B (gB)-derived epitope DYSNTHSTRYV, 
residues: 217-227 in the context of HLA-DRB1*07:01-restricted and CMV pp65-derived 
epitopes AGILARNLVPMVATV, residues: 489-503 with HLA-DRB3*02:02 
restriction, and epitope LLQTGIHVRVSQPSL, residues: 41-55 with HLA-DQB1*06:02 
restriction. The specificity of each clone was evaluated by measuring the in vitro IFN 
production after stimulation with the appropriate peptide-loaded LCL (gB217-227, pp6541-
55 or pp65489-503) and DMSO-loaded as negative control. The following figure shows an 
example of the DYS-, AGI- and LLQ-specific CD4+ T-cell clones (clone A, clone C and 
clone E, respectively) and some ‘potential’ clones that were not CMV-specific as they 
did not respond to their cognate CMV antigen (clone B, clone D and clone F) after 
stimulation with DYS, AGI or LLQ, respectively (Figure 29). 
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Figure 29. Representative examples of in vitro IFN+ production by ‘potential’ CMV-specific 
CD4+ T-cell clones after stimulation with either DYS-, AGI- and LLQ-peptides or DMSO as 
negative control. 
 Validation of MHC class II tetramers 
As described in Materials and Methods (section B1), a total of 55 CMV seropositive 
healthy volunteers were recruited into the study in order to characterise the phenotype of 
CMV-specific CD4+ T cells with the use of MHC class II tetramers. The donor cohort 
was grouped according to their age into young (18-40 years), middle aged (41-60 years) 
and older adults (over 60 years).  
We have used three MHC class-II tetrameric complexes that were directed against the 
CMV gB217-227 (DYS) in the context of HLA-DRB1*07:01 (DR7) restricted, or against 
the CMV pp65489-503 (AGI) with HLA-DRB3*02:02 (DR52b) restriction and CMV 
pp6541-55 (LLQ) HLA-DQB1*06:02 (DQ6) restriction. 
Before performing the phenotypic analyses of CMV-specific CD4+ T cells, the specificity 
of each tetramer was evaluated. 
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2.1 Specificity and sensitivity of MHC class II tetramers 
Initially, the specificity of each tetramer was confirmed by screening against epitope-
specific CD4+ T-cell clones or PBMCs from an HLA-matched CMV-seronegative donor. 
All three tetramers are highly specific as the background levels observed when staining 
PBMCs from a CMV-seronegative donor were very low (less than 0.06%) whereas more 
than 95% positive cells were observed when staining the CMV-specific CD4+ T-cell 
clone that recognizes the tetramer’s cognate MHC II-peptide complex.  
Similar results for each epitope were obtained when analysing decreasing amounts of 
CD4+ T-cell clones specific for DYS-, AGI- or LLQ-epitopes in a mixture with PBMCs 
from a CMV-seronegative donor with the corresponding HLA restriction (DR7, DR52b 
or DQ6, respectively) (Table 23 and Figure 30). For that purpose, the CD4+ T-cell clone 
was diluted with PBMCs from the CMV-seronegative donor to have 5%-1%-0.5%-
0.25%-0.10% of peptide-specific CD4+ T cells. A strong correlation was obtained with 
each tetramer with the predicted positive (Table 23). These results showed that each 
tetramer was able to detect low frequencies of epitope-specific T cells (as low as 0.1% 
CMV-specific CD4+ T cells).  
Table 23. Percentage of the DYS-, AGI- and LLQ-specific CD4+ T-cell clones after dilution with PBMCs 
from a CMV-seronegative donor with the same HLA restriction. 
Tetramer Percentage of the CD4+ T-cell clone (%) 
Negative 
donor 
ICC p value 
Theoric 100.00 5.00 1.00 0.50 0.25 0.10 0.00   
DYS 97.70 6.93 1.13 0.57 0.27 0.14 0.01 1.000 <0.001 
AGI 95.77 3.57 0.80 0.38 0.21 0.11 0.05 0.999 <0.001 
LLQ 98.18 13.72 2.94 1.13 0.60 0.35 0.06 0.996 <0.001 
ICC = Inctraclass Correlation Coefficient 
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Figure 30. Representative dot plots of decreasing amounts of DYS-specific CD4+ T-cell clone with 
PBMCs from a CMV-seronegative HLA-DR7 positive donor. 
Once the specificity and sensitivity of each class II tetramer was confirmed with the use 
of T-cell clones, the validation of each tetramer was performed by using PBMCs from 
CMV-seropositive healthy donors with HLA DR7, DR52b and DQ6. PBMCs were 
stained with DYS, AGI or LLQ class II tetramers and CD3 and CD4 surface markers. 
PBMCs from 3 CMV-seronegative donors with HLA DR7, DR52b and DQ6 were also 
stained as negative controls. As it was observed with clones, the specificity of each MHC 
class II tetramer was confirmed with PBMCs from healthy donors and they can be used 
to detect CMV-specific CD4+ T cells directly ex vivo (Figure 31). The range of detection 
of CMV-specific CD4+ T cells was different between different epitopes in our cohort of 
donors. DYS-specific CD4+ T cells ranged from 0.10 to 11.75% of the CD4+ T-cell 
population; AGI-specific CD4+ T cells ranged from 0.07 to 2.97% of total CD4+ T cells 
and LLQ-specific CD4+ T cells were between 0.10 to 24.02% of CD4+ T cells. 
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Figure 31. Representative dot plots of 3 different CMV-seropositive donors per HLA restriction (DR7, 
DR52b and DQ6). CMV-seronegative healthy donors were used as negative control. 
 Phenotypic characterisation of CMV-specific CD4+ T cells 
According to previous in vitro studies CMV-specific CD4+ T cells showed an effector 
memory phenotype in healthy individuals. However, we were interested in characterising 
their phenotype by direct staining ex vivo with class II tetramers without prior peptide 
stimulation. 
Firstly, we grouped donors according to their ages as young (n=16), middle aged (n=26) 
and older adults (n=13) and, subsequently, PBMCs from those donors were stained with 
the appropriate class II tetramer. We have observed that the frequency of CMV-specific 
CD4+ T-cell levels did not increase with age (Table 24 and Figure 32). 
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Table 24. Median frequencies of CMV-specific CD4+ T cells found in the different cohort of individuals. 
 
Median CMV-
specific CD4+ T cells 
(%) 
range 
Young (n=16) 0.78 0.10-7.62 
Middle aged (n=26) 0.28 0.07-2.97 
Older adults (n=13) 0.72 0.10-24.02 
 
Figure 32. Relation between tetramer+CD4+ T cells and age.  
By looking at the different epitopes, a total of 29 DYS- (DR7); 17 AGI- (DR52b) and 10 
LLQ- (DQ6) positive donors (n = 55) were stained with MHC class II tetramer in order 
to characterise the phenotype of CMV-specific CD4+ T cells directly ex vivo. 
The majority of DYS- (DR7), AGI- (DR52b) and LLQ- (DQ6) specific CD4+ T cells 
expressed high levels of CD45RO with a median of 97.22% (29.33–100) and lacked the 
expression of CCR7 showing an effector memory (EM) phenotype (Figure 33A). 
CD45RA expression was low for AGI- and LLQ-specific T cells (median 3.45% 
CD45RA+ (0–23.53) and 6.66% CD45RA+ (0-24.24), respectively) but higher values 
were found on some DYS-specific T cells (median of 10.87% CD45RA+ (0–82.04)) 
(Figure 33B), therefore showing a revertant memory phenotype (EMRA). The EM 
phenotype (CD45RA-CCR7-) was not related to age and it was observed in all three 
donors groups (Figure 33C). 
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Figure 33. Effector memory phenotype as defined by expression of CCR7 and CD45RA presented by 
CMV-specific CD4+ T cells (A). Expression levels of CD45RA marker by DYS- (DR7), AGI- (DR52b) 
and LLQ- (DQ6) specific CD4+ T cells (B). Levels of CD45RA-CCR7- expression on CMV-specific CD4+ 
T cells in young, middle aged and older adults (C). 
The expression of the co-stimulatory molecules CD28 and CD27 as well as CD57 allows 
to identify different stages of differentiation status that T cells present. In that sense, when 
looking at the expression of these markers on CMV-specific CD4+ T cells we did not 
observe a significant decrease of CD27 and CD28 with age, although there was lower 
expression in older adults. CD57 expression confirmed these observations as there was a 
slightly increased with age (p=0.059) (Table 25). 
Table 25. Median frequencies of CD28, CD27 and CD57 expression on young, middle aged and older 
adults. 
 
Median 
%CD28 
range 
Median 
%CD27 
range 
Median 
%CD57 
range 
Young (n=16) 62.09 9.76-100.00 14.67 0.00-99.01 17.50 0.00-65.10 
Middle aged 
(n=26) 
70.73 1.89-100.00 14.80 1.35-82.76 23.44 0.00-84.71 
Older adults 
(n=13) 
33.33 0.82-92.31 7.37 0.24-46.15 41.30 0.00-79.56 
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By contrast, significant differences were found in the expression of these markers 
according to the three different epitopes (gB (DYS) and pp65 (AGI and LLQ) epitopes). 
The expression of the co-stimulatory molecule CD28 was very similar on T cells specific 
for both pp65 epitopes (AGI and LLQ) but significantly lower on gB (DYS)-specific 
CD4+ T cells with a median of 31.07% CD28+ (0.82-95.62) for DYS compared to 75.00% 
CD28+ (15.31-100) for pp65 epitopes (p<0.001) (Figure 34A and Table 26). Expression 
of CD28 slightly decreased with age only on DYS-specific CD4+ T cells (rSpearman= -
0.3582; p=0.056) (Figure 34B).  
 
Figure 34. Expression of co-stimulatory molecule CD28 on DYS-, AGI- and LLQ-specific CD4+ T cells 
(A). CD28 expression decreases with age on DYS-specific CD4+ T cells (rSpearman=-0.3582; p=0.056) (B). 
**<0.01, ***<0.001. 
Table 26. Median frequencies of CD28, CD27 and CD57 expression on DYS, AGI and LLQ specific 
CD4+ T cells. 
Median % 
(range) 
AGI (n=17) 
p-value 
(DYS vs AGI) 
DYS (n=29) 
p-value 
(DYS vs LLQ) 
LLQ (n=10) 
CD28 
75.00 
<0.001 
31.07 
0.006 
75.66 
(15.31-100.00) (0.82-95.62) (21.21-100.00) 
CD27 
28.03 
0.010 
7.37 
0.135 
12.87 
(1.38-70.59) (0.00-99.01) (5.35-62.93) 
CD57 
12.78 
<0.001 
41.30 
0.010 
20.16 
(0.00-81.00) (0.00-84.71) (0.00-51.52) 
CD57 expression, a characteristic marker of highly differentiated T cells, showed marked 
variation in CMV-specific CD4+ T cells with an increase of 3 fold on DYS-specific CD4+ 
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T cells compared with AGI-specific CD4+ T cells (p<0.001) and 2 fold with respect to 
LLQ-specific CD4+ T cells (p=0.012) (Figure 35A) (Table 26). CD57 expression 
significantly increased with age on DYS-specific CD4+ T cells (rSpearman=0.508; p=0.005) 
(Figure 35B). 
 
Figure 35. Expression of CD57 molecule on DYS-, AGI- and LLQ-specific CD4+ T cells (A). Expression 
of CD57 molecule on DYS-specific CD4+ T cells significantly increases with age (rSpearman=0.508; p=0.005) 
(B). *<0.05, ***<0.001. 
The loss of the co-stimulatory receptor CD27 expression seems to be associated with 
CMV infection (179). In our cohort of individuals we have observed that CMV-specific 
CD4+ T cells presented lower levels of CD27 expression than CD28 with a median of 
12.80% CD27+ (0–99.01%) and 55.53% CD28+ (0.82–100%), respectively, but no 
differences were found related to age. 
However, when comparing CD4+ T cells specific for different epitopes, larger differences 
were found. For both pp65-derived epitopes, AGI and LLQ, the majority of specific T 
cells lacked the expression of the CD27 co-stimulatory molecule but expressed CD28 
showing marked differences with the gB-derived epitope as the majority of these cells 
lacked CD28 co-stimulatory molecule with a median of 69.42% DYS-specific 
CD4+CD27-CD28- T cells (0.49-99.18%) compared to 27.04% pp65-epitope-specific 
CD4+CD27-CD28- T cells (0.00-78.97%) (p<0.001). These observations suggest an end-
stage of differentiation of DYS-specific CD4+ T cells compared to AGI- and LLQ-
specific CD4+ T cells (Figure 36). 
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Figure 36. Proportion of CD27-CD28- cells within the multimer positive CD4+ T-cell population according 
to proteins (gB or pp65). ***p<0.001. 
Therefore, CMV-specific CD4+ T cells showed an effector memory phenotype which was 
not related to donor age, and DYS-specific CD4+ T cells showed a late differentiated 
phenotype characterised by the loss of expression of co-stimulatory molecules such as 
CD27 and CD28 and increase expression of the CD57 marker that was related to age. 
 Functionality of CMV-specific CD4+ T cells 
4.1 Cytotoxic potential of CMV-specific CD4+ T cells 
The cytotoxic potential of CMV-specific CD4+ T cells after in vitro stimulation has 
reported the use of perforin-dependent cytotoxic mechanism rather than the Fas-
dependant pathway. However, some authors have suggested that this cytotoxic capacity 
may be acquired during in vitro culture. 
For that reason, we have analysed the expression of two cytolytic molecules, granzyme 
B and perforin, and the expression of Fas ligand (FasL) in our cohort of donors by direct 
staining with tetramer multimer. FasL expression was very low within CMV-specific 
CD4+ T cells with a median of 0.45% FasL+ (0.00-12.84%) and it was not related with 
age suggesting that CMV-specific CD4+ T cells do not use this pathway as mechanism of 
cytotoxicity. 
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In general, few CD4+ T cells with granzyme B and perforin containing granules were 
detected in the circulation of most healthy individuals (median 7.86% CD4+granzymeB+ 
(0.66-75.62) and 5.26% CD4+perforin+ (0.27-36.63)) but significant differences were 
found when comparing these with CMV-specific CD4+ T cells. CMV-specific T cells 
expressed much higher levels of both molecules (median 73.91% (0.00-97.18%) and 
45.35% (0.00-93.60), granzyme B and perforin levels respectively, p<0.001) (Figure 37).  
 
Figure 37. Representative dot plots showing of expression of cytotoxic molecules granzyme B and perforin 
in CD4+ T cells and tetramer positive cells (A). Expression levels of granzyme B and peforin in CD4+ T 
cells (grey triangles) and CMV-specific CD4+ T cells (black circles) (B). ***p<0.001. 
Further differences were observed between gB- and pp65-specific T cells with an increase 
of 2.7 fold of perforin expression on DYS-specific CD4+ T cells (DR7-restricted) 
compared to AGI-specific CD4+ T cells (DR52b-restricted) (p<0.001) and 1.4 fold 
increase compared to LLQ (DQ6-restricted) (p=0.04) (Figure 38A) (Table 27). Equally 
to perforin expression, DYS-specific CD4+ T cells were found to have greater granzyme 
B levels (median 84.77% (16.67-97.18)) than AGI- and LLQ-specific CD4+ T cells 
(median 40.27% (0.00-96.48); p<0.001 and 67.68% (0.00-91.52); p=0.04, respectively) 
(Figure 38B). A positive correlation was observed between granzyme B and perforin 
values (rSpearman = 0.832; p<0.001) (Figure 39).  
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Table 27. Median frequencies of perforin and granzyme B expression in DYS-, AGI- and LLQ-specific 
CD4+ T cells. 
Median % 
(range) 
AGI (n=17) 
p-value 
(DYS vs AGI) 
DYS (n=28) 
p-value 
(DYS vs LLQ) 
LLQ (n=10) 
perforin 
22.73 
<0.001 
60.81 
0.04 
42.49 
(0.00-74.52) (9.09-93.60) (588-59.07) 
granzyme B 
40.27 
<0.001 
84.77 
0.04 
67.68 
(0.00-96.48) (16.67-97.18) (0.00-91.52) 
 
Figure 38. Percentage of expression levels of perforin (A) and granzyme B (B) in DYS-, AGI- and LLQ-
specific CD4+ T cells. *p<0.05, ***p<0.001. 
 
Figure 39. Correlation between perforin and granzyme B expression in CMV-specific CD4+ T cells 
(rSpearman=0.832; p<0.001). 
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The expression of NKG2D, a killer lectin-like receptor normally displayed by NK cells 
as well as TcR+ cells and TcR+ CD8+ T lymphocytes, has also been described on a 
particular subset of CD4+ T cells in patients with cancer, chronic autoimmune diseases or 
persistent infection, and after in vitro stimulation its expression increases (180, 181). In 
that sense, we have evaluated the expression of NKG2D on CMV-specific CD4+ T cells. 
There was a notable increase of NKG2D expression on CMV-specific CD4+ T cells 
compared to the overall CD4+ T cells, suggesting that CMV-specific CD4+ T cells were 
more differentiated (median 22.98% (0.00-73.78) vs. 1.57% (0.94-10.40), p<0.001, 
respectively) (Figure 40A). No differences were found in the group of individuals based 
on age with a median of 21.32% (11.56-54.05), 30.96% (0.00-50.00) and 20.16% (0.93-
73.78) for young, middle aged and older adults respectively (Figure 40B). NKG2D 
expression was pretty similar in gB- and pp65-specific CD4+ T cells and no differences 
were found (median of 21.33% (0.00-73.78) for DYS-specific CD4+ T cell, 38.33% (3.80-
54.05) and 12.78% (5.22-39.07) for AGI- and LLQ-specific CD4+ T cells, respectively) 
(Figure 40C). 
4.2 Analysis of regulatory function of CMV-specific CD4+ T cells  
A subset of CD4+ T cells is known to act as regulatory T cells (T regs) by supressing T-
cell responses against self-antigens. CD4+ T regs are characterised by expressing the 
surface marker CD25, a marker of T-cell activation that also mediates suppressor T-cell 
function (182), the intracellular FoxP3 transcriptor factor but have low or no CD127 
expression. We have evaluated if CMV-specific CD4+ T cells have regulatory function 
by directly ex vivo staining for these markers in combination with tetramer multimer. 
However, no presence of T regs was observed within the population of CMV-specific 
CD4+ T cells. No FoxP3+ cells were detected among the specific cells compared to overall 
CD4+ T cells which on average contained 2.30% (0.20-6.46) of FoxP3+ cells (p<0.001) 
(Figure 41).  
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Figure 40. Expression levels of NKG2D marker on total CD4+ T cells and CMV-specific CD4+ T cells (A). 
Expression of NKG2D on CD4+ T cells and CMV-specific CD4+ T cells in the three groups of individuals 
based on age (B). Expression of NKG2D on DYS-, AGI- and LLQ-specific CD4+ T cells (C). ***p<0.001 
 
Figure 41. Expression levels of the regulatory marker FoxP3 on total CD4+ T cells and CMV-specific CD4+ 
T cells. ***p<0.001. 
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4.3 Functional exhaustion of CMV-specific CD4+ T cells  
Functional exhaustion of T cells is induced by continued exposure to high levels of viral 
antigens and is characterised by partial or complete loss of capacity to produce effector 
cytokines. There is an increased expression of inhibitory receptors, such as PD-1 and T-
cell immunoglobulin and mucin domain-containing molecule 3 (Tim-3) and this increase 
is thought to be associated with late differentiation phenotype characterised by the loss of 
CD27 and CD28.  
In our cohort of individuals no expression of Tim-3 among the CMV-specific CD4+ T 
cells was observed and it was hardly expressed on overall CD4+ T cells (less than 1.5%). 
In contrast, the CMV-specific cells expressed the inhibitory molecule PD-1 and there was 
a marked increase compared to total CD4+ T cells (median 44.93% (5.72-96.97) vs. 8.98% 
(1.60-32.03), respectively; p<0.001) (Figure 42A), indicating that CMV can induce 
functional impairment of CD4+ T cells. No differences of PD-1 expression were observed 
with age but there was a significant increase on cells specific for both pp65-derived 
epitopes when compared to gB-specific T cells (median of 50.65% PD-1 (5.96-96.97) for 
pp65- and 28.92% PD-1 (5.72-81.82) for gB-specific T cells (p = 0.006)) (Figure 42B). 
 
Figure 42. Expression of the inhibitory molecule PD-1 on total CD4+ T cells compared to tetramer positive 
cells (A) and PD-1 expression on DYS- and AGI&LLQ- (pp65-) specific CD4+ T cells (B). **p<0.01, 
***p<0.001. 
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4.4 Proinflammatory receptor expressed on CMV-specific CD4+ T cells 
Latent CMV infection has been related to vascular diseases and immunosenescence (183). 
During CMV latency, there is a pool of highly differentiated effector T cells that produce 
inflammatory mediators which can activate endothelial cells that are infected by CMV. 
These activated endothelial cells produce cytokines such as fractalkine which can draw 
in immune cells which may be able to induce endothelial damage. The receptor for 
fractalkine is CX3CR1 and recent studies have shown that it is only expressed on CMV-
specific effector CD8+ T (184) and we wanted to know if CMV-specific CD4+ T cells 
also expressed it.  
CX3CR1 was highly expressed on CMV-specific T cells compared to the total CD4+ T-
cell pool with no differences with age, showing a median of 84.07% (13.46-98.84) on 
virus-specific CD4+ T cells and 9.52% (1.16-55.91) on the total CD4+ T-cell population 
(p<0.001) (Figure 43). 
 
Figure 43. Expression of the fractalkine receptor (CX3CR1) on the total CD4+ T-cell population and CMV-
specific CD4+ T cells within the different age groups.***p<0.001. 
However, when studying the expression of CX3CR1 between different epitope-specific 
CD4+ T cells, we have observed that there is a significant increase of the expression of 
this marker on DYS-specific CD4+ T cells compared to pp65 -specific CD4+ T cells 
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(median of 89.37% (44.70-98.79) and 82.14% (13.46-96.27), respectively; p=0.008) 
(Figure 44).  
 
Figure 44. Expression of the fractalkine receptor (CX3CR1) on CMV-specific CD4+ T cells of individuals 
with cells specific for the gB epitope and both pp65 epitopes.**p<0.01. 
The following figure (Figure 45) summarises expression levels of the different surface 
markers studied on CMV-specific CD4+ T cells of healthy individuals identified by 
staining with tetramer multimer and the total CD4+ T-cell population. This allows to 
observe the different phenotypes depending on the epitope-specificity and also the 
differences that CMV induces on these cells when comparing with the overall CD4+ 
subset. There is also correlation between the different markers 
As a summary, CMV-specific CD4+ T cells lose expression of the co-stimulatory 
molecule CD27 and acquire cytotoxic function in comparison to the overall CD4+ T cells. 
CMV-specific CD4+CD28- cells expressed higher levels of both granzyme B and perforin 
cytotoxic molecules. Besides, DYS-specific CD4+ T cells show a highly differentiated 
phenotype with lower levels of CD28 and increased expression of CD57 surface markers, 
and have higher cytotoxic potential with higher expression of perforin when compared to 
pp65-specific T cells. 
In conclusion, MHC class II tetramers allow a reliable detection of CMV-specific CD4+ 
T cells and it has been possible to characterise the phenotype of those cells ex vivo in 
healthy individuals prior to implementing this technology in the monitoring of CMV-
specific CD4+ T cells immune recovery following allo-HSCT. 
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Figure 45. Heatmaps of expression levels of phenotypic markers studied in CMV seropositive healthy 
donors. Phenotype of CMV-specific CD4+ T cells of DYS-. AGI- and LLQ-specific cells (A, C and E 
respectively) and phenotype of total CD4+ T cells from the same donors (B, D and E). 
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A Detection of CMV-specific CD8+ T cells 
 Selection of streptamer multimer as tool for monitoring CMV-specific CD8+ 
T-cell immune reconstitution in patients following allogeneic haematopoietic 
stem cell transplantation 
CMV infection or reactivation represents a major complication in allo-HSCT recipients 
due to the delayed recovery of T- and B-cell functions that leads to impaired cytotoxic T-
cell response (110). Development of a reliable method to evaluate CMV-specific 
immunity may facilitate the management of patients at risk for CMV 
infection/reactivation, allowing prompt initiation of antiviral treatment. In order to 
monitor disease-specific immune responses and to develop new immunotherapeutic 
strategies, it is essential to identify only those T cells that recognize a given MHC 
complex within the large pool of irrelevant T cells. In that sense, the use of multimer 
technologies (156) has become a useful tool in order to identify, quantify and monitor 
antigen-specific T-cells (155). Moreover, the use of multimer methodologies are 
nowadays being studied as new immunotherapeutic strategies to promote the 
reconstitution of antigen-specific immunity that could control viral infection following 
allo-HSCT (185).  
The most common format in use to monitor antigen-specific T-cell recovery is tetramer 
multimer although other multimerization approaches such as PMs, octamers, dextramers 
and streptamers are available. Several studies use tetramer multimer in order to monitor 
CMV immune reconstitution in patients following allo-HSCT (77, 78). However, there is 
not, to our knowledge, any study that monitors CMV immune recovery in allo-HSCT 
recipients with other mulitmerization strategies that offer some advantages over classical 
tetramers (143). In this study, we have chosen and compared two of these advancements 
of multimer technologies, PM and ST. We chose PM due to the closeness to tetramer 
multimer configuration however, it results in higher avidity interaction with the TCR 
because of the same direction of the MHC-peptide complexes and brighter staining due 
to the five fluorochromes than tetramer does (159). By contrast, we selected ST as it can 
be dissociated from cytotoxic CD8+ T-cell by adding the competitor molecule biotin and 
these ST-selected specific-CTLs can either be expanded or cloned and then adoptively be 
transferred to the patient (161, 163).  
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In order to select the best strategy for the incorporation into clinical monitoring practice, 
we first performed a detailed technical analysis of advantages and disadvantages of both 
technologies. In addition, the relative cost of using ST reagent was lower to the classical 
tetramer whereas the relative cost of PM multimer was similar to when considering its 
use for routine clinical monitoring. 
Low standard deviation was observed with both multimer staining, showing a highly 
repeatability. Moreover, both methods showed low intra-individual variability, 
demonstrating that could be considered equally precise. Similar values of CMV-specific 
CD8+ T cells were detected with both multimers and a significant correlation was detected 
between both techniques when frequencies more than 1% were detected but not a lower 
levels.  
On the contrary, we have observed that PM technology detects higher amounts of 
multimer-positive CD8+ T cells mainly at low dilutions when the sensitivity of these 
methodologies was studied. Our data differ from a previous study that reported similar 
results with both methodologies (186). We have observed that the PM technique is less 
accurate than the ST methodology, as the detected results with the PM multimer differed 
from the theoretical values. We confirmed these results by analysing multimer positive 
cells in non-HLA-A*02:01/CMV-seronegative, non-HLA-A*02:01/CMV-seropositive 
and HLA-A*02:01/CMV-seronegative volunteers, demonstrating that background signal 
levels detected were significantly higher with PM technology compared to ST 
methodology. This difference could be explained by the MFI observed for both 
multimers. PM staining provides lower MFI values than ST, and it is not easy to 
distinguish positive from negative populations when the proportion of specific cells is 
low (Figure 11). According to this, we can speculate that despite the binding affinity of 
MHC-TCR being the same for both multimers, the relative binding avidity may be 
different. This may, in turn, be higher for the ST multimer which makes a brighter 
staining. 
Furthermore, some authors have studied non-specific binding on tetramers by comparing 
them to MHC mutated ones (187). It is widely known that in T-cell recognition there is 
not only an interaction between both the TCR and the peptide joint to the MHC complex 
but also peptide-MHC interactions with the cell surface CD8 that binds to invariable 
regions of the MHC class I molecules. As a result, a single MHC molecule can be bound 
simultaneously by both TCR and CD8 (188). The affinity of the TCR-MHC interaction 
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can be more than 100-fold stronger compared to the MHC-CD8 interaction (189). By 
modifying the MHC in the 3 domain, the CD8 binding to non-specific cells is abolished. 
These results suggest that the tetramer interacts with the co-receptor CD8 of T cells whose 
TCR had a low affinity for the peptide complex and could explain the background 
observed in our results with PM. The spatial configuration of the PM (similar to the 
tetramer) leads the 3 domain more available to the CD8 of non-specific cells allowing 
the tripartite TCR-MHC-CD8 interaction. This could be hindered in the ST due to the 
different structural configuration and composition (188).  
The fact that ST is more reliable than PM especially at low frequencies of antigen-specific 
cells could be very useful in those patients that have little percentage of virus-specific 
CTLs that are not detected by other multimers. PM technology performed well when the 
monomeric TCR-MHC affinity was relatively high. However, it failed to detect T cells 
that are capable of recognizing a particular antigen, as T cells with weak, but functional 
TCRs might not be detected. Furthermore, due to unspecific bindings, positive staining 
could be obtained in the absence of virus-specific T cells. On the contrary, with the 
streptamer methodology, we could be able to monitor these specific T cells from the 
immediate post-transplant period, even when their frequencies are extremely low. 
Other forms of multimerization such as octamers and dextramers also provide higher 
binding avidity than tetramers as they contain higher amounts of MHC molecules and 
fluorochromes. It is even possible to detect T cells with low TCR-MHC binding affinity 
with dextramers (190). However, octamers have been shown to activate the cytotoxic 
CD8+ T cells for Fas dependent apoptosis (191). The use of tetramers for adoptive T-cell 
therapy has also been studied, however, their use as well as pentamers, octamers and 
dextramers offer a disadvantage over streptamer multimers as they cannot be dissociated 
from the antigen-specific CD8+ T-cell. Functional status of multimer-selected antigen-
specific T-cell might be hampered by the persistent binding of TCR-MHC interactions. 
By contrast, some side effects might be avoided with streptamer technology such as T-
cell anergy, immune responses directly against the multimers, harm from clinical in vivo 
application and loss of the capacity of the transferred T cells to migrate in vivo, offering 
a new therapeutic approach at good manufacturing practice (192). 
In conclusion, our results have shown that it is preferable to use ST technology that gives 
an accurate, precise and specific measurement to monitor the immune recovery of virus-
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specific T cells in HSCT recipients. It also offers a potential use for adoptive T-cell 
therapy. However, it is necessary to point that these results do not represent either the 
entire CMV repertoire or HLA restrictions. We have selected the most common HLA 
allele within the Caucasian population (HLA-A*02:01) but the results may vary 
depending on the peptide-specificity or HLA restriction as avidity and affinity of them 
may depend on chemical structure. Some studies have pointed out this fact (77, 193). 
Therefore, future studies should be performed with other HLA restrictions and CMV 
epitopes to support our findings. 
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 CMV-immune reconstitution after allogeneic haematopoietic stem cell 
transplantation 
2.1 Features that contribute to CMV reactivation 
CMV viremia is frequently seen within the first months following transplant and it is 
possible that allo-reactive immune responses contribute in some way to the process of 
reactivation.  
In the present study, we have evaluated T-cell immune reconstitution against CMV 
infection in 25 HLA-A*02:01 recipients during one year post allo-HSCT. T-cell recovery 
as well as CMV-specific CD8+ T-cell response have been analysed in order to predict the 
kinetics of CMV immune reconstitution. In our study we have monitored patients by 
using two different methodologies: ST multimer and in vitro IFN production to assess 
CMV-specific CD8+ T-cell recovery. 
In our cohort of patients, the cumulative incidence of CMV reactivation during the first 
year after allo-HSCT was not influenced by HLA compatibility as Jaskula et al. and Mead 
et al. observed in their studies that a lack of optimal donor/recipient HLA matching was 
associated with higher CMV reactivation or infection (68, 79). Conditioning treatment 
did not have any impact on CMV reactivation either as it has been shown by other 
researchers where CMV reactivation was less common in patients receiving RIC 
conditioning compared to MA treatment (84). On the contrary, CMV reactivation was 
significantly influenced by both HSCT donor type being more frequent in patients 
receiving transplant from unrelated donors, and T-cell depletion in conditioning 
treatment. Both data are related as in vivo T-cell depletion is administered in patients 
receiving unrelated donor transplant to reduce GvHD and thus, there is a delay on immune 
reconstitution. Our findings agree with previous studies by Lilleri and collaborators, 
where CMV infection/reactivation was more frequent in people receiving a T-cell 
depleted graft (71).  
Previous studies have shown the impact that donor CMV serostatus has on CMV 
reactivation after allo-HSCT. In that sense, CMV seropositive patients whose donors 
were CMV seronegative experienced a higher risk of CMV reactivation, compared to 
those whose donors were seropositive (68, 71). In our cohort of patients all but one were 
CMV seropositive, however 32% received a transplant from a seronegative donor. In our 
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cohort of patients, donor CMV-serology did not have any influence on CMV reactivation 
within our patients. This fact might be due to the low number of patients that could be 
monitored. 
2.2 T-cell immune recovery may influence on CMV reactivation following 
transplant 
The development of an effective T-cell immunity is important for the control of CMV 
infection/disease in patients following allo-HSCT. Previous studies have found a strong 
association between the lack of CMV-specific CD8+ T cells and the development of CMV 
disease after transplantation. Therefore the identification of the protective cell number 
against CMV infection and reactivation is of special interest.  
In our cohort of patients, normal median values of both CD4+ and CD8+ T cells (>100 
cells/L and >50 cells/L, respectively) were reached after two months of transplantation 
in patients that did not experience CMV-DNAemia, whereas recipients with CMV 
reactivation and short antiviral treatment reached those levels between two and three 
months post-transplantation. On the contrary, recipients that required prolonged antiviral 
treatment achieved those levels between 200 days and 300 days after allo-HSCT and they 
have experienced CMV reactivations after 100 days following transplant. Recurrent 
CD4+ T-cell counts lower than 100 cells/L during the first three months has been 
strongly associated with CMV reactivation, underscoring the adverse effect of impaired 
CD4+ T-cell reconstitution on infectious morbidity and late CMV disease (194, 195). Our 
results are supported by other authors, who estimated that cut-off values for CD4+ less 
than 100 cells/L and CD8+ less than 50 cells/L at three months after transplantation 
were associated with poor CMV specific immunity (196). These results agree with those 
obtained by Moins-Teisserenc and colleagues, in which they suggested that T-cell counts 
higher than 100 cells/L for both CD4+ and CD8+ may prevent the risk of CMV 
reactivation (197). 
We have observed a good correlation between CMV-specific CD8+ T cells absolute 
counts regardless of CMV reactivation status and total CD8+ and CD4+ counts in our 
cohort of patients. These observations differ from those found by Gratama et al., where 
CMV-CTL levels showed a moderate correlation with total CD8+ T-cell counts but a 
negligible correlation with absolute CD4+ counts (157). These results suggested that 
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CD4+ T-cell function might be essential for CMV-specific CD8+ T-cell immune 
reconstitution. 
2.3 CMV-specific CD8+ T-cell expansion after CMV reactivation prevents 
multiple CMV reactivations and affects antiviral treatment  
Similar to total CD8+ and CD4+ levels to prevent CMV reactivation, a protective number 
of CMV-specific CD8+ T cells has been suggested by several authors to avoid CMV 
reactivation and disease. In that sense, Borchers and colleagues (77) proposed that levels 
of 1 CMV-specific CD8+ T cell/L could protect against CMV reactivation when 
monitoring patients following allo-HSCT by tetramer multimer. However, it is interesting 
to mention that protective cell numbers may vary considerably for individual 
combinations of HLA molecules and CMV epitopes. 
In our study, no differences were found between levels of CMV-specific CD8+ T cells 
detected by the multimer technique when comparing patients without and with CMV 
reactivation at early time points after allo-HSCT (day +30). Besides, the median number 
of CMV-specific CD8+ T cells detected with the ST multimer was 0.780 cells/L (0.050-
1.080) during the year follow up in patients that did not reactivate. Those levels are similar 
to the ones found to be protective in immunocompetent subjects (more than 0.4 CMV-
specific T cells/L of blood) and therefore patients were able to control CMV infection 
without the need of antiviral treatment (71). However, we cannot use either 0.4 or 1 CMV-
specific CD8+ T cells/L as a cut-off value for all the cohort of patients, as we have 
observed CMV reactivations in several recipients despite the presence of 1 CMV-specific 
CD8+ T cell/L. We have evaluated patients that experienced CMV viremia according to 
duration of antiviral treatment. Patients with short antiviral treatment developed CMV-
CTL proliferation as measured by an increase on multimer positive cells after first CMV 
reactivation. This expansion of CMV-specific CD8+ T cells does correlate to protection 
against recurrent CMV reactivations after 100 days following transplant, while the 
absence of CMV-specific immune reconstitution leads to recurrent reactivation of CMV 
beyond day +100 post-transplant and prolonged antiviral therapy. The results published 
by Borchers and collaborators and Moins-Teisserenc et al. support our findings, as they 
found that non-proliferating CMV-CTL post CMV reactivation correlated with 
recurrence (78, 197).  
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In addition to currently controversial CMV-CTL quantity that provides protection against 
viral reactivation, the influence of CMV reactivations on immune reconstitution is also 
widely debated. While Chen et al. argue that CMV reactivation boots the reconstitution 
of CMV-specific CTLs (198), others find no influence of CMV reactivation on CMV-
CTL reconstitution (199). In our study, patients reactivating CMV had higher median 
CMV-CTL numbers than patients without CMV reactivations, implying a significant 
influence of CMV reactivation on levels of CMV-CTLs detected. Besides, we have 
observed a group of recipients within patients that required short antiviral treatment that 
only had one episode of CMV-DNAemia, whereas others had two or three CMV 
reactivations. Levels of CMV-specific CD8+ T cells detected after the first CMV 
reactivation were significantly higher in those patients compared to recipients with more 
than one reactivation. Interestingly, no differences were found in CMV-CTL levels after 
CMV reactivation in patients with only one reactivation, or the second reactivation in 
patients that reactivated twice or after the third reactivation in those with 3 episodes of 
CMV-DNAemia. The lowest number of CMV-specific CD8+ T cells reached after CMV 
reactivation in our cohort of individuals was 1.348 CMV-CTLs/L and therefore, it could 
be protective threshold against recurrent CMV reactivation. Patients without CMV 
viremia also expanded CMV-CTLs, but to a lesser extent than those with CMV 
reactivation, as it was observed by the increase of those cells between days +30 and +60. 
Borchers et al.’s study, carried out in almost 200 patients, supported our findings (77). 
However, it is necessary to point out that CMV-CTL numbers may vary for individual 
combinations of HLA molecules and CMV epitopes as reported by Borchers and 
colleagues (77). 
In summary, CMV ST-based immune monitoring, in conjunction with virology 
monitoring, can be an important new tool that permits clinicians to assess the risk of 
CMV-related complications and to guide pre-emptive therapeutic choices. Indeed, 
sequential monitoring of the post-transplant CMV-CTL immune reconstitution allows a 
more accurate interpretation of an individual patient’s response to CMV. In addition, we 
have demonstrated that expansion of CMV-specific CD8+ T cells after CMV reactivation 
adds to the protection against recurrent CMV reactivations whereas non-proliferating 
CMV-CTL post CMV reactivation correlated with recurrence. However, as there is a 
group of patients who did not develop CMV-DNAemia and CMV-CTL levels hardly 
expanded there must be other factors involved in this protection. 
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2.4 Functional recovery of CMV-specific CD8+ T cells after transplantation 
prevents CMV reactivation 
We were further interested in studying the group of patients that did not reactivate CMV 
despite not reaching the cut-off value for CMV-specific CD8+ T cells. In spite of finding 
no differences in the number of CMV-specific CD8+ T cells detected by multimer 
technology between patients with and without CMV reactivation at early time points (day 
+30) after allo-HSCT, significant differences were found in the functionality of those 
cells. CMV-CTLs from patients that never experienced CMV viremia were functional 
one month after transplantation, whereas functional recovery did not occur in recipients 
that developed CMV reactivation. Therefore, having functional CMV-specific CD8+ T 
cells at early time points following transplant may protect against CMV reactivation. The 
median number of in vitro IFN+CD8+ T cells of those recipients during the year follow 
up was 0.630 cells/L (0.094-55.159), which is closer to the protecting levels obtained in 
healthy individuals (>0.4 cells/L) (71).  
Most CMV reactivations occurred between the first and the second month after allo-
HSCT in our cohort of patients and thus, we analysed the functionality of CMV-specific 
CD8+ T cells two months post-transplantation. As observed with multimer technology, 
there was an increase of in vitro IFN production in patients that experienced CMV-
DNAemia, compared to recipients without CMV reactivation. This fact indicates that 
CMV reactivation induces expansion of functional CMV-CTL. 
In our study, patients receiving short antiviral treatment had median levels of functional 
CMV-CTLs signiﬁcantly lower in the presence of CMV-DNAemia than at the time of the 
ﬁrst negative PCR result. This supports the fact that CMV reactivation induces T-cell 
expansion. However, despite increasing the numbers of functional CMV-CTLs after 
reactivation, there are patients with more than one CMV reactivation. Therefore, not only 
the expansion, but also reaching threshold levels may be a prerequisite to resolve CMV 
reactivation. Taking into consideration the lowest value for IFN+CD8+ T cells found 
after CMV viremia clearance in this group, we can suggest 1.290 cells/L as a threshold 
value for predicting CMV-DNAemia clearance (negative PCR result). These cut-off level 
is remarkably closed to those previously determined by using functional assays for IFN 
and IL-2 secretion or ELISpot assays in a higher cohort of individuals by Tormo et al. 
(>1.3 CMV-CTLs/L) (200) and by other groups (1-3 CMV- CTLs/L) (86, 201, 202). 
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This implies that detection of 1 to 3 CMV-CTLs/L of blood may indicate the threshold 
of a functional immunity against CMV. 
The inability to control CMV reactivation is related to functional impairment of antigen-
specific CD8+ T cells. This fact has been demonstrated by Gratama et al. and Morita-
Hoshi. et al. (203, 204), and it may explain the behaviour of those patients requiring 
prolonged antiviral treatment in our cohort of recipients. There is no IFN production by 
CD8+ T cells upon in vitro stimulation with CMV-pp65495-503 antigen and several CMV 
reactivations are developed that are controlled by antiviral therapy. These patients did not 
show either CMV-CTLs when using multimer technology or in vitro IFN production 
upon stimulation with CMV-pp65495-503 antigen during the first months after allo-HSCT. 
After 200 days approximately following transplant, functional activity is recovered and 
these patients stop CMV reactivations.  
The use of a methodology that enables the detection of cytokines produced by virus-
specific cells upon in vitro stimulation would be very useful in monitoring the 
functionality that those specific cells may have. We have measured the IFN production 
by CMV-specific cells by using a -capture-based kit according to manufacturer’s 
instructions. It is interesting to mention that the differences that we detected on in vitro 
IFN production with this technology compared to ICS technique could be because of 
prelabelling the T cells with the pentamer multimer that may partially inhibit their ability 
to respond to the target peptide as it has been observed with other multimers (163, 192). 
Unfortunately, it has not been possible to optimize and use this technique to monitor 
functionality of multimer+CD8+ T cells due to the low number of patients that could be 
analysed. Further studies would be necessary in order to evaluate its use for the 
monitoring of functional antigen-specific T-cell recovery in patients following transplant. 
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On the basis of our results, we have observed three different kinetic patterns of CMV-
specific CD8+ T-cell reconstitution: 
(i) An early recovery of functional CMV-specific CTLs that might protect from 
CMV reactivation. 
(ii) An expansion of functional CMV-specific CD8+ T cells is observed after 
CMV reactivation. Those patients with increasing CMV-specific CTLs 
detectable at the time of PCR reactivation only need a short course of antiviral 
therapy. 
(iii) An inconsistent or a lack of expansion of functional CMV-specific CD8+ T 
cells with recurrent CMV-DNAemia and in need of prolonged antiviral 
therapy. 
In summary, our data suggest that routine immunological monitoring following transplant 
allows a more accurate interpretation of an individual patient’s response to CMV. The 
protective hallmarks might depend on reactivation status. Analysis of the CMV-CTL 
expansion may facilitate implementation of patient-specific antiviral therapy. 
In addition, our results have shown that not only the number of CMV-specific CD8+ T 
cells may be related to CMV reactivation but also their ability to respond to CMV through 
either CMV-specific T-cell expansion or IFN production which can confer protection 
against CMV reactivation. These observations agree with a recent study developed by 
Suessmuth Y and colleagues (205) in which it is shown that CMV reactivation drives 
post-transplant CMV-specific T-cell reconstitution and results in defects in the underlying 
TCR repertoire. 
2.5 Future perspectives 
The use of class I multimer technology allows direct measurement of the frequency of 
virus-specific T cells. There are kits available to detect CMV-specific T cells in whole 
blood by using dextramer technology that can be implemented in the monitoring of CMV 
immune recovery after allo-HSCT (190). 
Because CMV reactivation arises from impaired CMV-specific T-cell immunity, various 
adoptive transfer protocols have been developed in order to restore cellular immunity 
against CMV (120, 206). The main purpose of antiviral adoptive immunotherapy is to 
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provide a competent immunological response able to control the virus. Many groups have 
focused their interest on developing strategies for adoptive transfer of CMV-specific T 
cells. The isolation of CMV-specific CTLs by using ST technology has shown that these 
cells retain their effector function which is essential for a successful adoptive 
immunotherapy (192). Some clinical studies have been developed using this technology 
as ST is available at a good manufacturing practice level (185) 
(https://www.clinicaltrials.gov/ct2/NCT01077908/ or NCT01220895 or NCT01220895). 
According to our data, a lack of consistent expansion of CMV-speciﬁc T cells is 
associated with persistent CMV DNAemia, even in the absence of proven resistance to 
antivirals. In this regard, it would be reasonable to consider adoptive transfer of CMV-
speciﬁc functional T cells as a therapeutic option in episodes of active CMV infections 
that do not respond to antiviral therapy. (185, 207). 
Therefore, the analysis of the CMV-CTL expansion rate may facilitate implementation 
of patient-specific antiviral strategies, including adoptive transfer of CMV-CTLs to 
recipients unable to respond to CMV reactivation. 
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B Phenotypic characterisation of CMV-specific CD4+ T cells 
 Identification of CMV-specific CD4+ T cells by MHC class II tetramers 
For more than a decade, there is a debate on whether both CMV-specific CD4+ and CD8+ 
are required to confer protection against CMV reactivation, or whether only one of these 
two T-cell populations is sufficient to protect from CMV relapse. Some authors have 
indicated that CMV-specific CD4+ T cells may be sufficient to predict a reliable control 
of CMV infection (55, 203). By contrast, recent studies have shown that both T-cell 
subsets are required for a long-lasting protection against CMV reactivation (71, 200, 208). 
Moreover, effective control of CMV infection was attained in patients when CMV-
specific cells, were infused, of which 77% were CD4+ T cells (186). Gamadia et al. 
reported that during primary CMV infection, virus-specific CD4+ T cells precede the 
appearance of virus-specific CD8+ T cells in renal transplant recipients (43). Both the 
absence of antigen-specific CTLs, and particularly the absence of specific CD4+ T helper 
cells resulted in higher CMV loads (209). Thus, CD4+ T-helper cells are likely to 
participate in CMV control, as it has been observed, in out cohort of individuals, in the 
correlation between CMV-specific CD8+ T cells and CD4+ T cells. 
The presence of CMV-specific CD4+ T-cell clones has been reported based on cytokines 
produced upon in vitro stimulation with CMV peptides, virus lysate and CMV protein 
(210). CD4+ T cells usually recognize an antigen that has been taken up by the antigen 
presenting cell rather than presented directly from cytosol. Kern et al. reported that there 
is a high prevalence of CD4+ T-cell responses to pp65, and peptides derived from 
tegument proteins are likely to be presented in a MHC class II context after endocytosis 
or phagocytosis of viral material (37). Recent evidence has indicated that CMV gB is 
sorted to endosomes and can be presented efficiently by class II molecules which is 
especially relevant as it can directly be presented by CMV-infected cells without the need 
to be taken up by APCs(211).  
The study of antigen-specific CD4+ T cells by using class II multimer technology has 
been limited by the insensitivity of detection in ex vivo samples and paucity of defined 
CD4+ T-cell epitopes with known HLA restriction. Another limiting factor is simply 
technical issues in making them, as MHC class II are structurally different when 
compared with class I. In the last years, more epitopes have been defined, so the utility of 
Discussion 
 
126 
 
HLA class II tetramers is expanding (170). CMV-MHC class II tetramers have been 
previously studied without successful results, suggesting that due to the low frequencies 
it was necessary an enrichment step by using magnetic beads to allow accurate definition 
of a responder population, as it occurs with other virus such as EBV (171, 212). 
In our study, we have described for the first time, three MHC class II tetramers to identify 
CMV-specific CD4+ T cells directly ex vivo without the need of an enrichment step, 
allowing a reliable detection of CMV-specific CD4+ T cell. Besides, CMV-specific CD4+ 
T-cell response compared to other antigen-specific CD4+ T-cell responses, for example 
those to EBV) can be extremely large (although not in every donor) and it can be at least 
as marked as that seen within the CD8+ T-cell populations. Besides, the magnitudes of 
DYS-, AGI- and LLQ-specific CD4+ T cell responses averages from 0.07 to 24% of the 
total CD4+ T-cell repertoire and are much higher than those obtained by Harcourt et al. 
even after enrichment (171). However, we have only targeted a very limited HLA 
repertoire and there may be other dominant epitopes. The presentation of peptides through 
class II molecules could be of particular importance in control of CMV and other 
herpesviruses as these pathogens have developed immune evasion strategies to avoid 
recognition by CD8+ T cells and NK cells (213). 
 Cytotoxic function and effector memory phenotype of CMV-specific CD4+ T 
cells 
Over the last two decades, the ability of CD4+ T cells to display cytotoxic potential has 
been reported by several studies in humans. Nevertheless, the observation of such 
cytotoxic activity in CD4+ T cells has usually been restricted to cell lines and CD4+ T-
cell clones generated by long term in vitro culture and it has been considered an artefact 
by some authors (214). However, Appay et al. were the first to report the presence of 
CD4+ T cells with cytotoxic capacity without the need for in vitro stimulation in humans 
(144). In our study, we have also observed cytotoxic CD4+ T cells ex vivo as there is a 
population within the CD4+ T-cell subset that express the cytotoxic molecules perforin 
and granzyme B in healthy individuals. Appay et al. suggested that the presence of these 
cells was related to chronic viral infections. Interestingly, the direct staining with tetramer 
multimers has shown that the vast majority of CMV-specific CD4+ T cells showed this 
cytotoxic potential by expressing both perforin and granzyme B molecules. It is 
interesting to mention that this high cytotoxic potential varies depending on their peptide 
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specificity. DYS-specific CD4+ T cells present higher levels of both granzyme B and 
perforin than AGI- and LLQ-specific CD4+ T cells (39, 62). 
The phenotypic analysis of the tetramer-positive CD4+ T cells revealed that CMV-
specific CD4+ T cells showed predominantly an effector memory phenotype characterised 
by a complete loss of CCR7. Most cells expressed the memory marker CD45RO (this 
isoform is associated with antigen-experienced cells), although a minority had a revertant 
memory phenotype with high-level expression of CD45RA (TEMRA), which has only been 
observed on the DYS-specific CD4+ T-cell population (215, 216). The opposite is seen 
on CMV-specific CD8+ T cells that have been widely described to be mainly of the late 
differentiated effector memory phenotype (EMRA) (217-219). 
It has been observed that differentiating CD4+ T cells first lose expression of CD27 and 
only in a later phase they lose CD28, thus all CD28- are CD27-. It is the opposite for CD8+ 
T cells, where CD8+CD27- cells always have lost CD28 expression (39). The presence of 
CD4+CD28- T cells is not commonly seen and CMV infection is the major factor causing 
this differentiation step of CD4+ T cells (39). Besides, these cytotoxic CD4+CD28- cells 
display increased expression levels of CD57, which is a marker of replicative 
incompetence and it has been associated with a highly differentiated cytotoxic phenotype. 
Our results reported that CMV-specific CD4+ T cells present differences in their 
differentiation profile depending on the CMV protein-recognized (gB or pp65). gB-
(DYS) specific to the same extent as pp65-(AGI/LLQ) specific CD4+ T cells have lost 
CD27 surface expression marker; however, CMV-specific CD4+ T cells that recognize 
peptides from the CMV-pp65 protein, AGI and LLQ, presented higher levels of CD28 
co-stimulatory molecule and also had lower levels of CD57 compared to DYS-specific 
CD4+ T cells that showed a highly differentiated phenotype. We have also observed that 
this differentiation status of DYS-specific CD4+ T cells was related to age (30). 
This progressive differentiation with the loss of CD27 and CD28 molecules has been 
associated with the expression of intracellular cytotoxic granules and perforin, as 
observed with CD8+ T cells. Our analyses reported that both AGI- and LLQ-specific 
CD4+ T cells presented lower levels of perforin compared to DYS-specific CD4+ T cells 
which agree with higher expression of CD28 on pp65-epitope-specific CD4+ T cells. 
Therefore, highly differentiated CMV-specific CD4+ T cells become cytotoxic by the 
expression of perforin at the CD28 negative stage. We have observed that DYS-specific 
Discussion 
 
128 
 
cells are highly cytotoxic compared to AGI- and LLQ-specific cells probably due to the 
differences on the antigen process. 
Therefore, these results showed that CMV-specific CD4+ T cells are highly cytotoxic ex 
vivo and it varies depending on their peptide specificity. Further, these cells are mainly 
effector memory cells, with a late differentiation stage characterise by the loss of CD28 
co-stimulatory molecule. A possible explanation of the different phenotype between 
DYS- and AGI- or LLQ-specific CD4+ T cells could explain by the differences in priming 
of the response. Both proteins, gB and pp65, are quite abundant in the virion and also 
expressed late in the virus life cycle. gB is directed into the MHC class II pathway and 
directly presented, rather than indirectly by antigen presenting cells like pp65. Therefore, 
gB-specific T cells may be more driven towards a more “differentiated” phenotype. 
Similar to NK cells and cytotoxic CD8+ T cells, we have observed that CMV-specific 
CD4+ T cells express the killer lectin receptor NKG2D. These observations were also 
reported in a study by Sáez-Borderías et al. where an increase on NKG2D expression by 
CD4+ T cells after 10 days of in vitro stimulation with CMV virus was observed (180). 
We detected the same levels of NKG2D expression on CMV-specific CD4+ T cells by 
direct staining with multimers than they obtained after 10 days of stimulation, 
approximately, 20% of the CMV-specific CD4+ T cells expressed this receptor. Their 
study also suggested that the expansion of CD4+ T cells expressing NKG2D after 
stimulation corresponded to virus-specific memory cells that have acquired NKG2D 
while losing CD28. It is possible that the lack of co-stimulatory molecules such as CD27 
and CD28 can be overcome by activation through binding of activating NK cell receptors 
such as NKG2D with its specific ligand that is expressed on infected cells. Unfortunately, 
we have not included all three markers in the same staining panel to analyse the co-
expression of NKG2D and CD28, but NKG2D expression tends to increase while CD28 
decreases on cells detected in the same individual. 
Of note, T-cell exhaustion which is characterised by the up-regulation of inhibitory 
receptors, such as PD-1, and the progressive loss of cytokine production, proliferative 
capacity, and cytolytic function (220) has not been found applicable for CMV-specific 
CD8+ T cells (184, 221). It has, although been associated with other chronic viral 
infections mainly those where there were high levels of antigen like Human 
Immunodeficiency virus and Hepatitis C virus. Interestingly, the staining ex vivo with 
class II tetramer methodology has shown that a great proportion of CMV-specific CD4+ 
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T cells expressed PD-1 molecule in comparison with total CD4+ T cells. Our findings are 
supported by Sester et al.’s study, in which they observed expression of PD-1 on CMV-
specific CD4+ T cells after 5 days of in vitro stimulation with CMV antigen (222). This 
functional exhaustion of CMV-specific CD4+ T cells may determine impaired CMV 
control in patients following transplantation. Unfortunately, we have not performed 
functional assays with these cells, but previous studies have shown that PD-1 positive 
cells are less functional with lower IFN and IL-2 levels compared to PD-1 negative cells. 
This functional anergy of CMV-specific CD4+ T cells can be avoided by blocking PD-1 
signalling with its ligands PD-L1/L2 which has been shown to increase up to 10-fold on 
CMV-specific CD4+ T cells therefore, providing a potential target for enhancing the 
function of exhausted T cells in chronic CMV infection (222). Interestingly, PD1 
expression was reduced on DYS-specific CD4+ T cells compared to AGI- and LLQ-
specific CD4+ T cells. Further analyses need to be perform in order to understand why it 
occurred as it is the opposite to what it was expected since DYS-specific CD4+ T cells 
presented a highly differentiated phenotype and were thought to be more exhausted than 
AGI- and LLQ-specific CD4+ T cells. 
Another interesting observation that our study has revealed is that CMV-specific CD4+ T 
cells staining directly ex vivo do not appear to belong to the CD4+ T regulatory subset as 
these cells did not express neither CD25 surface marker nor FoxP3 transcriptor factor. 
Appay et al. came to the same conclusion when analysing cytotoxic CD4+ T cells (144). 
However, two previous studies showed the presence of inducible regulatory T cells within 
CMV-specific CD4+ T cells, although it was observed upon in vitro stimulation with 
CMV peptides or CMV lysate and in our study we performed a direct staining (223, 224).  
As it has previously been mentioned, CMV establishes latency in various cell types, 
including myeloid lineage cells but also endothelial cells. Activated endothelial cells upon 
inflammatory processes produce cytokines such as fractalkine that can recruit immune 
cells that are able to induce endothelial damage (225, 226). The receptor for fractalkine 
is CX3CR1, which has been shown to be expressed on macrophages, dendritic cells and 
fibroblasts (183). Recent studies have shown that CX3CR1 is only expressed on CMV-
specific effector CD8+ T cells when compared to EBV and influenza specific T cells 
(184). Interestingly, our results have shown that the majority of CMV-specific CD4+ T 
cells also expressed the fractalkine receptor. These cells also have high levels of 
granzyme B and perforin, which can cause tissue damage to the endothelial cells. The 
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potential of the host antigen-speciﬁc T-cell population to respond aggressively to CMV 
with a great cytokine response may initiate a chemokine cascade and direct an 
inﬂammatory inﬁltrate that has a self-destructive effect on the endothelium. Endothelial-
cell damage may be the end effect of a repeated cycle in which the cell and tissue damage 
results from innate immune defence mechanisms (monocyte-macrophage cells) activated 
by a strong T-cell response to a chronic pathogen that is present as either a persistent 
infection or a latent infection undergoing periodic reactivation episodes. This may be a 
problem associated with many inﬂammatory disorders if they involve a chronic pathogen 
such as CMV, with which the antigen-speciﬁc T-cell response can result in chemokine 
induction and lead to chronic inﬂammation. Breaking the cycle of antigen presentation to 
the T cells by restricting virus replication may help to limit or even reverse the 
development of this aggressive T-cell response to CMV (226). 
In conclusion, we have demonstrated that MHC class II tetramers allow reliable detection 
of CMV-specific CD4+ T cells. These cytotoxic CMV-specific CD4+ T cells that appear 
as a consequence of CMV infection may have a considerable importance in the clearance 
of viral infection and bear many phenotype similarities to their cytotoxic CD8 
counterparts. Antigen-presenting cell populations have constitutive expression of HLA 
class II proteins, whereas other cell types, such as endothelium, are induced to express 
HLA class II molecules by inflammatory mediators. These cell types are tropic for CMV 
infection, and thus become targets for CD4 mediated immune control. The role of CD4+ 
T cells and their recognition of MHC class II may be critical for activating the immune 
system and sustaining the balance between virus and host immunity during latency. 
We have been able to describe the phenotype of CMV-specific CD4+ T cells by direct 
staining ex vivo by using class II tetramers in healthy individuals and it is now possible 
to implement this technique for the monitoring of CMV immune recovery in allo-HSCT 
recipients, as it has been shown that effector memory CD4+ T cells are necessary for 
recovery of infection. By using class II tetramers, it would possible to study CMV-
specific CD4+ T-cell responses in transplant patients and it would help in the knwoledge 
of CMV reactivation. It would be possible to sort CMV-specific CD4+ T cells from those 
patients in order to perform molecular assays to the better understanding of CMV 
infection. 
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1. Streptamer multimer gives an accurate, precise and specific measurement in order 
to monitor immune recovery of CMV-specific CD8+ T cells compared to 
pentamer multimer. 
2. IFN+ CMV-CTL levels at early time points following transplant protects patients 
against CMV reactivation. 
3. CMV-CTL expansion levels after CMV reactivation protects against future 
reactivations in allogeneic haematopoietic stem cell transplant recipients. 
4. CMV-CTLs monitoring during episodes of CMV DNAemia yield useful 
information for the therapeutic management of active CMV infection in 
allogeneic haematopoietic stem cell transplant recipients. 
5. MHC class II tetramers allow reliable detection of CMV-specific CD4+ T cells. 
6. CMV-specific CD4+ T cells are highly cytotoxic ex vivo and these cytotoxic 
potential varies on the peptide-specificity. 
7. Cytotoxic CMV-specific CD4+ T cells present mainly an effector memory 
phenotype and present a differentiated phenotype which varies depending on 
peptide-specificity. 
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The thesis explores the T cell response to CMV in allogeneic hematopoietic stem cell 
transplant recipients using flow cytometric analysis of blood samples. In general it is a 
reasonable study although the analysis of CD8 responses is somewhat lacking in novelty.  
Tal y como indica el revisor, son muy numerosos los estudios de monitorización de linfocitos T-
CD8+ específicos de CMV en pacientes sometidos a trasplante alogénico de precursores 
hematopoyéticos (alo-TPH), pero todo ellos están realizados mediante la cuantificación de las 
células específicas bien mediante el marcaje con tetrámeros o bien determinando la respuesta de 
las mismas in vitro tras el estímulo antigénico. En nuestro estudio nos propusimos incorporar a la 
práctica clínica, la posibilidad de cuantificar las células CD8+ específicas frente a CMV con 
nuevos multímeros desarrollados recientemente y que “a priori” ofrecen ciertas ventajas sobre 
los tetrámeros convencionales.  
Para ello se ha realizado un estudio exhaustivo sobre las ventajas e inconvenientes desde el punto 
de vista técnico de dos multímeros (pentámero y estreptámero. Inicialmente, según los resultados 
obtenidos hemos  demostrado que el estreptámero (ST) es mejor que el pentámero para 
incorporarlo en la monitorización clínica de la respuesta inmune en estos pacientes ya que los 
resultados obtenidos son más específicos. De esta forma seleccionamos esta tecnología para 
realizar el estudio de monitorización en nuestros pacientes ya que no existen datos previos de la 
utilización de los ST en la monitorización de la respuesta inmune frente a CMV en pacientes 
sometidos a alo-TPH. Además, el estreptámero ofrece la posibilidad de ser utilizado en 
inmunoterapia adoptiva siendo uno de los objetivos de nuestro grupo a desarrollar en un futuro 
próximo. 
- Schmitt, A., T. Tonn, D. H. Busch, G. U. Grigoleit, H. Einsele, M. Odendahl, L. 
Germeroth, M. Ringhoffer, S. Ringhoffer, M. Wiesneth, J. Greiner, D. Michel, T. 
Mertens, M. Rojewski, M. Marx, S. von Harsdorf, H. Dohner, E. Seifried, D. Bunjes, and 
M. Schmitt. 2010. Adoptive transfer and selective reconstitution of streptamer-selected 
cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after 
allogeneic peripheral blood stem cell transplantation. Transfusion 51: 591-599. 
- Neudorfer, J., B. Schmidt, K. M. Huster, F. Anderl, M. Schiemann, G. Holzapfel, T. 
Schmidt, L. Germeroth, H. Wagner, C. Peschel, D. H. Busch, and H. Bernhard. 2007. 
Reversible HLA multimers (Streptamers) for the isolation of human cytotoxic T 
lymphocytes functionally active against tumor- and virus-derived antigens. J Immunol 
Methods 320: 119-131 
- https://www.clinicaltrials.gov/ct2/NCT01077908/ or NCT01220895 or NCT01220895 
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The analysis of CD4 responses is the main area of new work.  
El apartado de la respuesta específica de CMV por parte de las CD4, como bien dice el revisor, 
es más novedoso ya que todos los estudios que se conocen hasta la fecha se basan en la 
determinación de la respuesta CD4+ tras la estimulación antigénica. En esta parte del trabajo 
desarrollado en la Universidad de Birmingham hemos conseguido desarrollar tetrámeros para 
clase II y se han caracterizado las propiedades fenotípicas y funcionales de estas células CD4+-
CMV específicas. 
The organisation of the thesis is reasonable although there are multiple errors in the use of 
English (too many to list them fully). I recognise that English is not the student’s first 
language but I believe these errors need to be corrected to avoid misunderstanding of the 
text.  
De acuerdo a los consejos del revisor, se ha procedido a la corrección del inglés. 
The introduction is a reasonably comprehensive account of viral infections in transplant 
recipients, but lacks a general introduction to immunology and more specifically T cell 
biology. There is insufficient introduction to T cell receptors, antigen processing, HLA etc, 
all of which are relevant to the thesis and therefore in my opinion should be introduced in 
more detail.  
Teniendo en cuenta las sugerencias del revisor se ha incorporado en la Introducción  un apartado 
describiendo aspectos generales de inmunología, relacionados con nuestro estudio: linfocitos T y 
sus receptores, HLA y procesamiento antigénico.  
The hypothesis stated in the thesis has not formally been tested since the study is a 
retrospective one, rather than a prospective study seeking to determine whether 
immunological monitoring of CMV-specific immunity can predict CMV reactivations and 
help guide the choice of treatment.  
Siguiendo el comentario del revisor, se ha modificado la hipótesis de trabajo, si bien no es un 
estudio retrospectivo sino prospectivo. 
Throughout the study, immune responses to CMV are explored with very few (often one) 
multimeric reagents, and therefore are restricted to analysing T cell responses to just one 
or two epitopes. Can this be expected to give a true indication of the immune response to 
CMV in every transplant recipient? Equally can it be expected to determine the protective 
level required in all individuals to prevent CMV reactivations? What about responses to 
other epitopes and how should responses be monitored in people who are HLA A2 negative? 
All of this should be discussed. The sensitivity and specificity analysis was conducted with 
multimer reagents targeting a single epitope-specificity. Is this a fair test? Do these results 
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represent reagents that target other epitopes and HLA restrictions. Again, at the very least 
this issue should be discussed.  
En la Discusión hemos incluido un párrafo en el que se discute que nuestros resultados del análisis 
técnico de ambos multimeros no pueden extrapolarse al estudio con otros multimeros con otras 
restricciones HLA ya que la avidez y afinidad de cada uno de ellos puede depender de la estructura 
química. También se ha justificado porque se ha elegido realizar el estudio en pacientes con 
restricción HLA-A*02:01 ya que de todas las restricciones HLA relacionadas con la presentación 
del CMV es la más frecuente en nuestra población.  
I am concerned that there is little consideration of multiple comparisons. When conducting 
the statistical analyses and seeking for significant differences/correlations, a p value of 0.05 
will not necessarily indicate significance if 20 comparisons have been made to find one that 
gives this value (since this p value means that such a difference could have occurred by 
chance on 1/20 occasions). This point should be discussed, as well as how future experiments 
should aim to test the hypotheses generated by some of the current data.  
En este estudio sólo 6 variables clínicas han sido relacionadas con la reactivación del CMV y por 
lo tanto, no se considera necesario realizar ajustes de comparaciones múltiples. Por otro lado, no 
es el objetivo de nuestro estudio porque, tal y como se comenta en la discusión, ya existen muchos 
estudios relacionando dichas variables con la reactivación de CMV analizando un mayor número 
de  pacientes. 
The discussion chapter is more a summary of the results than a reflection on how the data 
compare with published studies and what it all means. There is some mention of other 
studies that give similar or contrasting results but little attempt to explain why others might 
have found a different result. More discussion is required on these points and others (e.g. 
what about using ST reagents to sort T cells for adoptive therapy? How is it best to 
determine the “protective cell number against CMV infection”? Expand upon why DYS-
specific T cells differ in phenotype compared with AGI and LLQ-specific effectors. How 
might tetramers be used to study/sort CD4 responses in transplant recipients and what 
results might you expect?  
De acuerdo a las sugerencias del revisor, el apartado de discusión se ha modificado intentando 
explicar las diferencias que nosotros observamos respecto otros investigadores así como incluido 
la utilización del ST en inmunoterapia adoptiva. También se ha dado una posible explicación a 
las diferencias observadas entre las distintas células T CD4+ específicas y cómo se podría 
incorporar el uso de tetrámeros en la monitorización de los pacientes sometidos a alo-TPH.  
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Page 15-table 2 there is an error in the reside numbers listed for the DR52-restricted epitope 
Se ha corregido el error (509-523) 
Page 17 – says CD45- when it should read CD45RA-  
Se ha corregido. 
Page 47 – why were the PM and ST reagents used at the concentrations stated? Had this 
been optimised in a titration experiment beforehand? If so show the data.  
Las concentraciones y condiciones de marcaje de los multímeros (PM y ST) fueron optimizadas 
previamente en nuestro laboratorio (unpublished data). No se ha realizado en esta tesis por lo que 
no se añaden los resultados. 
What is the relative cost of using PM vs ST reagents? This is a factor that should be 
discussed when considering which is the most appropriate to use for routine clinical 
monitoring. 
Tal y como señala el revisor, en la elección de estos multímeros para su estudio y su posible 
incorporación en la monitorización de la respuesta inmune frente a CMV en pacientes que han 
sido sometidos a trasplante alogénico de precursores hematopoyéticos (alo-TPH), no sólo se 
tuvieron en cuenta las semejanzas o diferencias estructurales de los mismos sino también su coste. 
El PM tiene un coste similar al tetrámero, utilizado en muchos estudios, mientras que el ST tiene 
un coste menor, por lo que, no sólo ofrece ventajas técnicas sino también económicas respecto al 
PM (página 114). 
Page 50 – “Detection of IFNgamma secreting cells by pentamer+ cells”. In this protocol 
might not prelabelling the T cells with the pentamer at least partially inhibit their ability to 
then respond to the target peptide?  
En el presente estudio realizamos el marcaje de la técnica siguiendo las instrucciones del kit 
utilizado (IFN Secretion Assay-Detection Kit, Miltenyi Biotec) y observamos diferencias 
respecto a la producción de IFNy la técnica de ICS. Tal y como nos comenta el revisor, el hecho 
de marcar con el pentámero previamente a la estimulación con el antígeno podría ser una posible 
explicación de las diferencias que observamos en la producción de IFN mediante ambas 
técnicas. Este comentario se ha incluido en la discusión. Es por lo tanto conveniente realizar 
futuros estudios para poder optimizar esta técnica que puede tener una gran utilidad para evaluar 
la funcionalidad de las células específicas del CMV. 
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Page 51 – “CMV-antigen detection in whole blood” – this is a misleading title because in 
fact it describes a serological assay which is detecting antibodies rather than antigen.  
Se ha cambiado el título, ya que el revisor está en lo cierto y lo que detectamos son anticuerpos 
en el suero del individuo y no el antígeno de CMV “Anti-CMV antibody detection in whole 
blood”. 
Page 51 – give more details on the standard curve (what is it and how was it prepared)  
Se ha explicado con más detalle la preparación de la curva estándar. 
Page 55 – reference required for the MLA 144 cell line 
Se ha añadido la referencia de la línea cellular MLA144. 
Page 55 – LCLs were pulsed or labelled with peptide, not “stimulated”  
Se ha modificado. 
Page 55 – “50ul of the supernatant of each clone” – I assume you mean 50ul of cell 
suspension of each clone?  
Se ha corregido puesto que es suspensión celular y no el sobrenadante. 
Page 55 “negative and antigen-specific” – the meaning of this phrase is unclear 
Se ha explicado correctamente a qué se refiere en esta frase para evitar confusiones. 
Page 61 – comparing donors 20 and 29 in table 8 suggests PM are twice as sensitive as ST. 
Discuss.  
En este análisis estamos evaluando la repetitividad del multímero utilizado, PM o ST, para lo cual 
se utilizaron 12 muestras diferentes. Los sujetos 20 y 29 fueron utilizados para evaluar tanto PM 
como ST, pero el análisis se realizó en momentos diferentes, por lo que el porcentaje de células 
específicas no tiene por qué coincidir con ambos multímeros. De ahí las diferencias encontradas 
entre ambos multímeros y que el revisor ha señalado. Es como si se tratara de sujetos diferentes. 
Para evitar confusiones y no cambiar la nomenclatura se ha añadido un comentario al pie de la 
tabla 8. 
Page 63 – table 9 – what were the background levels of non-specific staining seen with these 
reagents (eg in CMV seronegative donors)?  
El ‘background’ observado con cada multímero está explicado en la tabla 10. 
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Page 64 – the same sentence is repeated twice on this page. 
Se ha eliminado la frase que estaba repetida: ‘The median MFI values of the undiluted fraction of 
CMV-specific CD8+ T cells were 19255 (10067 - 41913) and 8191 (5700 - 17127) for ST and 
PM respectively’. 
Page 65 – figure 11 – how were the gates set that determine positively stained CMV-specific 
cells? There appear to be intermediate levels of staining for some T cells with both PM and 
especially ST reagents – why not include these as positive if they are above background?  
Atendiendo a la pregunta del revisor, los gateos se fijaron definiendo clusters positivos. La 
población dispersa que se observa como positiva no se incluyó ya que no es una población clara 
y definida y puede ser debida a la inespecificidad del multímero, siendo mayor en el PM que en 
el ST. 
Page 90 – it is important to remember that a T cell is not necessarily “non functional” 
because it does not make IFNgamma, it may yet make a different cytokine.  
Esta
significa que la célula no sea funcional. Sin embargo, nosotros nos centramos en la producción 
de esta citoquina ya que la gran mayoría de estudios relacionados con la respuesta inmune frente 
demuestra que la respuesta por parte de los linfocitos CD8+ T citotóxicos correlaciona 
antígeno específica y puede ser 
citotóxicas específicas de CMV y está asociada con la infección por CMV. Por otro lado, existe 
un kit comercial para poder ser utilizado a escala clínica, conocido como QuantiFERON-CMV, 
restricciones alélicas que cubren más del 95% de la población (4). Además, el kit utilizado para 
medir la producción de citoquinas por parte de las células específicas de CMV (Miltenyi) sólo 
combinar más de un kit. 
1. Lilleri, D., G. Gerna, C. Fornara, A. Chiesa, G. Comolli, M. Zecca, and F. Locatelli. 2009. 
Human cytomegalovirus-specific T cell reconstitution in young patients receiving T cell-
depleted, allogeneic hematopoietic stem cell transplantation. The Journal of infectious 
diseases 199: 829-836 
2. Lilleri, D., P. Zelini, C. Fornara, G. Comolli, M. G. Revello, and G. Gerna. 2009. Human 
cytomegalovirus-specific CD4+ and CD8+ T cell responses in primary infection of the 
immunocompetent and the immunocompromised host. Clin Immunol 131: 395-403 
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3. Ghanekar, S. A., L. E. Nomura, M. A. Suni, L. J. Picker, H. T. Maecker, and V. C. Maino. 
2001. Gamma interferon expression in CD8(+) T cells is a marker for circulating 
cytotoxic T lymphocytes that recognize an HLA A2-restricted epitope of human 
cytomegalovirus phosphoprotein pp65. Clinical and diagnostic laboratory immunology 
8: 628-631 
4. Tey, S. K., G. A. Kennedy, D. Cromer, M. P. Davenport, S. Walker, L. I. Jones, T. 
Crough, S. T. Durrant, J. A. Morton, J. P. Butler, A. K. Misra, G. R. Hill, and R. Khanna. 
2013. Clinical assessment of anti-viral CD8+ T cell immune monitoring using 
QuantiFERON-CMV(R) assay to identify high risk allogeneic hematopoietic stem cell 
transplant patients with CMV infection complications. PloS one 8: e74744 
Page 92 – fig 28 A and B – was a paired analysis used here?  
Agradecemos al revisor esta apreciación y se ha realizado el test estadístico pareado apropiado 
(Wilcoxon). 
Page 95 – “decreasing amounts of CD4 T cell clones” – by how much were they diluted? 
What were the predicted % positives and how well did the results correlate with these 
predictions?  
Tal y como el revisor ha comentado se ha explicado cómo se realizaron las diluciones de los 
clones de células T CD4, así como cuáles eran los valores teóricos que se esperaban y la 
correlación de lo obtenido con lo esperado. 
Page 97 – fig 31 – how many seronegative donors were studied and what was the range of 
responses seen with these donors? Show a graph of % tetramer positive cells seen with CMV 
seronegative donors vs seropositive donors so we can see the relative spread of responses in 
these two groups.  
Desafortunadamente no se ha hecho el marcaje de los tetrámeros en sujetos seronegativos para 
CMV. Realizar dicho estudio podría ser de gran ayuda para determinar el punto de corte (cut-off) 
de la población positiva de la negativa. No obstante esto puede variar entre sujetos y hay que 
seleccionar cada caso. Sin embargo, no es posible realizar este marcaje ya que el estudio fue 
realizado durante la estancia en Birmingham y actualmente no tenemos los tetrámeros para 
realizar este marcaje y poder hacer el gráfico que muestre la diferencia entre sujetos positivos y 
negativos que el revisor comenta. 
Los marcajes con los tetrámeros fueron considerados como positivos únicamente cuando se 
identificaba un cluster claro y bien definido. Los sujetos negativos que aparecen en la figura 31 
son los que se utilizaron para el estudio de sensibilidad de cada clon de células T CD4 para dar 
una idea de la diferencia entre sujetos seropositivos y negativos para el CMV. 
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Page 98 – fig 32 there is no need for the split y axis in this figure 
El eje de la figura se ha dividido para poder ver más claramente los puntos y que no queden tan 
juntos. No se ha modificado. 
Page 98 and beyond – when characterising the tetramer positive population, there is a 
danger that results may include relatively few events and therefore the data could be 
unreliable. What was the minimum number of events used to determine a result and below 
which data were considered inadmissible? 
Esta puntualización del revisor es una cuestión bastante discutida hoy en día en el ámbito de la 
citometría de flujo ya que existen diferentes criterios para definir la población positiva. Como 
bien hemos comentado anteriormente, en nuestros análisis se ha seguido el criterio de seleccionar 
la población tetrámero-específica como un cluster positivo claro y bien definido. No se ha 
establecido ningún número mínimo de células tetrámero positivas necesario para considerar el 
resultado como positivo. Sí que, en todos los sujetos analizados, al menos 300,000 linfocitos vivos 
fueron adquiridos (single life lymphocytes). Analizando el número de eventos positivos, 
CD4+tetrámero+, en aquellos sujetos en los que se identificó un cluster definido como positivo, el 
número mínimo de eventos adquirido fue de 40.  
Page 99 – fig 33 B – should y axis title include CCR7-ve?  
No debe incluir CCR7- ya que se está hablando de la frecuencia de expresión de CD45RA en las 
células específicas de DYS, AGI o LLQ, no de CD45+CCR7-. 
Page 100 – differences found in the DYS-specific T cells vs the AGI and LLQ –specific T 
cells – might these be explained by a disproportionate number of old or young donors 
respectively studied for each of these responses?  
En nuestro caso concreto, no hemos observado grandes cambios en relación a la edad. Sin 
embargo, puede que sea cierto lo que el revisor señala, si bien no se ha hecho el estudio 
comparativo de las células específicas de DYS, AGI o LLQ dentro de cada grupo de edad por la 
imposibilidad de encontrar el mismo número de sujetos para cada condición. 
Page 102 – fig 36 legend should say CD27-CD28-  
Se ha corregido. 
Page 105 – how did NKG2D expression compare on the DYS-specific T cells vs the AGI and 
LLQ –specific T cells? The data should already be available.  
Se han incluido las frecuencias de expresión de NKG2D en las células específicas de CMV en 
función del epítopo (DYS, AGI y LLQ) (figura 40, pag.106). 
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Page 107 – why is PD1 expression reduced on DYS-specific T cells vs the AGI and LLQ –
specific T cells? Discuss.  
Agradecemos esta puntualización del revisor. Los resultados obtenidos de la expresión de PD1 
son contrarios a lo esperado, puesto que al ser un marcador de ‘agotamiento’ celular (del inglés 
T-cell exhaustion), era de esperar que se expresara en mayor proporción en aquellas células que 
se encuentran en un estadío de mayor diferenciación. En nuestro caso, las células específicas de 
CMV que reconocen el péptido DYS están más diferenciadas que las que reconocen los péptidos 
AGI o LLQ, presentando un fenotipo memoria efector, ausencia de las moléculas coestimuladoras 
CD27 y CD28 y un aumento de la expresión de CD57. Estudios preliminares realizados a 
posteriori mediante selección de células PD1+ y PD1- específicas de CMV demuestran que no 
existen diferencias ni desde el punto de vista funcional ni de expresión génica. Son necesarios 
realizar futuros estudios para explicar estos resultados.  
Page 108 – fig 43 – how does expression of CX3CR1 compare on the CMV-specific T cells 
with other effector memory T cells in these donors? Is this a CMV-specific T cell phenotype 
or a marker of effector memory T cells in these donors? 
En realidad, no tenemos en el panel en el que miramos la expresión de CX3CR1, ningún marcador 
que nos permita distinguir entre las distintas subpoblaciones celulares por lo que no podemos ver 
y comparar la expresión de CX3CR1 en otras células memoria efectora, como el revisor sugiere. 
Tampoco podemos determinar, mediante este estudio si la expresión de CX3CR1 está asociado 
con la infección por CMV o si es un marcador de las células memoria efectoras. Sin embargo, un 
estudio realizado por Hertoghs y colaboradores (1), sugiere que CX3CR1 parece ser un marcador 
de las células memoria efectoras CD8+ específicas de CMV, ya que no se observa este marcador 
ni en células específicas de EBV o influenza. Un estudio realizado por Sacre y colaboradores 
demuestra que pacientes con VIH tenían presencia de células T CD4+ específicas de CMV que 
expresaban CX3CR1 tras estimulación antigénica (2). 
Se han realizado estudios posteriores, no incluidos en esta tesis, en sujetos seropositivos y 
seronegativos de CMV en los cuales se marcó con CD4, CD8, CD28 y CX3CR1. La expresión 
de CX3CR1 se detectó únicamente en sujetos CMV seropositivos, siendo mayoritariamente CD28 
negativos. Por lo que podríamos decir que la expresión de CX3CR1, es un marcador de fenotipo 
de las células específicas de CMV más que de células memoria efectoras. Cabe resaltar que estas 
células específicas de CMV son en su mayoría memoria efectoras. 
1. Hertoghs, K. M., P. D. Moerland, A. van Stijn, E. B. Remmerswaal, S. L. Yong, P. J. van 
de Berg, S. M. van Ham, F. Baas, I. J. ten Berge, and R. A. van Lier. 2010. Molecular 
profiling of cytomegalovirus-induced human CD8+ T cell differentiation. The Journal of 
clinical investigation 120: 4077-4090 
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2. Sacre, K., P. W. Hunt, P. Y. Hsue, E. Maidji, J. N. Martin, S. G. Deeks, B. Autran, and 
J. M. McCune. 2012. A role for cytomegalovirus-specific CD4+CX3CR1+ T cells and 
cytomegalovirus-induced T-cell immunopathology in HIV-associated atherosclerosis. 
Aids 26: 805-814 
 
   
 
   
  
 
 
